PROGRAM GUIDE

AACC
Better health through laboratory medicine.

69TH AACC ANNUAL SCIENTIFIC MEETING & CLINICAL LAB EXPO

JULY 30 - AUGUST 3, 2017
SAN DIEGO, CA USA

NEW PORTFOLIO

DxONE™

FOR THE ONE LAB VALUE THAT MATTERS MOST

• Workflow • Standardization
• Analytics • Inventory
• Performance

Clinical information and analytics that put people first

DxONE informatics portfolio empowers clinical laboratories to do what they do best—make a difference. It's all about optimized workflows, impactful analytics, standardized processes and streamlined inventory. When all these things work together, your team can dedicate themselves to the high-value work that elevates healthcare.

See DxONE in action at booth #3117
beckmancoulter.com/dxone

For Beckman Coulter's worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact

AD-52543

BECKMAN COULTER

Move healthcare forward.

CONTENTS

OFFICES & MEETING SERVICES

REGISTRATION

Location: Lobby D

Saturday	Noon - 5:00pm
Sunday	8:00am - 6:30pm
Monday - Wednesday	7:00am - 5:00pm
Thursday	8:00am - 1:00pm

AACC STORE

Location: Lobby E

Plan to visit the AACC store to examine some of AACC's new titles that have been released since last year's meeting and all the other bestsellers. AACC merchandise is available for purchase including t-shirts, AACC wearables, and gifts. The AACC Store is open from Monday through Thursday.

AACC Store Hours

Monday - Wednesday	9:00am - 5:00pm
Thursday	9:00am - 1:00pm

AACC EDUCATION AND ACCENT/CME BOOTH

Location: Lobby F

Learn about AACC Education offerings and get assistance claiming ACCENT® and CME credit. See page 96 for detailed instructions and getting a certificate of attendance. This information can also be found on www.aacc.org/AMCredits17. If you have additional questions, visit the ACCENT/CME booth or send an email to education@aacc.org.

HOUSING

Location: Lobby F

Representatives from Spargo, AACC's official housing agency, will be available to assist with your hotel accommodations.

INTERNATIONAL TRADE CENTER

Location: Sails Pavilion

The Center is staffed by international trade specialists who will help international visitors identify and meet suppliers of products they wish to purchase, either for their own use or as distributors.

Monday - Wednesday	9:00am - 5:00pm
Thursday	9:00am - 1:00pm

Note: All locations are in San Diego Convention Center unless otherwise noted.

AACC MEMBERSHIP

Membership information and applications are available in the AACC Store, the AACC Booth #3539, and at the AACC Conference Registration Desk. One year Professional Member dues are $229, Professional Affiliate dues are $135, Transitional Dues are $77 and Trainee dues are $37. You can customize your membership by joining one or more divisions that target your specialized area(s) of interest for an additional $15, $20 or $25 each, depending on the division(s) you select.

AACC HEADQUARTERS OFFICE

Location: Room 23AB **Phone: 619.525.6219**

Contact the AACC Office if you have questions about registration, or general questions about the meeting (session times/locations or expo times/locations).

Also use this number if you have an emergency situation.

Nursing Room Access – Visit the AACC Office for access to the designated nursing room facilities onsite.

AACC Headquarters Office Hours

Friday	Noon - 5:00pm
Saturday	Noon - 5:00pm
Sunday	8:00am - 6:30pm
Monday - Wednesday	7:00am - 6:00pm
Thursday	8:00am - 4:00pm

BAGGAGE CHECK

Location: Lobby A and Lobby G

Tuesday - Wednesday	7:00am - 6:00pm
Thursday	7:00am - 2:00pm

Per item: Coat Check, Bag or Poster $5

CLINICAL LAB EXPO

Location: Exhibit Hall A – H, Ground Level

Tuesday - Wednesday	9:30am - 5:00pm
Thursday	9:30am - 1:00pm

Refer to *Exhibit Guide* for exhibit listing and booth descriptions.

AACC permits individuals age 16 and 17 with a photo ID to register for and attend the 69th AACC Annual Scientific Meeting & Clinical Lab Expo if accompanied by a registered adult. Children under 16 are not permitted on the exhibit floor or in the educational sessions at any time.

FIRST AID/EMERGENCY

Emergency Phone Number:

Dial 5911 from any telephone in the Convention Center. In hotels, dial 0 from any phone.

PRESS ROOM

Location: Room 25A

Phone: 619.525.6214 and 619.525.6215

Sunday	9:00am - 5:00pm
Monday	8:00am - 8:00pm
Tuesday - Wednesday	8:00am - 5:00pm
Thursday	8:00am - 1:00pm

Members of the media can register for the Annual Scientific Meeting in the press room, where pre-registered media can pick up their badges and other meeting materials. The press room serves as the coordination point for reporters to set up interviews with participants and is available for exhibitors and journalists who wish to meet away from the exhibit floor and other public areas. Additionally, registered media are welcome to work on stories here.

Materials

AACC media kits that include fact sheets and AACC press releases will be available, as well as Expo and conference program books. Phones, WiFi, and laptop hookups are available for the press. Free breakfast and lunch also is available for registered press each day of the meeting.

The press room is available to exhibitors to display promotional materials and media kits. However, only registered media may use the rest of the press room, and company and public relations representatives will not be permitted beyond the entryway table after dropping off their materials.

Interviews

Registered media can reserve space in Room 26A to conduct interviews. Use of this room is by appointment only and subject to availability.

Press Conferences

Press conferences take place in Room 25B or 25C. Details of scheduled press conferences are available from the press room. Press conferences are open to all registered journalists.

PHOTOGRAPHY

Except for photography specifically authorized by AACC, use of video and photographic equipment is prohibited on the exhibit floor and in the meeting rooms. Photography of poster sessions is permitted only with express permission of the presenting author.

LOCATION OF ACTIVITIES

San Diego Convention Center

- Scientific Sessions, Plenary Sessions, Symposia, Meet the Expert Sessions, Brown Bag Sessions, Short Courses, AACC University, Oral Abstract Sessions, President's Invited Sessions, Chair's Invited Session
- Special Session
- AACC Clinical Lab Expo
- New Products Showcase
- Poster Sessions
- Registration
- Industry Workshop Theater Presentations
- OEM Lecture Series Presentations

Marriott Marquis San Diego Marina

- AACC Community Opening Mixer
- AACC Governance Activities
- Affiliated Organization Meetings
- Industry Workshops

Manchester Grand Hyatt

- Affiliated Organization Meetings

DOWNLOAD THE 2017 MOBILE APP

With hundreds of exhibitors to navigate and dozens of educational sessions to attend, planning your busy days at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo is essential to make the most of this dynamic event.

Now you can do all that and more with the FREE 2017 AACC Annual Scientific Meeting & Clinical Lab Expo app. Available for smartphones and tablets from the Apple App store and on Google Play for Android devices.

- Plan each day with a built-in calendar
- Browse exhibitors and map out your path through the Expo
- Browse through new products available at the Expo
- Organize your notes about exhibitors or check off which ones you've visited
- Follow live tweets and other social media about the meeting

To Download:

- visit www.aacc.org/2017app
- Search for the app on the Apple App Store or on Google Play

SHUTTLE SCHEDULE

SHUTTLE BUS SERVICE TO THE SAN DIEGO CONVENTION CENTER

Date	Service Hours	Departures
SUNDAY JULY 30	9:00am - 6:00pm* 7:00pm - 8:30pm	Every 15 minutes from Opening Mixer from SDCC
MONDAY JULY 31	6:00am - 10:00am 10:00am - 3:00pm 3:00pm - 6:30pm*	Every 15 minutes Every 30 minutes Every 15 minutes
TUESDAY AUGUST 1	6:00am - 10:00am 10:00am - 3:00pm 3:00pm - 6:30pm*	Every 15 minutes Every 30 minutes Every 15 minutes
WEDNESDAY AUGUST 2	6:00am - 10:00am 10:00am - 3:00pm 3:00pm - 6:30pm*	Every 15 minutes Every 30 minutes Every 15 minutes
THURSDAY AUGUST 3	7:00am - 11:00am 11:00am - 6:00pm*	Every 15 minutes Every 30 minutes

** Last time shuttle departs convention center to hotels. Last shuttle departs hotel going to the Convention Center one hour prior to this time.*

Shuttle Schedule may vary due to traffic & weather conditions.

SPECIAL TRANSPORTATION

AACC Community Opening Mixer – Marriott Hotel and Marina
Sunday, July 30

Return transportation from the Convention Center 7:00pm - 8:30pm, every 15 minutes

Morning Industry Workshops
Tuesday, August 1 and Wednesday, August 2

Transportation provided from Route Hotels to the Marriott Hotel and Marina and Manchester Grand Hyatt and from 6:30am - 8:30am, every 15-20 minutes.

WALKING HOTELS TO/FROM THE CONVENTION CENTER

- Hard Rock Hotel
- Hilton San Diego
- Hilton Sand Diego Gaslamp Quarter
- Horton Grand Hotel
- Hotel Solamar
- Omni San Diego
- Pendry San Diego
- Residence Inn by Marriott Gaslamp
- San Diego Marriott Gaslamp Quarter
- San Diego Marriott Hotel and Marina

IF YOU NEED TO ARRANGE WHEELCHAIR-ACCESSIBLE TRANSPORTATION

Please call 404.597.7757 at least 12 hours prior to pick-up or see a shuttle supervisor at the Convention Center.

SAN DIEGO 2017

ROUTES & BOARDING LOCATIONS

Route#/Color	Hotel	Boarding Location
#1 - Red	Embassy Suites San Diego Bay Downtown	Curbside in front
	Wyndham Sand Diego Bayside	Curbside on Harbor Drive
	Residence Inn Bayfront	Curbside on Pacific Hwy
	Springhill Suites Bayfront	At Residence Inn Bayfront
	Manchester Grand Hyatt	Curbside on Harbor Drive
#2 - Blue	Westin Gaslamp	Curbside 1st Ave. at E Street
	The Westgate	Walk to Westin Gaslamp on 1st Ave. at E Street
	Westin San Diego	Curbside on Broadway
	The Sofia Hotel	Walk to Westin Gaslamp on 1st Ave.
	Renaissance Hotel Downtown	Walk to Westin Sand Diego on Broadway
#3 - Green	Hampton Inn by Hilton San Diego Downtown	Curbside on Pacific Highway
	Residence Inn by Marriott San Diego Downtown	Curbside on Pacific Highway
	Hilton Garden Inn Bayside	Curbside on Pacific Highway
	Homewood Suites Bayside	Curbside on Pacific Highway
	Doubletree by Hilton San Diego Downtown	Curbside Union Street Entrance
	Four Points by Sheraton San Diego Downtown	At Doubletree by Hilton on Union Street
#4 - Yellow	Courtyard by Marriott Downtown Gaslamp	Curbside on 6th Ave.
	The US GRANT	At Courtyard by Marriott Downtown Gaslamp
	Andaz San Diego	Curbside on F Street
	Courtyard by Marriott Downtown	At Andaz Curbside on F Street
#5 - Orange	Sheraton San Diego Hotel & Marina	Curbside Harbor Island Drive for Marina Tower and Bay Tower
	Hilton San Diego Harbor Island	Curbside Harbor Island Drive

HOTEL INFORMATION

	Hotel	Address	Fitness Center	Restaurant	Room Service	Miles To Convention Center
1	Andaz San Diego	600 F Street	✚	✚	✚	0.70
2	Courtyard by Marriott San Diego Downtown	530 Broadway	✚	✚	✚	0.80
3	Courtyard San Diego Gaslamp/Convention Center	453 6th Avenue	✚	✚		0.30
4	DoubleTree San Diego Downtown	1646 Front Street	✚	✚	✚	1.00
5	Embassy Suites San Diego Bay Downtown	601 Pacific Highway	✚	✚	✚	0.40
6	Four Points by Sheraton San Diego Downtown	1617 1st Avenue	✚	✚	✚	1.00
7	Hampton Inn San Diego Downtown	1531 Pacific Highway	✚			2.00
8	Hard Rock Hotel San Diego	207 5th Avenue	✚	✚	✚	0.10
9	Hilton Garden Inn San Diego Downtown/Bayside	2137 Pacific Highway	✚	✚	✚	2.00
10	Hilton San Diego Airport/Harbor Island	1960 Harbor Island Drive	✚	✚	✚	5.00
11	Hilton San Diego Bayfront	One Park Boulevard	✚	✚	✚	0.00
12	Hilton San Diego Gaslamp Quarter Hotel	401 K Street	✚	✚	✚	0.10
13	Homewood Suites by Hilton San Diego Downtown/Bayside	2137 Pacific Highway	✚	✚	✚	2.00
14	Horton Grand Hotel	311 Island Avenue		✚	✚	0.30
15	Hotel Solamar, A Kimpton Hotel	435 6th Avenue	✚	✚	✚	0.30
16	Manchester Grand Hyatt San Diego - Co-Headquarters Hotel	One Market Place	✚	✚	✚	0.30
17	Marriott Marquis San Diego Marina - Co-Headquarters Hotel	333 West Harbor Drive	✚	✚	✚	0.00
18	Omni San Diego Hotel	675 L Street	✚	✚	✚	0.20
19	Pendry San Diego	550 J Street	✚	✚	✚	0.30
20	Renaissance San Diego Downtown	421 West B Street	✚	✚	✚	0.90
21	Residence Inn San Diego Downtown	1747 Pacific Highway	✚	✚		1.00
22	Residence Inn San Diego Downtown/Bayfront	900 Bayfront Court	✚			2.00
23	Residence Inn San Diego Downtown/Gaslamp Quarter	356 6th Avenue	✚			0.20
24	San Diego Marriott Gaslamp Quarter	660 K Street	✚		✚	0.20
25	Sheraton San Diego Hotel & Marina	1380 Harbor Island Drive	✚	✚	✚	4.00
26	Sofia Hotel, The	150 West Broadway	✚	✚		0.70
27	SpringHill Suites San Diego Downtown/Bayfront	900 Bayfront Court	✚			2.00
28	US GRANT, a Luxury Collection Hotel	326 Broadway	✚	✚	✚	0.70
29	Westgate Hotel San Diego	1055 2nd Avenue	✚	✚	✚	0.70
30	Westin San Diego	400 W Broadway	✚	✚	✚	0.90
31	Westin San Diego Gaslamp Quarter	910 Broadway Circle	✚	✚	✚	0.50
32	Wyndham San Diego Bayside	1355 North Harbor Drive	✚	✚	✚	1.50

All hotels have high-speed internet available, and are non-smoking properties.


SAN DIEGO INTERNATIONAL AIRPORT
GRAPE STREET PIER
EMBARCADERO
HARBOR DR.
LITTLE ITALY
GRAPE ST.
FIR ST.
ELM
ELM ST.
DATE ST.
CEDAR ST.
BEECH ST.
ASH ST.
PACIFIC HWY.
KETTNER BLVD.
INDIA ST.
COLUMBIA ST.
STATE ST.
UNION ST.
FRONT ST.
A ST.
B ST.
C ST.
10TH AVE.
11TH AVE.
BALBOA PARK
CRUISE SHIP TERMINAL
SANTA FE TRAIN DEPOT
BROADWAY PIER
USS MIDWAY
E ST.
F ST.
G ST.
1ST AVE.
2ND AVE.
3RD AVE.
4TH AVE.
5TH AVE.
6TH AVE.
7TH AVE.
8TH AVE.
9TH AVE.
BROADWAY
MARKET ST
ISLAND AVE
HORTON PLAZA
GASLAMP QUARTER
THE HEADQUARTERS
SEAPORT VILLAGE
J ST.
K ST.
L ST.
PETCO PARK
PARK BLVD.
SAN DIEGO CONVENTION CENTER
CONVENTION WAY
EMBARCADERO MARINA PARK NORTH
EMBARCADERO MARINA PARK SOUTH
FERRY LANDING
DOWNTOWN SAN DIEGO
COASTER/AMTRAK LINE
MTS/SAN DIEGO TROLLEY LINE
INTERNATIONAL VISITOR INFO. CENTER

2017 SUPPORTERS

AACC thanks the following companies for their generous support in 2017.

As of June 2, 2017

ANNUAL MEETING ORGANIZING COMMITTEE

Chair
Stanley Lo, PhD, DABCC, FACB
Children's Hospital of Wisconsin
Medical College of Wisconsin
Milwaukee, WI

Vice Chairs
Nathalie Lepage, PhD
Children's Hospital of E. Ontario
Ottawa, ON, Canada

Gary Myers, PhD, FACB
Myers Consulting
Smyrna, GA

Plenary/Meet the Expert Coordinator
Ann Gronowski, PhD, DABCC
Washington University School of Medicine
St. Louis, MO

Short Course Coordinators
Kara Lynch, PhD, DABCC, FACB
University of California, San Francisco
San Francisco, CA

Mark Marzinke, PhD, DABCC
Johns Hopkins University
Baltimore, MD

Brown Bag Coordinator
Joely Straseski, PhD, DABCC, FACB, MT(ASCP)
University of Utah & ARUP Laboratories
Salt Lake City, UT

Symposium Coordinators
Gary Horowitz, MD
Department of Pathology and Laboratory Medicine, Tufts Medical Center
Boston, MA

Shannon Haymond, PhD, DABCC
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

Abstract Coordinators
Paul Yip, PhD, DABCC
University Health Network
Toronto, ON, Canada

Christina Lockwood, PhD, DABCC
University of Washington
Seattle, WA

Scientific Session Coordinator
Robert Fitzgerald, PhD, DABCC, FACB, NRCC
University of California, San Diego
San Diego, CA

2017 BOARD OF DIRECTORS

PRESIDENT
Michael J. Bennett, PhD, DABCC, FACB
Children's Hospital of Philadelphia,
Philadelphia, PA

PRESIDENT-ELECT
Dennis J. Dietzen, PhD, DABCC
Washington University, St. Louis, MO

PAST PRESIDENT
Patricia M. Jones, PhD
Children's Medical Center, Dallas, TX

TREASURER
Corinne Fantz, PhD, DABCC, FACB
Roche Diagnostics, Indianapolis, IN

SECRETARY
Anthony A. Killeen, MD, PhD
University of Minnesota, Minneapolis, MN

Lorin Bachmann, PhD
Virginia Commonwealth University Health,
Richmond, VA

Linnea M. Baudhuin, PhD, DABMG
Mayo Clinic, Rochester, MN

William Clarke, PhD, MBA, DABCC
Johns Hopkins University School of
Medicine, Baltimore, MD

Paul J. Jannetto, PhD, DABCC, FACB, MT(ASCP)
Mayo Clinic, Rochester, MN

Stephen R. Master, MD, PhD
Weill Cornell Medicine, New York, NY

Carmen L. Wiley, PhD, DABCC
Roche Diagnostics, Indianapolis, IN

CHAIR OF AACC ACADEMY COUNCIL (EX OFFICIO)
James C. Ritchie, PhD, DABCC, FACB
Emory University Hospital, Atlanta, GA

CHAIR OF CLINICAL LABORATORY SCIENTISTS COUNCIL (EX-OFFICIO)
Steven J. Zibrat, MS, MT(ASCP)
University of Chicago Medical Center, Chicago, IL

CEO (EX-OFFICIO)
Janet Kreizman
AACC, Washington, DC

GOVERNANCE & SPECIAL EVENTS

SATURDAY JULY 29		Marriott Marquis San Diego Marina	Manchester Grand Hyatt	Location
7:00am - 2:00pm	CACB Oral Exams		■	Hillcrest D
8:00am - 5:00pm	CSCC Council Meeting		■	Torrey Hills
Noon - 4:00pm	CACB Board of Directors Meeting		■	Mission Beach B
1:00pm - 4:00pm	Management Sciences & Patient Safety Division Executive Committee Meeting		■	Hillcrest C
1:00pm - 5:30pm	SYCL Workshop: Developing an Influential Leadership Role for Laboratory Professionals	■		Marina Ballroom Salon E
5:30pm - 8:30pm	22nd Annual Management Sciences & Patient Safety Leadership Seminar		■	Hillcrest A
6:00pm - 8:00pm	SYCL Mixer: Anchors Aweigh	■		Coronado/Coronado Terrace
SUNDAY JULY 30				
7:00am - 12:30pm	CACB Oral Exams		■	Hillcrest D
7:30am - 9:00am	CSCC Annual Meetings Committee Meeting		■	Cortez Hill A
	CSCC Pediatric Focus Group Meeting		■	Cortez Hill B
	CSCC Quality Management Working Group		■	Cortez Hill C
9:30am - 11:30am	Critical and Point-of-Care Division Executive Committee Meeting	■		Del Mar
11:00am - 6:00pm	AACC Philadelphia Local Section Mini-Symposium: Current Topics in Lab Medicine	■		Marina Ballroom Salon G
Noon - 2:30pm	NGSP Steering Committee Meeting	■		Cardiff
Noon - 4:30pm	GLQI Mini-Workshop: Adding Value to Patient Care Using Quality Control	■		Marina Ballroom Salon E
6:45pm - 8:00pm	AACC Community Opening Mixer	■		Marriott Grand Ballroom
7:30pm - 9:00pm	Pediatric and Maternal-Fetal, Industry, Informatics & Clinical Translational Science Divisions Joint Mixer	■		Mission Hills
7:45pm - 10:30pm	AACC Awards Recognition Dinner	■		Presidio
MONDAY JULY 31				
6:30am - 8:00am	Ohio Valley/Northwest Ohio/Michigan Local Sections Breakfast		■	Balboa A
7:00am - 8:30am	AACC Southeast Local Section Breakfast & Business Meeting	■		Presidio
7:00am - 9:00am	Tumor Markers & Cancer Diagnostics Inaugural Lecture	■		Santa Rosa
7:30am - 9:00am	CSCC Quality Management Working Group		■	Cortez Hill A
7:30am - 10:30am	CSCC CALIPER Breakfast		■	Balboa C
8:00am - Noon	American Board of Clinical Chemistry Board Meeting	■		Cardiff
Noon - 1:30pm	NGSP IFCC Manufacturer Forum	■		Marriott Grand Ballroom Sect. 4
	Biomarkers of Acute Cardiovascular Diseases Division Lunch Meeting	■		Miramar
	IFCC Working Group PTH	■		La Costa
Noon - 2:00pm	Molecular Pathology Division Poster Award Viewing Session	■		Marina Ballroom Salon E
	TDM & Toxicology Division Membership Meeting & Luncheon	■		Mission Hills
	Endocrinology Division Annual Luncheon & Mixer	■		Palomar
Noon - 2:30pm	Clinical Translational Science Division Lunch & Learn	■		Marriott Grand Ballroom Sect. 10
1:00pm - 2:00pm	Student Oral Presentation Contest			SDCC Room 6D/6E
1:00pm - 3:00pm	Industry Division Membership Meeting	■		Catalina
2:15pm - 3:30pm	Student Poster Contest			SDCC Room 6C/6F
5:30pm - 6:30pm	LVD Division Membership Reception & Poster Viewing	■		Marina Ballroom Salon G
5:30pm - 7:00pm	Clinical & Lab Standards Institute Reception	■		Leucadia
	CLSI Member Open House	■		Del Mar
6:15pm - 7:45pm	ABCC-SYCL Joint Reception	■		Presidio
6:30pm - 9:30pm	LVD Division Dinner Lectures & Awards	■		Marina Ballroom Salon F

TUESDAY AUGUST 1

		Marriott Marquis San Diego Marina	Manchester Grand Hyatt	Location
7:00am - 8:30am	AACC's Asia-Pacific Working Group Meeting	■		Malibu
7:00am - 9:00am	AdvaMedDx Leadership Views on Diagnostics	■		Cardiff/Carlsbad
	AACC Capital Local Section Breakfast	■		Mission Hills
7:00am - 9:30am	CACB Maintenance of Competence Committee		■	Cortez Hill B
7:00am - 10:00am	ComACC Program Directors' Breakfast Meeting	■		Leucadia
7:30am - 9:00am	CSCC Promotion Committee Meeting (EPOCC)		■	Cortez Hill A
9:00am - 11:00am	Division of Animal Clinical Chemistry General Business Meeting		■	Mission Beach C
11:00am - Noon	Molecular Pathology Division Board Meeting	■		Del Mar
11:00am - 3:00pm	History Division & Membership Meeting	■		Laguna
11:30am - 3:00pm	Informatics Division Membership Meeting & Luncheon	■		Santa Rosa
Noon - 1:30pm	Joint Personalized Medicine & Molecular Pathology Division Luncheon & Awards Presentation	■		Marina Ballroom Salon E
12:30pm - 2:30pm	AACC New Jersey Local Section Meeting	■		Encinitas
	CSCC CLB Editorial Board Meeting		■	Balboa BC
12:30pm - 3:00pm	Division of Animal Clinical Chemistry Lunch & Learn		■	Solana Beach AB
1:30pm - 2:00pm	Personalized Medicine Division Board Meeting	■		Marina Ballroom Salon E
2:00pm - 4:00pm	AACC's Latin American Working Group Business Meeting	■		Malibu
4:30pm - 6:30pm	CSCC "Canada Party" Reception		■	Gaslamp A-D
	AACC Midwest Local Section Mixer	■		Miramar
5:00pm - 7:00pm	CLSI U.S. Tag Meeting	■		Mission Hills
5:30pm - 6:30pm	LVD Division Executive Committee Meeting	■		Dana Point
5:30pm - 7:00pm	Clinical Diagnostic Immunology and Hematology/Coagulation Divisions Joint Mixer	■		Santa Rosa
5:30pm - 7:30pm	Washington University School of Medicine Alumni Reception	■		Presidio
5:30pm - 8:00pm	Laboratory Diagnoses and Therapeutic Monitoring of Patients with Bleeding Disorders: Avoiding Pitfalls... Enhancing Care	■		Marina Ballroom Salon D
6:00pm - 7:30pm	CPOCT Division Business Meeting & Mixer	■		Marriott Grand Ballroom Sect. 10 & 11
	University of Toronto Alumni & Friends Reception		■	Mission Beach B
	CDC Standardization Forum	■		Point Loma/Solana
6:00pm - 9:30pm	Nutrition Division Networking Seminar	■		Catalina
7:00pm - 11:00pm	MS3 Division Mass Spectacular Party	■		Marina Ballroom Salon E
7:30pm - 10:30pm	CPOCT Division Afterglow	■		Marriott Grand Ballroom Sections 10 & 11

WEDNESDAY AUGUST 2

7:00am - 9:00am	NGSP C-peptide/Insulin Standardization Manufacturer Meeting	■		Catalina
	CACB Oral Exams		■	Hillcrest D
	IFCC CPD Executive Meeting	■		Cardiff
7:30am - 9:00am	CSCC Monoclonal Gammopathy Interest Group Meeting		■	Bankers Hill
	CACB Training Program Accreditation Committee Meeting		■	Cortez Hill A
	CSCC Point-of-Care Testing Interest Group		■	HIllcrest D
Noon - 1:30pm	CSCC Lunch			SDCC Room 6C/D
Noon - 2:00pm	CSCC AGM Luncheon & Awards Presentation		■	Balboa A-C
12:15pm - 1:45pm	AACC Rocky Mountain Local Section Business Meeting	■		Mission Hills
Noon - 2:00pm	AACC Academy (formerly NACB) Membership Meeting & Luncheon	■		Marina Ballroom Salon D
5:30pm - 7:30pm	Winning Organization-Wide Support for Laboratory Proposed Acquisitions	■		Marina Ballroom Salon D

THURSDAY AUGUST 3

7:00am - 9:00am	CACB First Board of Directors Meeting		■	Cortez Hill A
	CSCC First Council Meeting		■	Cortez Hill B
7:30am - 10:00am	15th Annual Point-of-Care Coordinators Forum			SDCC Room 31AC
Noon - 1:30pm	IFCC Task Force on Clinical Application of Cardiac Bio-Markers	■		Catalina

If no location is specified, the session will take place at the San Diego Convention Center.

SCIENTIFIC POSTER SESSIONS

TUESDAY AUGUST 1

9:30pm - 5:00pm

Cancer/Tumor Markers	A-001 – A-063
Cardiac Markers	A-064 – A-099
Clinical Studies/Outcomes	A-100 – A-153
Endocrinology/Hormones	A-154 – A-223
Factors Affecting Test Results	A-224 – A-280
Hematology/Coagulation	A-281 – A-330
Immunology	A-331 – A-385
Mass Spectrometry Applications	A-386 – A-446

WEDNESDAY AUGUST 2

9:30pm - 5:00pm

Nutrition/Trace Metals/Vitamins	B-001 – B-028
Animal Clinical Chemistry	B-029 – B-033
Automation/Computer Applications	B-034 – B-056
Electrolytes/Blood Gas/Metabolites	B-057 – B-076
Infectious Disease	B-077 – B-157
Lipids/Lipoproteins	B-158 – B-186
Management	B-187 – B-231
Molecular Pathology/Probes	B-232 – B-272
Pediatric/Fetal Clinical Chemistry	B-273 – B-299
Point-of-Care Testing	B-300 – B-353
Proteins/Enzymes	B-354 – B-385
TDM/Toxicology/DAU	B-386 – B-438
Technology/Design Development	B-439 – B-478

Posters of accepted abstracts can be viewed in the Sails Pavilion of the San Diego Convention Center, on Tuesday, August 1 and Wednesday, August 2. All posters will be displayed from 9:30am until 5:00pm. Presenting authors for all posters will be in attendance from 12:30pm until 1:30pm. Please refer to the onsite *Abstracts Title Guide* for a complete schedule of posters.

DIVISION POSTER WALKS

Led by AACC Division subject matter experts, the walks highlight posters selected by the division for further discussion. Poster walks are free, limited to about 20-30 participants, and last about 30-minutes. Participants must have a full or daily conference registration and are asked to line up next to the tour signs outside the entrance to the poster display. Tours will leave at the following times.

TUESDAY AUGUST 1

12:30pm - 1:30pm

DIVISION	TOUR LEADER
Biomarkers of Acute Cardiovascular Disease	Alan Wu
Clinical and Diagnostic Immunology	Maria A. Willrich
Clinical Translational Science	Zhen Zhao, Vincent Ricchiuti and Octavia Palmer
Endocrinology	Bill Winter
Mass Spectrometry and Separation Sciences	Frederick Strathmann
Hematology and Coagulation	John V. Mitsios
Nutrition	Elizabeth Frank
Tumor Markers and Cancer Diagnostics	Joshua Hayden

WEDNESDAY AUGUST 2

12:30pm - 1:30pm

DIVISION	TOUR LEADER
Critical and Point-of-Care Testing	Scott Isbell
Informatics	Chris McCudden
Management Sciences and Patient Safety	Christine Schmotzer
Pediatric and Maternal Fetal	Mark Kellogg





ALL POSTERS ARE LOCATED IN THE SAILS PAVILION OF THE SAN DIEGO CONVENTION CENTER

AACC STUDENT POSTER CONTEST

THE AACC STUDENT POSTER CONTEST SHOWCASES AACC'S FINEST YOUNG SCIENTISTS. THE CONTEST CONSISTS OF TWO SESSIONS. THE FIRST HALF IS AN ORAL COMPETITION WITH FOUR STUDENTS PRESENTING THEIR WORK.

A panel of judges will rate the presentations on the basis of scientific content, originality/novelty, and presentation (including slide appearance, verbal presentation, style and clarity). Four awards will be given: first place, second place, and two honorable mentions.

The second session of the competition consists of poster presentations. Over 70 posters will be displayed and reviewed. Judges will evaluate each poster individually in timed rounds. Student presenters are rated on their ability to convey their work concisely. Posters are scored on scientific merit and oral and visual presentation. Four awards will be given: first place, second place, and two honorable mentions.

MONDAY, JULY 31
San Diego Convention Center

ORAL PRESENTATIONS
1:00pm - 2:00pm
Room 6D/6E

POSTER PRESENTATIONS
2:15pm - 3:30pm
Room 6C/6F

AACC ORAL PRESENTATIONS

Predicting Drug Exposure in Breast-Feeding Infants: Using Physiologically-Based Pharmacokinetic Modeling of Escitalopram in Breast Milk to Simulate Infant Plasma Concentrations
Sarah Delaney, University of Toronto, Toronto, ON, Canada

Fulvestrant Interference with Six Automated Estradiol Immunoassays and an LC-MS/MS Method: An Analytical and Clinical Investigation
Carmen Gherasim, University of Utah, Salt Lake City, UT

Breaking Free From the Ratio: Analytical Performance of an Immunoenrichment-Coupled MALDI-TOF MS Detection Method for Monoclonal Immunoglobulin Free Light Chains
Lusia Sepiashvili, Mayo Clinic, Rochester, MN

Frequency of Instrument, Environment, and Laboratory Technologist Contamination During Routine Diagnostic Testing of Infectious Specimens
Melanie Yarbrough, Washington University School of Medicine, St. Louis, MO

2017 STUDENT POSTER PRESENTERS

A-002 Lawson Ekpe
Diagnostic Significance of Plasma and Ascitic Fluid Cholesterol, Albumin, Protein, and Serum Ascites Ascites Gradient (Saag) in Differentiating Malignant from Cirrhotic Ascite

A-010 Rongxue Peng
A Novel Biomimetic Reference Material for ctDNA

A-018 Claire Knezevic
Development of Multiplexed Mass Spectrometry-based Assays for Urine Biomarkers of Aggressive Prostate Cancer

A-019 Patrick Erdman
Validation of the Ella™ Chromogranin A (CgA) Immunoassay

A-033 Felix Leung
A Biomarker Discovery Platform for Non-serous Ovarian Cancers Using Integrative Proteomics

A-035 Yu-Ping Yang
A Novel Bioluminescence/Fluorescence Platform for Rapid Detection and Post-detection Analysis of Circulating Tumor Cells

A-036 Mi Soon Han
Expression of miRNAs Disregulated by Human Papilloma Virus 16 E5, E6, E7 Oncoproteins in Cervical Carcinogenesis

A-048 Joseph Annunziata
Clinical Significance of Pancreatic Cyst Fluid CEA Level

A-059 Liyun Cao
Genetic Variants in the Vascular Endothelial Growth Factor Pathway as Potential Markers of Ovarian Cancer Risk, Therapeutic Response, and Clinical Outcome

A-062 Ventzi Hristova
The Potential for Ubiquitin Occupancy Profiles in Cancer Biomarker Screening

A-076 Fatemeh Fouladkou
Dietary Biotin Causes a Negative Interference for Troponin in the Advia Centaur Assay

A-095 Xander van Wijk
Evaluation of Free and Complex Cardiac Troponin I in Serial Samples of MI Patients

A-101 Saadet Celik
Comparison of Neutrophil/Lymphocyte Ratio & Red Blood Cell Distribution Width with Cardiac Markers in Acute Coronary Syndrome

A-111 John Hoon Rim
Effects of Laboratory Results and Lifestyle Parameters on the Development of Non-alcoholic Fatty Liver Disease: The Korean National Health Insurance Service-National Sample Cohort 2009-2013

A-159 Zainab Ibrahim
Adrenocortical Dysfunction Among HIV Infected Patients: Correlation Between Duration of Haart and Development of Dysfunction

A-161 Prashant Regmi
Assessment Of Thyroid Disorders In Rheumatoid Arthritis Patients

A-164 Sunkeshari Deshar
Serum Leptin Level In Hypothalamic Amenorrhea

A-193 Aastha Chauhan
Retrospective Analysis of the Utility of Anti-Thyroglobulin Antibody Testing to Assess Thyroid Autoimmunity

A-198 Carmen Gherasim
Fulvestrant Interference with Six Automated Estradiol Immunoassays and an LC-MS/MS Method: An Analytical and Clinical Investigation

A-200 Jessica Gifford
A High-throughput Test for Diabetes Care: An Evaluation of the Next Generation Roche cobas c 513 Hemoglobin A1c Assay

A-213 Danting Liu
RNase L is Involved in Glucose Homeostasis and Insulin Resistance

A-251 Sydney Strickland
Recognition of Rare Hemoglobin Variants During Hemoglobin A1c Analysis by Capillary Electrophoresis

A-252 Joesph Wiencek
Effect of Seasonal Temperature on Specimens Stored Outside in Courier Lock Boxes

A-255 DeLu (Tyler) Yin
Comparison of Electrophoretic Systems to Detect Occult IgA Monoclonal Immunoglobulins

A-259 Victoria Higgins
National Survey of Adult and Pediatric Reference Intervals in Clinical Laboratories across Canada: A Report of the CSCC Working Group on Reference Interval Harmonization

A-261 Yun Wang
Correction of Lactate Dehydrogenase and Potassium Values of Hemolyzed Specimens

A-263 Yifei Yang
Between-generation Hemoglobin A1 Discrepancies for the Roche Tina-quant Assay

A-267 Po-Hsin Lai
Assessment of Body Fluid Testing Requests and Validation of Methods on the VITROS® 5600

A-281 Sandeep Thapa
Spectrum of Mutations in Hbb Gene Among Thalassemia Major Patients in a Cohort of Nepalese Population

A-335 Maryam Salehi
Investigating the Regulatory Role of a Negative Checkpoint Molecule, VISTA in Endothelial Cells

2017 STUDENT POSTER PRESENTERS

A-341 Lusia Sepiashvili
Breaking Free from the Ratio: Analytical Performance of an Immunoenrichment-Coupled MALDI-TOF MS Detection Method for Monoclonal Immunoglobulin Free Light Chains

A-342 Jonathan Brestoff
Diagnosis of Red Meat Allergy with Antigen-Specific IgE Tests In Serum

A-351 Talent Theparee
Adjusted Serum Free Light Chain Reference Ranges on the SPAPlus Platform

A-372 Stacy Kenyon
Assessing the Laboratory Protocol for the Hevylite® Assay on a Multiple Myeloma Patient Cohort

A-381 Nansy Albtoush
TSG-6 Neutralizing Monoclonal Antibodies (MAb) as a Potential Therapeutics for Asthma Treatment

A-382 Kendall Cradic
Comparison of Fecal Lactoferrin and Calprotectin as Screening Markers of Inflammatory Bowel Disease

A-389 Emma Dewar
Development of an LC-MS/MS Method for Biomarkers of Alcohol Ingestion for Use with Post-Mortem Samples

A-422 Yufei Wang
Determination of Serum Progesterone by Isotope Dilution Liquid Chromatography Tandem Mass Spectrometry: A Modification of JCTLM Approved Reference Measurement Procedure

A-426 Siaw Li Chan
Development of a Novel, High-sensitivity LC-MS/MS Serotonin Assay for Assessing Platelet Function Using a Minimal Amount of Whole Blood

A-430 Brittany Carroll
Simultaneous Measurement of ThioTEPA and its Metabolite TEPA in Serum and CSF by Turbulent Flow LC-MS/MS

A-451 Yicong Yin
Analysis of Serum Uric Acid Level and the Prevalence of Hypouricemia </B><B>Based on a Multicenter Study In Chinese Population

A-456 M Prasad
Association of 25 OH-Vitamin D and hsCRP in Adults with Essential Hypertension

A-457 Eworo Ekong
Seminal Plasma Total Antioxidant Capacity (Tac), Magnesium and Calcium Levels of Infertile Men

B-001 Lizette Rios
Antidiabetic Activity of Aqueous Kalanchoe pinnata Preparation: Potential Mechanism of Action

B-024 Mitchell McGill
Changes in Laboratory Testing Turnaround Times at a Major Academic Medical Center After Converting to a Total Laboratory Automation System for Chemistry and Hematology

B-034 Bingqing Han
Determination of Serum Calcium Levels by 42 Ca Isotope Dilution Inductively Coupled Plasma Mass Spectrometry

B-045 Michelle Parker
Validation of Spinal Fluid Lactate Measurements and Effect of HIL Interferences Using the Abbott ARCHITECT Plasma Lactic Acid Assay

B-047 Dorothy Truong
Increased Disialotransferrin Evident with Chronic Alcohol Consumption

B-072 Ticiane Santa Rita
Automated and Laboratory Information System Integrated Workflow for Simultaneous Detection of Zika, Chikungunya and Dengue Viruses by RT-qPCR in EDTA-plasma, Urine and Seminal-Plasma: A Unique and Comprehensive Test Routine for Brazilian Arboviral Threats

B-092 Melanie Yarbrough
Frequency of Instrument, Environment, and Laboratory Technologist Contamination During Routine Diagnostic Testing of Infectious Specimens

B-143 Tianqi Qi
Comparability of Commercial Assays & Commutability of Evaluated Materials for Apolipoprotein A1 Measurement

B-153 Ruhan Wei
RNASE L Regulates the Expression of Fatty Acid Synthase in The Mouse Liver

B-154 Stephen Roper
The Performance of Calculated and Directly-Measured Low Density Lipoprotein Cholesterol in a Pediatric Population

B-158 Gabriel Lima-Oliveira
Only Fresh Samples Should Be Allowed for Lipid Profile Evaluation

B-166 Yuzhu Huang
Summary and Analysis of Six Years' Blood Pb Internal Quality Control Practice in China

B-194 Gabrielle Winston-McPherson
Failure to Retrieve: A Follow Up Study on Unacknowledged Send-out Results

B-204 Moustafa Ahmed
SHOX2 and SEP9 Genes Hypermethylation as Biomarkers for Plasma-based Discrimination Between Malignant and Nonmalignant Colorectal Lesions

B-224 Sean Campbell
Minimal Residual Disease Monitoring in AML by RT-qPCR of NPM1 mutations

B-239 Antony Campos-Salazar
Polymorphisms on MTOR and FOXP3 Genes are Associated with Impaired Renal Function at One-Year Post-Transplant In Kidney Recipients

B-243 Tiyash Bose
Electrochemically Modified Sensitive Nitric Oxide Sensors for Detecting Nitric Oxide at the Level of Single Cells.

B-247 Alicia Andrews
Heads Up! Fetal Scalp Lactate Misclassification Error Rates Based on Simulation Modelling for the Lactate Pro Meter

B-251 Mahesheema Ali
Comparison of Two Automated Immunoassays for Progesterone to Mass Spectrometry to Aid in the In Vitro Fertilization Setting

B-253 Lisa Johnson
Comparison of LeadCare Ultra® to ICP-MS as an Initial Screen for Blood Lead Levels

B-265 Nicole White-Al Habeeb
Verification of CALIPER Pediatric Reference Intervals Using a Large Community Based Pediatric Population

B-279 Susan Aketch
Prevalence and Factors Associated with Diabetes Mellitus in Patients with Tuberculosis

B-286 Ian Gunsolus
Low pO2 Contributes to Potential Error in Oxygen Saturation Calculations Using a Point-of-Care Assay

B-304 Yaling Zhao
A Sensitive Multiplex Assay for High-Throughput Screening of Malaria Without Nucleic Acid Extraction

B-305 Daniella Jardim
qPCR Genotyping in Crude Serum Separated by Ultralow-cost, Portable and Hand-Powered Paper Centrifuge: Simplification of the Pre-analytic and Extraction Steps for a Future Molecular Point-of-Care Diagnostics

B-314 Albert Tsui
Comparison of Creatinine on the Alere Epoc Blood Analysis System Against Multiple Point-of-Care and Central Laboratory Assays

B-317 Michael Elias
Design and Testing of a Novel Point-of-Care (POC) Device to Convert Whole Blood to Serum at the Bedside for Medical Diagnostics

B-331 Norah Alghamdi
Role of RNase L in Kidney

B-352 Hao Wang
A mutation at Factor VII Protease Domain N-Glycosylation Site May Contribute to the Coagulation Disorder

B-359 Angela Fung
Evaluation of the Semi-Automated Electrochemiluminescence Immunoassay for Cyclosporine, Tacrolimus, and Sirolimus

B-367 Valentinas Gruzdys
Evaluation of Quantitative Microsampling for Immunosuppressant Drug Monitoring

B-381 Ashton Brock
Exploration of Ion Ratio Challenges with Routine THC GC-MS Confirmation Assays

B-385 Uvaraj Uddayasankar
Method Validations for Identification and Quantification of Fentanyl Analogs

B-395 Sarah Delaney
Predicting Drug Exposure in Breast-Feeding Infants: Using Physiologically-Based Pharmacokinetic Modeling of Escitalopram in Breast Milk to Simulate Infant Plasma Concentrations

B-397 Adam McShane
Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Assay for the Simultaneous Quantitation of 5 Azole Antifungals and 1 Active Metabolite

B-400 Karen Yannell
Automated Blood Sampling with Paper Spray Ionization Mass Spectrometry: Improving Workflow and the Safe Handling of Human Blood for Personalized Medicine and Clinical Trials

B-405 Terence Agbor
Pilot Study for determination of Infliximab Levels in Inflammatory Bowel Disease Patients

B-410 Yachana Kataria
A Comparison of Methods for Measurement of Plasma Methotrexate in a Pediatric Population

B-434 Ye Zhao
High-throughput, Multiplex Genotyping Directly from Saliva and Buccal Swabs Without DNA Purification

AACC ACADEMY HONORS NEW ACADEMY FELLOWS

AACC ACADEMY (FORMERLY NACB) IS PROUD TO ANNOUNCE NEW FELLOWS. AS MEMBERS OF THE ACADEMY, THESE DISTINGUISHED SCIENTISTS ARE ACCOMPLISHED DOCTORATE-LEVEL PROFESSIONALS WHO HAVE DEMONSTRATED DEDICATION TO ENHANCING THE SCHOLARSHIP AND PRACTICE OF LABORATORY MEDICINE.

New Fellows will be honored during the Academy awards luncheon on Wednesday, August 2 during the AACC Annual Scientific Meeting.

AACC Academy honors the achievements of its members, recognizes and advances excellence in the field of laboratory medicine, and develops the next generation of leaders. To learn more about the Academy and its activities, visit www.aacc.org.

JOIN THE CONVERSATION
Follow AACC @_AACC and use the hashtag #2017AACC to join the conversation.

ACADEMY FELLOWS ADMITTED SINCE JUNE 2016

Ronald Booth, PhD
Jing Cao, MD, PhD
Allison Chambliss, PhD
Ronald Henriquez, PhD
Roy Huchzermeier, PhD
Imir Metushi, PhD
Kent Mitchell, PhD
Shyamali Pal, PhD
Kushbu Patel, PhD
Matthew Petrie, MD
Steve Phagoo, PhD
Peela Rao, MD
Chamila Rupasinghe, PhD
Kristian Schafernak, MD
Joseph Sebastian, PhD
Rajeevan Selvaratnam, PhD
Preetpal, Sidhu, PhD
Kimia Sobhani, PhD
Sarah Wheeler, PhD
Sarina Yang, PhD

ASSOCIATE FELLOWS ADMITTED SINCE JUNE 2016

Bolonghoge Dayanath, PhD
Jayesh Warade, MD

AACC ACADEMY: 2017 DISTINGUISHED ABSTRACTS AWARDS

The AACC Academy is pleased to announce the winners of the 2017 Distinguished Abstracts Awards. A group of Fellows selected these 25 abstracts for their scientific excellence from a pool of 921 abstracts accepted for the AACC Annual Scientific Meeting. Winning abstracts will display the Academy blue ribbon during the poster sessions.

A-005 **Wenbin Jiang, Chongqing, China**
Methylation of KLF2 Associates With its Expression and Non-small Cell Lung Cancer Progression

A-012 **Chunni Zhang, Nanjing, China**
Clinical Implications and Multiple Antitumor Effects of miR-651 and miR-708 in Renal Cell Carcinoma

A-031 **Tracy Morrison, Toronto, ON, Canada**
Improved Detection of Hidden Beta-2 Monoclonal Proteins by Capillary Electrophoresis Using the Beta-2 to Beta-1 Ratio

A-055 **Brady Culver, Chapel Hill, NC**
Sensitive and Specific Detection of Variants in Circulating Tumor DNA by Anchored Multiplex PCR and Next-Generation Sequencing

A-075 **Karen Schulz, Minneapolis, MN**
Diagnostic Performance of High Sensitivity Cardiac Troponin I for the Diagnosis of Myocardial Infarction

A-118 **Shahram Shahangian, Atlanta, GA**
Prostate-Specific Antigen (PSA) Screening Rates in the United States, 2010-2015: Implications for Practice Interventions

A-165 **David Lin, Salt Lake City, UT**
Detection and Characterization of Serum Free Light Chains by MALDI-TOF MS in Immunofixation Thyroid-Related Testing Utilization: A Multi-Center Benchmark Study

A-183 **Zhimin Cao, Atlanta, GA**
Accuracy-Based Proficiency Testing for Testosterone Measurement—A Follow-up Study 2016

A-252 **Joseph Wiencek, Nashville, TN**
Effect of Seasonal Temperature on Specimens Stored Outside in Courier Lock Boxes

A-259 **Victoria Higgins, Ottawa, ON, Canada**
National Survey of Adult and Pediatric Reference Intervals in Clinical Laboratories Across Canada: A Report of the CSCC Working Group on Reference Interval Harmonization

A-341 **Lusia Sepiashvili, Rochester, MN**
Breaking Free from the Ratio: Analytical Performance of an Immunoenrichment-coupled MALDI-TOF MS Detection Method for Monoclonal Immunoglobulin Free Light Chains

A-349 **Roberta Alexander, Vista, CA**
Complement Activation in Systemic Lupus Erythematosus with Antiphospholipid Antibodies

A-377 **Kari Gurtner, Rochester, MN**
CSF Free Light Chain Identification of Demyelinating Disease: Overcoming Challenges of Oligoclonal Banding

A-403 **Jeffrey Whitman, San Francisco, CA**
Adapting High-Resolution Mass Spectrometry for Clinical Toxicology: Comparison and Optimization of SWATH to Data-dependent Acquisition for Drug Screening

A-404 **Lisa Ford, Boston, MA**
Analytical and Clinical Validation of a Novel Metabolite-based Serum Test to Precisely Determine the Glomerular Filtration Rate (GFR)

A-424 **Robert McCall, Winston-Salem, NC**
Identification of FLT3 Internal Tandem Duplications by Liquid Chromatography/Tandem Mass Spectrometry

A-426 **Siaw Li Chan, Houston, TX**
Development of a Novel, High-sensitivity LC-MS/MS Serotonin Assay for Assessing Platelet Function Using a Minimal Amount of Whole Blood

A-444 **Mindy Kohlhagen, Rochester, MN**
Making the Right Call: Distinguishing Residual M-proteins from Monoclonal Antibody Therapies Used in the Treatment of Multiple Myeloma

B-64 **Stacy Beal, Gainesville, FL**
Clinical Benefits of the FilmArray GI Panel in an Academic Medical Center

B-186 **John Yundt-Pacheco, Plano, TX**
Computing a Risk Management Index: Correlating a Quality Control Strategy to Patient Risk

B-188 **Kate Bernhardt, Maywood, IL**
Urinalysis with Reflex Culture—Test Utilization Initiative and Quality Improvement Model

B-204 **Moustafa Ahmed, Cairo, Egypt**
SHOX2 and SEP9 Genes Hypermethylation as Biomarkers for Plasma-based Discrimination Between Malignant and Nonmalignant Colorectal Lesions

B-214 **Fang Wu, Salt Lake City, UT**
Application of Matrix Assisted-Laser Desorption Ionization Time-of-Flight Mass Spectrometry for CYP2D6 Genotype and Copy Number Analysis

B-261 **Antonio Noto, Bari, Italy**
Urinary Metabolome in Autistic Children and in Their Unaffected Siblings: Preliminary Data on the Role of Oxidative Stress and Gut Dysbiosis

B-395 **Sarah Delaney, Toronto, ON, Canada**
Predicting Drug Exposure in Breast-Feeding Infants: Using Physiologically-based Pharmacokinetic Modeling of Escitalopram in Breast Milk to Simulate Infant Plasma Concentrations

SESSION INFORMATION

FACULTY DISCLOSURE INFORMATION

The AACC, in compliance with the ACCME Standards for Commercial Support, requires anyone who is in a position to control the content of an educational activity to disclose (or an immediate family member) has had a relevant financial relationship (within the last 12 months) with a commercial interest whose products/services may be related to or discussed in the activity.

Faculty members whose names are preceded by:

- **(*) An asterisk** – disclosed that they may have had a relevant financial relationship with a commercial interest within the last 12 months. These relationships were reviewed by the Annual Meeting Organizing Committee and conflicts of interest were resolved prior to the Annual Scientific Meeting.
- **(#) A pound sign** – disclosed that they have had no relevant financial relationships with a commercial interest within the past 12 months.
- **(+) A plus sign** – had not submitted a disclosure form at the time of printing.

Completed disclosure forms are on file in the AACC office, and a handout summarizing all faculty disclosure information is distributed to Annual Scientific Meeting attendees in their registration materials.

SESSION LEVEL CONTENT

Basic – Introductory content appropriate for participants who lack previous training or experience in the subject, or whose previous experience or training is minimal.

Intermediate – Requires knowledge of the basic theory applicable to the general subjects as well as some prior training and education in the subject.

Advanced – Specialized content appropriate for those with working knowledge of current theory and practices who wish to refine their skills or learn the newest principles and techniques.

SESSION CREDITS

Credit amounts displayed in this program guide are subject to change. For the most up-to-date information on credits available by session, check the mobile app or visit www.aacc.org/2017AM and select "Conference Program."

SESSION DESCRIPTIONS

All of the following sessions are open to conference registrants.

PLENARY SESSIONS

Designed for all levels, and featuring visionaries in clinical practice, research, business and policy.

SYMPOSIA SESSIONS

These sessions are presented by highly regarded speakers in traditional lecture format.

SHORT COURSES

These sessions offer in-depth learning about specific areas of clinical laboratory practice.

MEET THE EXPERT SESSIONS

Attendance limited to 75 participants per session.

These sessions are intense interactive discussions with plenary speakers.

CHAIR'S INVITED SESSION

The chair of the 2017 Annual Meeting Organizing Committee created this special session of particular importance to attendees. Details on page 41.

PRESIDENT'S INVITED SESSION

The AACC President has created this special session of particular importance to attendees. Details on page 40.

ORAL ABSTRACT PRESENTATIONS

Selected abstracts identified by the Annual Meeting Organizing Committee will be presented.

This year's meeting features several special sessions in innovative formats described below.

MOCK TRIAL – PRESENTING EXPERT TESTIMONY IN THE COURTROOM

A courtroom setting will be used to demonstrate the importance of expert witness testimony in resolving toxicology and clinical chemistry related litigation. Details on page 44.

LABORATORY MEDICINE FAMILY FEUD

Scientific topics will be covered using the Family Feud game show format, pitting AACC leadership against SYCL members. Details on page 65.

INFECTIOUS DISEASE QUIZ SHOW

Using a "Quiz Show" format, this case-based session will highlight enhancements in the diagnosis of infectious disease. Details on page 85.

FXP TOUCH

FXP TOUCH

AACC is excited to offer the second screen technology for audience response, FXP | touch, as a new resource for speakers and attendees. Innovative learning formats and new audience engagement technology will be featured in some Symposia and Short Course presentations. This system will allow attendees to easily ask questions and share thoughts during presentations using their mobile devices. Look for session with this symbol that will utilize this technology.

CONFERENCE RECORDING

The 69th AACC Annual Scientific Meeting will be recorded and access to the streaming content is available for purchase as an 11-month subscription that will commence in August 2017 and will close at the end of June 2018. The content is made available as streaming content only and is not available for download. The recording will include audio and presentation slides from most of the scientific sessions.

The recordings will be available approximately two weeks after the close of the meeting.

Price: $199 with registration or at the meeting/$299 after close of the meeting (August 3, 2017, 1:00pm PDT). To purchase, visit www.aacc.org/2017AM.

REGISTRATION TYPES & EVENTS

REGISTRATION TYPE	FULL CONFERENCE	GUEST/SPOUSE	DAILY	EXPO ONLY	NO REGISTRATION
EVENTS	- AACC Member - Non-member - Trainee/Student Member - Emeritus Member	Limit 1 per full registrant	Admission/tickets for day registered *only*	Expo only, Exhibit Hall	
Plenary Sessions 10000 Series	✔	✔	✔	✖	✖
Symposia 30000 Series	✔	✔	✔	✖	✖
Short Courses 70000 Series	✔	✔	✔	✖	✖
Meet the Experts 60000 Series	✔	✔	✔	✖	✖
AACC University 190000 Series T TICKET	$	$	$	$	$
Brown Bag Sessions 40000 Series morning 50000 Series afternoon T TICKET	$	$	$	$	$
Special Events T TICKET	$	$	$	$	$
AACC Community Opening Mixer Sunday, July 30	✔	✔	✔	✖	✖
Clinical Lab Expo Exhibit Hall, August 1 - 3	✔	✔	✔	✔	✖
Lunch Wednesday only, Exhibit Hall (Ticket included with registration)	✔	✔	✔	✔	✖
Poster Sessions Abstracts	✔	✔	✔	✖	✖
Industry Workshops	✔	✔	✔	✔	✖
OEM Lectures	✔	✔	✔	✔	✖

✔ Included with registration type T TICKET Ticket required $ May purchase ticket $ May NOT purchase ticket ✖ May NOT attend

AACC REGISTRATION RESOURCE CENTER

Access your handouts, obtain CE credit and get a copy of your receipt

1. **Open the Resource Center**
   Go to www.aacc.org/handouts **OR** Scan the QR code
2. **Login** – Enter the following to login:
   A. Badge Number: Listed on left side of badge
   B. Last Name: Exactly as entered when registering



SUNDAY JULY 30

PLENARY & EDUCATION SESSIONS

2017 WALLACE COULTER LECTURESHIP AWARD

PLENARY SESSION 11001
CRISPR BIOLOGY, TECHNOLOGY & ETHICS: THE FUTURE OF GENOME ENGINEERING

#JENNIFER DOUDNA, PhD
University of California Berkley
Berkley, CA

SUNDAY, JULY 30
5:00pm - 6:30pm
San Diego Convention Center - Ballroom 20
Level: Basic **CE Credit:** 1

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, molecular biologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: Facile genome manipulation, using precision DNA and RNA recognition, is transforming biology. This presentation will describe how the bacterial adaptive immune system, called CRISPR (which stands for clustered regularly interspaced short palindromic repeats), continues to inspire the development of powerful genome engineering tools. These tools are enabling advances in both fundamental biology and applications to the mammalian brain.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe CRISPR systems and how they work; 2) explain how CRISPR-Cas9 was harnessed as a gene editing technology; and 3) identify current and future applications of CRISPR technology in health and agriculture.

WALLACE H. COULTER LECTURESHIP AWARD

The Wallace H. Coulter Lectureship Award recognizes an outstanding individual who has demonstrated a lifetime commitment and made important contributions to laboratory medicine and patient care, significantly advanced education, practice or research.

This award honors Wallace H. Coulter, founder of Coulter Corporation and inventor of the Coulter Principle, a simple but elegant innovation that revolutionized hematology and the practice of laboratory medicine, pioneered the field of flow cytometry and defined particle characterization. AACC's most prestigious award—presented annually at the AACC Annual Scientific Meeting & Clinical Lab Expo—commemorates Coulter's outstanding contributions to diagnostics and his championship of research and innovation. It is fitting that his legacy will be celebrated with lectures by renowned leaders in healthcare.

2017 AACC AWARD WINNERS

To be presented during the Opening Plenary Session

Jennifer Doudna, PhD
University of California Berkeley
Wallace H. Coulter Lectureship Award

Susan Evans, PhD
BioDecisions Consulting
Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine

Larry Thomas Mimms, PhD
Prometheus Labs
The AACC Edwin F. Ullman Award for Technology Innovation

Eleftherios P. Diamandis, MD, PhD
Mount Sinai Hospital
Outstanding Contributions in Education

Ian Young, MD
Queens University Belfast
Outstanding Contributions Through Service to the Profession of Clinical Chemistry

Mark Marzinke, PhD
Johns Hopkins University
Outstanding Scientific Achievements by a Young Investigator

Patricia Jones, PhD
Children's Medical Center of Dallas
AACC Past President's Award

Supported by Abbott Diagnostics, BD and Siemens Healthineers

2017 AACC ACADEMY AWARD RECIPIENTS

Roland Valdes, PhD
University of Louisville
AACC Academy Professor Alvin Dubin Award for Outstanding Contributions to the Profession and the Academy

Roy Peake, PhD
Boston Children's Hospital
AACC Academy George Grannis Award for Excellence in Research and Scientific Publication

Jerry Katzmann, PhD
Mayo Clinic
AACC-AACC Academy Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research

Supported by Abbott Diagnostics, BD, and Siemens Healthineers

AACC UNIVERSITY 10:30AM - NOON

Guidance for Evaluating the Hypoxemic Patient in the Critical Care Setting

191001
San Diego Convention Center - 30ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
***John Toffaletti, PhD, DABCC**
Duke University Health System, Durham, NC

INTENDED AUDIENCE: Pathologists, clinicians, laboratorians, and industry scientists.

SESSION OVERVIEW: Despite the frequency of measurement and physiologic importance of oxygen, laboratorians are often not familiar with how pO2, %O2Hb, Hb and other measurements are used to calculate oxygen-related parameters, such as O2 content, O2 delivery, A-a difference, Pa02/Fi02 ratio, Oxygenation Index, and how the clinician uses them to evaluate and monitor hypoxemia, pulmonary ventilation, and perfusion in critically ill patients.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) outline the conformational changes of Hb alter its oxygen binding and releasing functions; 2) evaluate pO2 and sO2 (%O2Hb) measurements in patients breathing room air or oxygen supplemented air, and on ventilators and ECMO (extracorporeal membrane oxygenation); 3) develop skill in evaluating pO2, pCO2, and oxygen-related calculations for determining the adequacy of arterial oxygenation and ventilation by the lungs; 4) utilize blood gas and cooximetry results to calculate alveolar-arterial pO2 difference, pO2/FIO2 ratios, and evaluate pulmonary ventilation/perfusion (V/Q) balance; 5) list the potential pitfalls in handling samples for blood gas analysis; 6) explain how a clinician uses these oxygen and oxygen-related calculations to evaluate and monitor patients for possible hypoxemia and hypoxia in critical care settings; 7) list the situations when a clinician would request an arterial blood gas test; and 8) employ oxygen measurements and oxygen-related calculations in determining when a patient should be placed on nasal cannula, non-invasive ventilation, mechanical ventilation, or ECMO.

SPEAKERS

Providing Accurate Measurements of Oxygen and Oxygen-Related Parameters for Assessing Hypoxemia and Oxygen Physiology
*John Toffaletti, PhD, DABCC
Duke University Health System, Durham, NC

Clinical Use of Oxygen-Related Measurements and Calculations to Guide Patient Management
#Craig Rackley, MD, ABIM
Duke University Medical Center, Durham, NC

Trust, But Verify: Getting the Most Out of Verification Protocols for FDA Approved Methods

191002
San Diego Convention Center - 31ABC

Level: Basic
CE Credit: 1.5

MODERATOR
***Sten Westgard, MS**
Westgard QC, Inc., Madison, WI

INTENDED AUDIENCE: Laboratory directors, laboratory supervisors and managers, medical technologists, and laboratory technicians.

SESSION OVERVIEW: Laboratories cannot assume that all FDA-approved methods are acceptable for use in a clinical environment. Therefore, laboratories are responsible for verifying that approved methods perform "as advertised." However, laboratory staff may not have the requisite expertise or knowledge to perform verification studies. During this session, tools will be provided to enable attendees to identify how to implement and interpret the required verification studies performed when evaluating an approved method. The session will draw on both CLSI guidelines as well as assessment tools such as Sigma-metrics.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) establish clinically relevant performance goals for laboratory methods; 2) utilize CLSI guideline documents to verify method performance; 3) recognize and avoid common pitfalls encountered when performing verification studies; and 4) judge objectively the performance of an approved method and if an assay meets the required metrics for the provision of good patient care.

SPEAKERS

Setting Objective Goals for Analytical Performance and Selecting Methods That Can Meet Those Goals
*Sten Westgard, MS
Westgard QC, Inc., Madison, WI

CLSI Guidelines for Method Verification
#David Koch, PhD, DABCC
Grady Memorial Hospital & Emory University, Atlanta, GA

AACC UNIVERSITY 10:30AM - NOON

New External Programs for Laboratory Quality Assurance

191003
San Diego Convention Center - 29ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Keri Donaldson, MD
Penn State Milton S. Hershey Medical Center, Hershey, PA

INTENDED AUDIENCE: Laboratory directors, pathologists, clinical chemists, medical technologists/medical technicians, and IVD industry personnel.

SESSION OVERVIEW: The session will provide an overview of external quality assurance/proficiency testing programs from the CAP and review relevant CMS requirements and CAP checklists: 1) accuracy based grading PT surveys; 2) multiple instrument comparison (Quality Cross Checks) PT survey; and 3) applications of linearity validation and analytical measurement range for coagulation testing. In addition, the session will review CAP's experience and reporting procedures in these areas.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the new CAP and CMS requirements for quality assessment; 2) describe the importance of commutable PT samples; 3) discuss the importance of multiple instrument comparisons; 4) apply AMR validation and linearity to coagulation testing; and 5) implement an ongoing quality assessment program that meets the CMS and CAP guidelines.

SPEAKERS

CAP's Quality Cross Checks Program
#Keri Donaldson, MD
Penn State Milton S. Hershey Medical Center, Hershey, PA

PT Surveys for Coagulation Assays
*Charles Eby, MD
Washington University School of Medicine, St. Louis, MO

Accuracy Based PT Surveys
#Anthony Killeen, MD, PhD
University of Minnesota, Minneapolis, MN

Bridging the Gaps Between Laboratory Medicine and Clinical Decision Making: Challenges and Conundrums

FXP TOUCH

191004
San Diego Convention Center - 32AB

Level: Intermediate
CE Credit: 1.5

MODERATOR
***Andrew Don-Wauchope, MBBCh, BScMed(Hons), MD, FRCP Edin, FCPath(SA), FRCPath**
McMaster University, Toronto, ON, Canada

INTENDED AUDIENCE: Technologists, clinical chemists, laboratory director, and pathologists.

SESSION OVERVIEW: A mix of theory and case-based examples will illustrate the theory of standardization, concepts of traceability and uncertainty of measurement, and how to use external quality control to establish bias or accuracy. An overview of the different types of interferences that affect laboratory results and how the laboratory detects and deals with interferents will also be presented.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the concepts of traceability and uncertainty of measurement; 2) establish bias and accuracy; 3) determine the appropriate and inappropriate use of clinical cut-points and reference intervals; and 4) differentiate the different types of interferences in general chemistry and endocrine immunoassay testing and how these can be circumvented or investigated.

SPEAKERS

Clinical Cut-Points and Reference Intervals in the Clinical Laboratory: A Case Based Perspective of Issues in Clinical Practice
*Patrick Twomey, BSc, MBBCh, FRCPath, EurClinChem, FACB
St. Vincent's University Hospital, Dublin, Ireland

Standardization in the Clinical Laboratory: A Case Based Perspective of Why We Should Aim for Standardization
*Andrew Don-Wauchope, MBBCh, BScMed(Hons), MD, FRCP Edin, FCPath(SA), FRCPath, *McMaster University, Toronto, ON, Canada*

Investigation of Interferences in General Chemistry and Endocrine Testing
#Tahir Pillay, MD, PhD
University of Pretoria, Pretoria, Gauteng, South Africa

T TICKET Registration fees apply for each session.

AACC UNIVERSITY 10:30AM - NOON

Communicating Effectively When Facing Potential Conflict

TICKET

191005
San Diego Convention Center - 28DE

Level: Basic
CE Credit: 1.5

MODERATOR
#Cherie Petersen, BA
ARUP Laboratories, Salt Lake City, UT

INTENDED AUDIENCE: Laboratory directors, pathologists, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals who participate in patient care.

SESSION OVERVIEW: The work conducted by clinical laboratorians is critical in providing timely patient care. Due to the nature and high-pressure environment as members of the healthcare team, laboratory personnel may encounter conflicts both within and external to the laboratory. This session will detail a simple three-part strategy for managing communication situations where the potential for conflict exists. Session attendees will gain the tools to apply a successful communication strategy and facilitate satisfactory outcomes while avoiding conflict.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) utilize a simple strategy in conflict management and resolution; 2) apply the concepts of personal responsibility, showing vulnerability, and acting with humility when managing conflict; and 3) identify points of common agreement while creating a "safe" environment for addressing potential conflict.

SPEAKER
Communicating Effectively When Facing Potential Conflict
#Cherie Petersen, BA
ARUP Laboratories, Salt Lake City, UT

Making Your Core Lab Safe from Ebola and Zika

TICKET

191006
San Diego Convention Center - 28ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Bonny Van, PhD, FACB, HCLD(ABB)
LifeOmic, Indianapolis, IN

INTENDED AUDIENCE: Laboratory medicine physicians, laboratory directors, pathologists, clinical chemists, managers, supervisors, medical technologists, residents/fellows, and other healthcare professionals who participate in patient care.

SESSION OVERVIEW: Biosafety is an integral part of quality laboratory systems. The Association of Public Health Laboratories (APHL), in partnership with the CDC, is working with a forum of experts from the AACC, ASM, FDA, AAB, CAP, COLA, CMS and the Joint Commission, to provide tools and resources to strengthen biosafety practice in public health and clinical laboratories. The purpose of this session is to facilitate information exchange among clinical laboratory stakeholders to improve biosafety in the nation's clinical laboratories. The session will cover practices, policies, as well as gaps and training needs, with the overall objective of empowering participants to transfer and apply lessons learned to their home institutions.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) define the responsibilities of a biosafety officer; 2) identify resources to update biosafety guidelines and plans within their organization; 3) conduct a biosafety risk assessment to ensure that the lab can safely handle and dispose of highly infectious specimens; and 4) recognize the role of the public health-private clinical lab partnership to improve biosafety at both.

SPEAKERS
Assembling a Biosafety Toolkit to Keep Your Lab Safe
#Bonny Van, PhD, FACB, HCLD(ABB)
LifeOmic, Indianapolis, IN

State Public Health Laboratory as Resource for Biosafety
#Andrew C. Cannons, PhD, HCLD(ABB)
Bureau of Public Health Laboratories, Tampa, FL

Bad Bugs Don't Stay in the Micro Lab
*James Snyder, PhD, D(ABMM), F(AAM)
University of Louisville, Louisville, KY

AACC UNIVERSITY 1:30PM - 4:00PM

TICKET

The Essential Elements of a Point-of-Care Coordinator (POCC) Boot Camp

192007
San Diego Convention Center - 30ABC

Level: Basic
CE Credit: 2.5

MODERATOR
#Monica Thomas, MPA, CLS(ASCP)
Cedars-Sinai Medical Center,
West Hollywood, CA

Developed in cooperation with Critical and Point-of-Care Testing Division

INTENDED AUDIENCE: Point-of-care coordinators, medical technologists, lab managers/supervisors, pathologists, laboratory directors, clinical chemists, and IVD industry scientists who are involved with Point-of-Care Testing.

SESSION OVERVIEW The findings of a recent national survey show a demand for targeted point-of-care (POC) education and application of skills. This session will focus on important elements of communication and networking, device connectivity and operator training techniques, using interactive techniques and audience response.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list available resources for point-of-care (POC) coordinators; 2) demonstrate professional and diplomatic tips to enable POC operator coaching and checking; 3) outline implementation steps for connectivity and review troubleshooting strategies; and 4) describe competency assessment and training programs for operators and POC trainers.

SPEAKERS

Training and Competency: What Scares You About Training the Nurses? Simple Strategies and Processes May Help!
*Peggy Mann, MS, MT(ASCP)
University of Texas Medical Branch, Galveston, TX

Connectivity: Get Out the Tin Cans and String! Saving Your Sanity Using Connectivity for POCT
*Kerstin Halverson, MS
Children's Hospitals & Clinics, Minneapolis, MN

Policies and Procedures: It's Not OUR Fault That Nurses Won't Read Our SOPs! Tips for Making POC Documents User Friendly
#Lou Ann Wyer, MS, MT(ASCP), CQA(ASQ)
Sentara Healthcare, Norfolk, VA

Integrating Quality and Compliance into POCT: I Don't Know But I've Been Told, POC Programs Can Be SMART and BOLD
*Kimberly Skala, MT (ASCP)
Instrumentation Laboratory, Oak Lawn, IL

SPEAKER DISCLOSURE (*) (+) (#)

* Speakers whose names are preceded by an asterisk (*) have disclosed, in accordance with ACCME Standards and the policy of the AACC, that they have a relationship that, in the context of their presentation, could be perceived by some people as a real or potential conflict of interest (e.g., ownership of stock, research grants, or consulting fees). The speakers do not consider their presentations to be influenced by these relationships.

Speakers who disclose that they have no relationships that could be perceived as a conflict of interest are noted with a (#). Disclosure forms are on file in the AACC office.

+ Speakers who had not returned a disclosure form by the time of printing are noted with a (+).

All speakers will have completed forms prior to the start of the Annual Scientific Meeting. A detailed handout on speaker disclosure will be distributed at the Annual Scientific Meeting.

AACC UNIVERSITY 1:30PM - 4:00PM

TICKET

Laboratory Developed Tests—What's a Laboratory to Do?

FXP TOUCH

192008
San Diego Convention Center - 28ABC

Level: Intermediate
CE Credit: 2.5

MODERATOR
#J. Rex Astles, PhD, FACB
Centers for Disease Control and Prevention, Atlanta, GA

INTENDED AUDIENCE: Research and development scientists and anyone else who works to develop new test methods, whether in commercial entities or laboratories that create LDT methods The session is also appropriate for laboratory staff such as pathologists, laboratory directors, clinical chemists, medical technologists, and other laboratorians who implement manufactured test methods, regardless of whether the methods are commercial or LDTs.

SESSION OVERVIEW This session will explore concepts and guidelines for the development and validation of laboratory-developed tests (LDTs) using CLSI documents. The FDA's Quality System Regulations will be described as it applies to manufacturers including laboratories that create LDTs. The session content will reflect the status of the FDA's LDT proposed approach in 2017.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the various steps that occur during the "establishment" of a test method; 2) list the available guidelines for establishment; 3) describe the critical elements of assay validation; 4) explain how the same CLSI protocols that are used by commercial industry to produce reliable test methods are useful to clinical laboratories that develop them; 5) explain how checklists provided in EP19-A can help users document how they demonstrate acceptable evaluations during each step of establishment and implementation; 6) explain the importance of the FDA's Quality System Regulation; 7) explain the relevance of ISO standards to the LDT life cycle, including ISO 15189; and 8) explain how EP19-A,CLSI QSR Guidance, and ISO standards apply in specific scenarios.

SPEAKERS

Introduction to the Assay Lifecycle Model for Manufacturers and End-Users of Clinical Assays
#Paula Ladwig, MS, MT(ASCP)
Mayo Clinic, Rochester, MN

CLSI Practical Guide to FDA's Quality System Regulation for Laboratory Developed Tests
*Luann Ochs, MS
Clinical and Laboratory Standards Institute, Wayne, PA

The Role of ISO Standards in Laboratory Developed Tests
*Lucia Berte, MA, MT(ASCP)SBB,DLM; CQA(ASQ)CMQ/OE
Laboratories Made Better! P.C., Broomfield, CO

AACC UNIVERSITY 1:30PM - 4:00PM

Practical Integration of Clinical, Electrophoretic, and Molecular Features of Hemoglobin Disorders

192009
San Diego Convention Center - 28DE

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Jennifer Oliveira, MD
Mayo Clinic, Rochester, MN

Developed in cooperation with College of American Pathologists

INTENDED AUDIENCE: Pathologists, hematopathologists, clinical chemists, laboratory technologists and clinical hematologists and oncologists as well as any practicing clinician as they will encounter these common diagnoses.

SESSION OVERVIEW Hemoglobin disorders are common and can be associated with a wide variety of clinical phenotypes and severity. These disorders are an excellent model to understand the molecular mechanisms of diseases. There are many different methodologies to evaluate these disorders. This session is a case-based discussion of clinically significant hemoglobin and thalassemia disorders, integrating clinical and laboratory data into the presentation.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify the pathogenesis of hemoglobin disorders; 2) review molecular mechanisms of disease as a model using hemoglobin disorders; 3) compare the advantages and limitations of commonly used methods; and 4) recognize situations when ancillary testing is appropriate and beneficial.

SPEAKERS

Common Methods, Mass Spectrometry, and Case Study Review
#James Hoyer, MD
Mayo Clinic, Rochester, MN

Molecular Methods and Case Study Review
#Jennifer Oliveira, MD
Mayo Clinic, Rochester, MN

Systems, Stakeholders, and Sustaining: Successful Strategies for Improving Laboratory Stewardship

192010
San Diego Convention Center - 32AB

Level: Basic
CE Credit: 2.5

MODERATOR
#Julia Drees, PhD, DABCC
Kaiser Permanente, Richmond, CA

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, laboratory technologists, IVD industry scientists, and others involved with managing laboratory operations.

SESSION OVERVIEW Laboratory stewardship programs to ensure appropriate test utilization and improve test value are becoming increasingly necessary as the costs of complex laboratory testing increases. Modifying electronic ordering systems, improving communication between the laboratory and clinical teams, and implementing structured review of test orders are strategies that are effective in the correct context but can be challenging to develop and sustain. This session will present a variety of proven laboratory utilization tools by describing utilization case studies from three different health systems with different business models and patient populations.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) outline successful strategies for optimizing computerized provider order entry systems and alerts to guide appropriate laboratory utilization; 2) describe the relative strengths and weaknesses of additional test utilization tools such as reflex testing, utilization report cards and education; and 3) identify challenges in ordering genetic tests that contribute to diagnostic error.

SPEAKERS

A Lab-Developed Algorithm for Testosterone and Four Tools for Chipping Away at Vitamin D Volumes
#Julia Drees, PhD, DABCC
Kaiser Permanente, Richmond, CA

Tackling Inpatient and Critical Care Utilization with Stakeholder Engagement and Provider Feedback
#Patrick Mathias, MD, PhD
University of Washington, Seattle, WA

The Secret Sauce: Facilitating Case Review for Complex Test Requests
#Jane Dickerson, PhD, DBACC
University of Washington and Seattle Children's Hospital, Seattle, WA

AACC UNIVERSITY 1:30PM - 4:00PM

T TICKET

Kidney Disease—Laboratory Testing Makes a Difference

192011
San Diego Convention Center - 29ABC

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Christine Collier, PhD, FCACB
Kingston General Hospital and Queen's University, Kingston, ON, Canada

Developed in cooperation with CSCC

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, fellows and trainees, laboratory technologists, and industry scientists.

SESSION OVERVIEW: Early detection of kidney disease provides opportunities for targeted interventions that may alter the disease progression and outcomes. This session will examine the clinical value of traditional biomarkers that are currently being used for detecting, investigating and treating patients with AKI and CKD. Participants will be required to assess if the biomarkers are fit for purpose.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) critically discuss the current standard practice for the investigation and monitoring of AKI and CKD; 2) consider ways to improve testing and result interpretation to optimize patient care and outcomes in Kidney Disease; and 3) anticipate new methods that are on the horizon.

SPEAKERS

Optimizing eGFR Use and Interpretation
#Graham Jones, DPhil, MBBS, FRCPA
St Vincent's Hospital (SydPath), Darlinghurst, NSW, Australia

Mobile Screening Programs for Early Detection of CKD
*David Seccombe, MD, PhD, FRCPC
CEQAL, Vancouver, ON, Canada

CKD—What's New? eGFR Rate of Change and KFRe
#Christine Collier, PhD, FCACB
Kingston General Hospital and Queen's University, Kingston, ON, Canada

AKI—Zoom Ahead Five Years!
*John Kellum, MD, MCCM
University of Pittsburgh School of Medicine, Pittsburg, PA

AACC UNIVERSITY 1:30PM - 4:00PM

TICKET

From a Brick to a Fortress: Building a Solid Clinical Mass Spectrometry Method One Brick at a Time

192012
San Diego Convention Center - 31ABC

Level: Basic
CE Credit: 2.5

MODERATOR
#Grace Van der Gugten, BSc
St. Paul's Hospital, Vancouver, BC, Canada

INTENDED AUDIENCE: Laboratory directors, clinical chemists, laboratory administrators, laboratory managers and supervisors, IVD industry scientists, pathologists, physicians, and medical technologists.

SESSION OVERVIEW: This session aims to assist clinical laboratories interested in implementing mass spectrometry. It will cover the fundamentals of liquid chromatography and tandem mass spectrometry, essential considerations and effective approaches for method development and validation, and post-implementation monitoring.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the basics of liquid chromatography and tandem mass spectrometry; 2) create a plan for method development, pre-validation and validation testing; and 3) develop a program for post-implementation monitoring.

SPEAKERS

Basics of LC-MS/MS
#Deborah French, PhD, DABCC, FACB
University of California San Francisco, San Francisco, CA

LC-MS/MS Method Development and Pre-Validation
#Grace Van der Gugten, BSc
St. Paul's Hospital, Vancouver, BC, Canada

Validation and Post-Implementation Monitoring for LC-MS/MS Methods
#Julianne Botelho, PhD
Centers for Disease Control and Prevention, Atlanta, GA

2017 GLOBAL LAB QUALITY INITIATIVE MINI-WORKSHOP 12:30PM - 4:30PM

TICKET

Adding Value to Patient Care Using Quality Control

Marriott Marquis San Diego
Marina Ballroom, Salon E

The workshop, "*Adding Value to Patient Care Using Quality Control,*" is a practical half-day workshop designed to train students and bench technicians on the 'nuts and bolts' of quality control techniques to improve laboratory medicine. With content originally designed to be delivered outside the U.S., AACC has delivered similar, longer-format workshops in Bolivia, Dominican Republic, El Salvador, Ecuador, Guatemala, Mexico, Panama, Paraguay, and Peru, with considerable success. This workshop will be presented in English. **Learn more and register at www.aacc.org/GLQIworkshop.**

MONDAY JULY 31

PLENARY & EDUCATION SESSIONS

PLENARY SESSION 12001

ONCOFERTILITY: FROM BENCH TO BEDSIDE TO BABIES

#TERESA WOODRUFF, PhD
Northwestern University,
Chicago, IL

MONDAY, JULY 31
8:45am - 10:15am
San Diego Convention Center - Ballroom 20
Level: Basic **CE Credit:** 1

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, immunologists, molecular biologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: Life preserving cancer treatments can threaten fertility. More than 1.4 million people are diagnosed in the U.S. with cancer annually; 10% of these individuals are in their reproductive years. As the survival rate for adolescents and children continues to rise, late effects of treatment are taking on new urgency for survivors of this disease. Oncofertility is a new term that describes the effort to preserve fertility for young people with cancer and includes basic reproductive biology, clinical science, ethics, law, economics, pediatric surgery and education sciences. The Oncofertility Consortium was founded to provide fertility options for young cancer patients, develop relationships between oncologists and fertility specialists as a team, and create a global community of practice that is coordinated and sustainable.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the fertility threat posed by cancer treatment; 2) review fertility preservation options available to young cancer patients; and 3) identify challenges to integrating fertility preservation into the medical management of patients with cancer.

PLEASE REFER TO THIS GUIDE WHEN MAKING YOUR SESSION SELECTIONS

Each session is identified by a five- or six-digit session number.

EXAMPLE
Session **72105** is a:
A. Short Course
B. On Monday
C. In the Morning

SESSION TYPE
A. FIRST DIGIT
1 =Plenary Sessions
3 =Symposia
4 =AM Brown Bag Sessions
5 =PM Brown Bag Sessions
6 =Meet the Expert Session
7 =Short Courses
19 = Sunday AACC University Sessions

SESSION DAY
B. SECOND DIGIT
1 = Sunday
2 = Monday
3 = Tuesday
4 = Wednesday
5 = Thursday

SESSION TIME
C. THIRD DIGIT
1 = am
2 = pm
4 = Mid-day

The last two digits are AACC internal numbers.

BROWN BAG SESSIONS 7:30AM - 8:30AM & 12:30PM - 1:30PM

TICKET Brown Bag Sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. AACC does not provide meals for these sessions. You will be able to purchase your own food in the Convention Center prior to the session.

CE Credit: 1.0 (per Brown Bag Session) unless otherwise noted San Diego Convention Center - 6A/6B

TITLE	SESSION NUMBER AM	PM	LEVEL	SPEAKERS
Reducing Errors While Improving Quality in Your POCT Program *Developed in cooperation with Critical and Point-of-Care Testing Division*	42101	52201	Basic	**#Brenda Suh-Lailam, PhD, DABCC** Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
CLIA Requirements for Validation of Laboratory Developed Tests (LDTs)* *Developed in cooperation with Clinical Translational Science Division*	42102	52202	Basic	**#Vincent Ricchiuti, PhD** Laboratory Corporation of America Holdings, Dublin, OH
Critically High Ammonia in an Adolescent: Review of a Clinical Case Study from the Clinical Chemistry Journal*	42103	52203	Intermediate	***Lawrence de Koning, BSc MSc PhD, DABCC FACB FCACB** Calgary Laboratory Services, Calgary, AB, Canada
Immunoglobulin Paraprotein Interference with Chemistry Assays	42106	52206	Advanced	***Lu Song, PhD, DABCC** UCLA Medical Center, Los Angeles, CA
Prognostication of Heart Failure: Perspectives from Transforming Growth Factors (TGF) Super-Family Members	42107	52207	Intermediate	**#Damien Gruson, PhD** Cliniques Universitaires Saint Luc, Bruxelles, Belgium
Measurement of Free Vitamin D in the Clinical Laboratory*	42108	52208	Intermediate	***Nicolas Heureux, PhD** DiaSource ImmunoAssays, Louvain-la-Neuve, Belgium
How People Try to Beat Drug Testing and Defend Positive Results	42109	52209	Basic	**#Amitava Dasgupta, PhD, DABCC, NRCC** University of Texas at Houston Medical School, Houston, TX
Sigma Value—A Performance Indicator and Quality Improvement Tool	42110	52210	Basic	**#Vanessa Lo, BSc(First Hons), MSc, MBA, MISM, MPA, FFSc(RCPA)** Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong
Troubleshooting Analytical Interferences	42111	52211	Basic	**#Janet Simons, MD, FRCPC** McMaster University, Hamilton, ON, Canada
Matrix Effects in LC-MS Assays: Evaluation and Strategies to Overcome Testing Issues	42112	52212	Intermediate	**#Yifei Yang, PhD** University of Chicago, Chicago, IL
Anti-Mullerian Hormone (AMH): An Emerging Biomarker for the Assessment of Reproductive Function	42113	52213	Intermediate	***Alicia Algeciras-Schimnich, PhD, DABCC** Mayo Clinic, Rochester, MN

TITLE	SESSION NUMBER AM	PM	LEVEL	SPEAKERS
The Role of Pharmacogenomics in Therapeutic Drug Monitoring of Immunosuppressants	42114	52214	Intermediate	**#Stephen Roper, PhD, MB(ASCP)** Baylor College of Medicine, Houston, TX
Perils of Hemoglobin A1c Assays: Hidden Hemoglobinopathies, A Case Based Approach	42115	52215	Basic	**#Sydney Strickland, PhD** University of Virginia School of Medicine, Charlottesville, VA
Sensitive Estrone and Estradiol Quantitation in the Clinical Lab: Why, When, and How?	42116	52216	Intermediate	***Run Zhang Shi, PhD** Stanford Medical Center Clinical Laboratories, Palo Alto, CA
Troubleshooting and Method Development for the Extraction and Quantification of Cannabinoids from Oral Fluid	42117	52217	Intermediate	***Philip Sobolesky, PhD** University of California San Diego, San Diego, CA
MAAA, Oh My! Exploring the Algorithms Behind Multianalyte Assays with Algorithmic Analyses, and How to Judge Their Clinical Value	42118	52218	Basic	**#James Mays, MD** University of Washington, Seattle, WA
Beyond PSA: Novel Biomarkers for Detection of Prostate Cancer	42119	52219	Intermediate	**#Bernard Cook, PhD, DABCC, FACB** Henry Ford Hospital, Detroit, MI
100% Connectivity in Point-of-Care Testing is Achievable	42120	52220	Intermediate	**#Christiane Nooney, MBA/MHA, MT(AMT)** Duke University Health System, Durham, NC
Updates in Pediatric Lipid Testing	42121	52221	Intermediate	**#Jing Cao, PhD, DABCC** Texas Children's Hospital, Houston, TX
The CDC Lipids Standardization Programs—Ensuring the Quality of Clinical Chronic Disease Biomarker Measurements	42122	52222	Intermediate	**#Uliana Danilenko, PhD** Centers For Disease Control and Prevention, Atlanta, GA
Test Utilization Strategies in the New Healthcare Environment—Controlling Laboratories' Costs and Providing Quality Patient Management	42123	52223	Basic	**#Alina Sofronescu, MSc, PhD, NRCC-CC; FACB** University of Nebraska Medical Center, Omaha, NE
Leadership Strategies: Cultivating Engagement Through Leadership	42124	52224	Basic	**#Cherie Petersen, BA** ARUP Laboratories, Salt Lake City, UT
Patient-Centered Clinical Laboratory Activities and Measurement of Outcomes	42125	52225	Intermediate	**#Ibrahim Hashim, MSc, PhD, DABCC, FACB** University of Texas Southwestern Medical Center, Dallas, TX
Examination of the Peripheral Blood Smear	42126	52226	Basic	**#Sherri Flax, MD, FCAP** University of Florida, Gainesville, FL
Integrating Preanalytical Quality Indicators for Laboratory Testing Efficiency*	42127	52227	Intermediate	***Aparna Ahuja, MD** BD Diagnostics, Franklin Lakes, NJ
Doping with Testosterone: Testing Strategies and Factors Influencing Detection	42129	52229	Basic	**#Sami Albeiroti, PhD** University of California, Los Angeles, CA

** Credits for these sessions are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

MEET THE EXPERT 10:30AM - 11:30AM

CRISPR Biology, Technology & Ethics: The Future of Genome Engineering

62101
San Diego Convention Center - 29D

Level: Basic
CE Credit: 1

MODERATOR
#Christina Lockwood, PhD
University of Washington, Seattle, WA

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, molecular biologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: This session provides an excellent opportunity for a limited number of attendees to meet with Dr. Jennifer Doudna to discuss the novel gene-editing tool, CRISPR. Her research seeks to understand how RNA molecules control the expression of genetic information. Dr. Doudna is a world-renowned researcher with numerous awards. Dr. Doudna has also been recognized outside the scientific community being named one of *Time's* 100 most influential people in 2015 and listed as a runner-up for *Time's* Person of the Year in 2016 alongside other CRISPR researchers.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe CRISPR systems and how they work; 2) explain how CRISPR-Cas9 was harnessed as a gene editing technology; and 3) identify current and future applications of CRISPR technology in health and agriculture.

SPEAKER
CRISPR Biology, Technology and Ethics: The Future of Genome Engineering
#Jennifer Doudna, PhD
University of California Berkley, Berkley, CA

Oncofertility: From Bench to Bedside to Babies

62102
San Diego Convention Center - 22

Level: Basic
CE Credit: 1

MODERATOR
#Ann Gronowski, PhD, DABCC, FACB
Washington University School of Medicine, St. Louis, MO

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, immunologists, molecular biologists, laboratory technologists and IVD industry scientists.

SESSION OVERVIEW: This session provides an excellent opportunity for a limited number of attendees to meet with Dr. Teresa K. Woodruff, a pioneer in the field of fertility preservation. Dr. Woodruff coined the term "oncofertility" which describes the effort to preserve fertility for young people with cancer and includes basic reproductive biology, clinical science, ethics, law, economics, pediatric surgery and education sciences. Dr. Woodruff will discuss her efforts to provide fertility options for young cancer patients and create a global community of practice that is coordinated and sustainable.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the fertility threat posed by cancer treatment; 2) review fertility preservation options available to young cancer patients; and 3) identify challenges to integrating fertility preservation into the medical management of patients with cancer.

SPEAKER
Oncofertility: From Bench to Bedside to Babies
#Teresa Woodruff, PhD
Northwestern University, Chicago, IL

SYMPOSIA 10:30AM - NOON

Clinical Endocrine Assays: What Endocrinologists Will Ask You

32104
San Diego Convention Center - 28ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#David Sacks, MD, MB, ChB, FRCPath
National Institutes of Health, Bethesda, MD

Developed in cooperation with Endocrine Society, Clinical Societies Collaboration Committee

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, IVD industry scientists, students, trainees, and endocrinologists.

SESSION OVERVIEW: Endocrinologists frequently contact the clinical lab for guidance on test selection and interpretation. An informal survey of clinicians attending the 2016 Endocrine Society conference revealed their concerns as problems with insulin-like growth factor 1 (IGF-1) analysis, use of tumor markers in thyroid tumors and measurement of cortisol in different samples. This session will address these topics to enable clinical laboratorians to answer these questions.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain challenges and progress in the measurement of IGF-1; 2) describe the optimal approach the diagnose and monitor thyroid carcinoma and potential problems with the assays; and 3) discuss the clinical value of measuring cortisol in hair.

SPEAKERS

Differentiated Thyroid Cancer Tumor Markers
#Carole Spencer, PhD, MT, FACB
University of Southern California, Pasadena, CA

Insulin-Like Growth Factor I (IGF-1) Assays
*Martin Bidlingmaier, MD
Ludwig-Maximilians University, Munich, Germany

Measurement of Hair Cortisol: What Can it Tell Us?
#Stan Van Uum, MD, PhD
Western University, London, ON, Canada

Novel Psychoactive Substances in Emergency Toxicology

32105
San Diego Convention Center - 30C

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Jennifer Colby, PhD, DABCC, FACB
Vanderbilt University, Nashville, TN

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, medical technologists, residents, fellows, and toxicologists.

SESSION OVERVIEW: This highly interactive session will focus on emergency toxicology and the role of the comprehensive drug screen in the diagnosis and management of acutely intoxicated patients. In particular, the session will explore poisonings that occur with novel psychoactive substances, or so-called designer drugs.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list specific examples of novel psychoactive substances and explain the challenges associated with detecting them; 2) recognize toxidromes that may be associated with novel psychoactive substances use; and 3) identify clinical and analytical information that will be helpful in diagnosing novel psychoactive substances intoxications.

SPEAKERS

NPS History, Mass Spectrometry for Emergency Toxicology
#Jennifer Colby, PhD, DABCC, FACB
Vanderbilt University, Nashville, TN

Introduction to Toxidromes; Cases
#Kai Li, MD
University of California, San Francisco, San Francisco, CA

Interactive Case Discussion
#Jennifer Colby, PhD, DABCC, FACB
Vanderbilt University, Nashville, TN

#Kai Li, MD
University of California, San Francisco, San Francisco, CA

SYMPOSIA 10:30AM - NOON

Is Bigger Always Better? Pros and Cons of Targeted vs. Comprehensive Genetic Testing

32106
San Diego Convention Center - 30DE

Level: Basic
CE Credit: 1.5

MODERATOR
***Jason Park, MD, PhD**
University of Texas Southwestern and Children's Medical Center, Dallas, TX

INTENDED AUDIENCE: Clinical chemists, laboratory directors, pathologists, medical technologists, IVD scientists, and geneticists.

SESSION OVERVIEW: Genetic testing is advancing precision medicine. This point-counterpoint session will highlight the relative advantages and limitations of targeted (selected gene panel) vs. comprehensive (exome and genome) genetic testing. The speakers will use case studies to emphasize the utility of each approach.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) discuss the basic concepts, benefits, and limitations of next-generation sequencing; 2) explain the need for both targeted and comprehensive genetic testing; and 3) identify appropriate clinical contexts for exome and genome testing.

SPEAKERS

Clinical and Analytical Benefits of Targeted Genetic Testing
#Linnea Baudhuin, PhD
Mayo Clinic, Rochester, MN

Shortening the Diagnostic Odyssey in Pediatric Testing
#Carol Saunders, PhD, FACMG
Children's Mercy Hospital, Kansas City, MO

Diagnostics in Global Health: Time to Strengthen This Weakest Link

32107
San Diego Convention Center - 28DE

Level: Basic
CE Credit: 1.5

MODERATOR
#Lee Schroeder, MD, PhD
University of Michigan, Ann Arbor, MI

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, medical technologists, and laboratory administrators with an interest in laboratory testing in resource-poor settings.

SESSION OVERVIEW: While medicines treat disease, diagnostics find disease. Yet, in global health initiatives, diagnostics receive much less attention. The WHO's Model List of Essential Medicines has been critical to the efficient delivery of medicines. This session will describe how a Model List of Essential Diagnostics will help strengthen laboratory capacity in resource-poor settings.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the state of laboratory capacity in low-resource countries; 2) explain the impact of the Model List of Essential Medicines; and 3) list the barriers to diagnostics implementation and how an essential diagnostics list can help overcome those barriers.

SPEAKERS

How Can We Create an Essential Diagnostics List?
#Lee Schroeder, MD, PhD
University of Michigan, Ann Arbor, MI

How Will an Essential Diagnostics List Help Laboratories and Laboratory Systems?
#Timothy Amukele, MD, PhD
Johns Hopkins University, Baltimore, MD

Why the World Needs an Essential Diagnostic List
#Cristina Giachetti , PhD
Bill & Melinda Gates Foundation, Seattle, WA

SYMPOSIA 10:30AM - NOON

Invited Oral Abstracts:
Improving Patient Outcomes

32108
San Diego Convention Center - 29ABC

Level: Intermediate
CE Credit: 1.5*

MODERATOR
#Edward Randell, PhD
Eastern Health, St. Johns, NB, Canada

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: Postdoctoral fellows, pathologists, laboratory directors, clinical chemists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: AACC is dedicated to advancing the science and practice of laboratory medicine. A select group of members has reviewed and ranked the abstracts submitted for the AACC annual scientific meeting. The Annual Meeting Organizing Committee has reviewed the accepted abstracts in the area of improving patient outcomes and has chosen five authors to present their research as oral presentations. Each 15-minute presentation will be followed by a 3-minute question-and-answer session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe and evaluate the latest advances in improving patient outcomes; 2) compare and contrast the research in improving patient outcomes to the practice of pathology and laboratory medicine; and 3) integrate and translate state of the art knowledge in improving patient outcomes into the roles and responsibilities of the clinical laboratory professional.

SPEAKERS

National Survey of Adult and Pediatric Reference Intervals in Clinical Laboratories Across Canada: A Report of the CSCC Working Group on Reference Interval Harmonization
#Victoria Higgins, PhD Candidate
The Hospital for Sick Children, Toronto, ON, Canada

Growth Differentiation Factor-15 is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chanin (AL) Amyloidosis
#Ioannis Papassotiriou, PhD
Aghia Sophia Children's Hospital, Athens, Greece

Evaluation of the European Society of Cardiology Recommended Rapid Diagnostic Algorithums in a Challenging Low Risk Cohort
#Paul Collinson, MB, BChir, MD, FRCPath
St. George's Hospital, London, United Kingdom

Suppression of the Non-Involved Heavy/Light chains Pair Isotype as a New Biomarker of Poor Prognosis in Multiple Myeloma
#Jose Luis Garcia de Veas Silva
Complejo Hospitalario Universitario de Granada, Granada, Spain

Multivariate Models for Combinations of Hemolysis, Icterus and Lipemia Interference
#Alan Burgess
EORLA, Greely, ON, Canada

***Clinical Chemistry's* Hot Topics of 2017**

32109
San Diego Convention Center - 31ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Nader Rifai, PhD
Children's Hospital, Boston, MA

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, molecular diagnostics specialists, technologists, and IVD industry scientists.

SESSION OVERVIEW: Clinical utility of high-sensitivity troponin and successes and failures of omics in cardiovascular disease are the subjects of numerous highly cited articles published in *Clinical Chemistry* and will be discussed in this session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe current strategies in using hs-cT in early diagnosis of myocardial infarction and in risk assessment in apparently healthy individuals; and 2) describe the promises and challenges of omics in cardiovascular medicine.

SPEAKERS

Impact of hs-cTn on the Practice of Cardiovascular Medicine
*David Morrow, MD, MPH
Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Successes and Challenges of Omics in Cardiovascular Medicine
*Geoffrey Ginsburg, MD, PhD
Duke University, Durham, NC

SYMPOSIA 10:30AM - NOON

President's Invited Session:
The Microbiome in Health and Disease

32128
San Diego Convention Center - 33AB

Level: Basic
CE Credit: 1.5

MODERATOR
#Michael Bennett, PhD, DABCC, FACB
University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA

INTENDED AUDIENCE: All clinical laboratorians, physicians, health care researchers from industry; particularly from pharmaceutical companies.

SESSION OVERVIEW: The physiological and pathological significance of the human body's microbiome is one of the most significant areas of current medical interest. However, we contain more bacteria and other microorganisms than we have our own cells. It is becoming increasingly apparent that the qualitative nature of the microbiota we possess and microbial metabolism determine levels of wellness and may ultimately be responsible for many pathological conditions; in particular some complex conditions which classical genetic studies have been unable to explain. This session will explore two significant areas where the microbiome and metabolism are under intense evaluation. This session will explore the gastrointestinal microbiota under normal physiological conditions and relate shifts in patterns of microbiota to non-physiological conditions. Pre-term delivery (premature birth) is an area of great concern in neonatal health provision as there are huge costs in keeping premature babies in neonatal intensive care units; costs which impact laboratories greatly. Elements of both the microbiome and placental metabolism have been implicated as potentially causative mechanisms and these will be discussed in the session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) understand the physiological significance of the gastrointestinal and placental microbiomes; 2) understand and describe the pathological changes to the microbiomes and how this may relate to disease processes; 3) explain the health care implications of pre-term delivery and how this may relate to the microbiome and placental metabolism; and 4) understand the health-care impact of reducing pre-term delivery.

SPEAKERS

The Diet, the Gut Microbiome, and its Metabolome in Health and Disease
*Gary Wu, MD
University of Pennsylvania, Philadelphia, PA

The Role of the Microbiome in Programming of Adult Disease
#Rebecca Simmons, MD
University of Pennsylvania, Philadelphia, PA

SHORT COURSE 10:30AM - NOON

A Biomarker Strategy to Detect and Predict Cancer Therapy Cardiotoxicity

72103
San Diego Convention Center - 32AB

Level: Intermediate
CE Credit: 1.5

MODERATOR
***Alan Wu, PhD, DABCC, FACB**
University of California/San Francisco General Hospital, San Francisco, CA

Developed in cooperation with Biomarkers of Acute Cardiovascular Diseases Division

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, cardiologists, oncologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: Cancer therapy-induced cardiotoxicity has become an increasingly important clinical problem faced by oncologists and cardiologists. This session will review the pathophysiology and clinical assessment approaches of cancer therapy induced cardiomyopathy, and discuss the utilities of cardiac biomarkers for early diagnosis of acute cardiotoxicity and prediction of late-onset cardiotoxicity and heart failure secondary to cancer therapy.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain the pathophysiology of cardiomyopathy induced by cancer therapy agents; 2) discuss the current clinical approaches in the assessment of cardiomyopathy; and 3) identify the clinical utility of cardiac biomarkers in prediction and detection of cancer therapy-induced cardiomyopathy.

SPEAKERS

The Pathophysiology and Mechanism of Cardiac Biomarker Release
*Alan Wu, PhD, DABCC, FACB
University of California/San Francisco General Hospital, San Francisco, CA

Biomarkers of Cancer Therapy Induced Cardiotoxicity
*Qing Meng, MD, PhD, DABCC, FCACB
The University of Texas MD Anderson Cancer Center, Houston, TX

SYMPOSIUM 12:30PM - 2:00PM

Chair's Invited Session:
Is Artificial Intelligence in Genomics Ready for Prime Time?

32416
San Diego Convention Center - 28ABC

Level: Basic
CE Credit: 1.5*

MODERATOR
#Stanley Lo, PhD, DABCC, FACB
Children's Hospital of Wisconsin, Milwaukee, WI

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, and IVD industry scientists.

SESSION OVERVIEW: Usefully integrating genomic data into patient care is essential for continuing to advance precision medicine. Machine-learning algorithms have made remarkable strides in recent years. This session will discuss the current landscape of artificial intelligence-aided precision therapeutics in oncology using Watson Genomics as an example.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify interpretive challenges associated with genomic oncology tests; 2) describe advantages of automated computational analysis of genomic data; and 3) understand how complex genomic features can be inferred from tumor sequencing and influence diagnostic and treatment decisions.

SPEAKERS

Enhanced Clinical Decision Support Enabled by High-Throughput Genomic Profiling in Oncology
*Michael Berger, PhD
Memorial Sloan Kettering Cancer Center, New York, NY

Watson Genomics: Moving Forward on Precision Therapeutics
*Evan Leibovitz
IBM, Cambridge, MA

Enabling Precision Medicine in Oncology Through Advanced Analytics
#Nirali Patel, MD
University of North Carolina, Chapel Hill, Chapel Hill, NC

SHORT COURSES 12:30PM - 2:00PM

The Marriage of Informatics and Laboratory Operations

72411
San Diego Convention Center - 30AB

Level: Basic
CE Credit: 1.5

MODERATOR
#Anna Merrill, PhD
University of Washington, Seattle, WA

Developed in cooperation with Biomarkers of Acute Cardiovascular Diseases Division

INTENDED AUDIENCE: Laboratory directors, clinical chemists, pathologists, laboratory supervisors, and medical technologists with an interest in using informatics and operations management to implement quality assessment and quality control strategies for clinical laboratories.

SESSION OVERVIEW: High-volume laboratory testing requires robust automated processes to ensure quality results. These processes include active surveillance for system vulnerabilities and implementation of procedures to fill quality gaps. This requires experience in both informatics and laboratory testing to collect, analyze, and interpret data and then implement data-informed quality control strategies. This session will illustrate the power of combining laboratory and informatics expertise to overcome limitations in automated chemistry testing.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) define an operational problem that informatics can help to evaluate and solve; 2) list the components needed to successfully use informatics for quality improvement; 3) illustrate an operational flow diagram; and 4) compare different approaches to assess and ensure compliance for quality improvement/assurance procedures.

SPEAKERS

Operational Oversight for the Execution of Data-Derived Quality Assurance
#Dina Greene, PhD, DABCC
University of Washington, Seattle, WA

How to Use Clinical Informatics Tools to Develop and Implement Robust Quality Practices
*Daniel Herman, MD, PhD
University of Pennsylvania, Philadelphia, PA

SHORT COURSES 12:30PM - 2:00PM

The Complement System: Overview and Laboratory Testing

72412
San Diego Convention Center - 31ABC

Level: Basic
CE Credit: 1.5

MODERATOR
#Maria Alice Willrich, PhD, DABCC, FACB
Mayo Clinic, Rochester, MN

INTENDED AUDIENCE: Laboratory directors, clinicians, pathologists, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals.

SESSION OVERVIEW: Interest in complement testing has increased in recent years, as its role in infectious, autoimmune and inflammatory diseases is better understood. Further, members of the complement system have been recognized as a potential target for therapeutics. This session will include an overview of the complement system, and cover pre-analytical challenges associated with laboratory evaluation, modern laboratory testing and examples of complement deficiency and dysregulation through interactive case presentations, as well as the opportunity to become a "Complement Whiz."

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the complement system pathways; 2) evaluate and mitigate challenges associated with clinical testing for the complement system; and 3) list the most used biomarkers and their patterns to assess complement dysfunction in several disease states.

SPEAKERS

Understanding Complement in the Clinical Laboratory
*Ashley Frazer-Abel, PhD
University of Colorado School of Medicine, Denver, CO

Complement Testing Overview and Interpretation for the Clinical Laboratorian
#Maria Alice Willrich, PhD, DABCC, FACB
Mayo Clinic, Rochester, MN

Micronutrient Testing in the Clinical Laboratory, from A to Zinc

FXP TOUCH

72413
San Diego Convention Center - 32AB

Level: Basic
CE Credit: 1.5

MODERATOR
#Sarah Hackenmueller, PhD, DABCC
University of Wisconsin, Madison, WI

Developed in cooperation with Nutrition Division

INTENDED AUDIENCE: Laboratory directors, clinicians, pathologists, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals.

SESSION OVERVIEW: Micronutrients, including vitamins and some trace metals, are essential but found in low concentrations in the body. Deficiency of micronutrients results in disease processes can be corrected with adequate nutrient supplementation. The clinical impetus for and utility of vitamin and trace element testing will be discussed. Using active learning strategies, participants will explore micronutrient absorption, test utilization, methods of analysis, and limitations associated with these analytes. Session attendees will gain information and strategies to successfully manage requests for micronutrient testing.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) evaluate the clinical utility of micronutrient testing for patients; 2) recognize the value and limitations of vitamin and trace element analysis and results; and 3) recommend appropriate testing to assess micronutrient status and avoid unnecessary test orders.

SPEAKERS

Micronutrients—Physiology and Pathophysiology
#Vilte Barakauskas, PhD, FCACB
BC Children's and Women's Health Centre, Vancouver, BC, Canada

Micronutrients—Vitamins
#Elizabeth Frank, PhD, DABCC
University of Utah/ARUP Laboratories, Salt Lake City, UT

Micronutrients—Nutritional Metals
#Sarah Hackenmueller, PhD, DABCC
University of Wisconsin, Madison, WI

SHORT COURSES 12:30PM - 2:00PM

Anti-Mullerian Hormone from the Laboratory Perspective

FXP TOUCH

72414
San Diego Convention Center - 30DE

Level: Intermediate
CE Credit: 1.5

MODERATOR
***Geralyn Lambert-Messerlian, PhD, FACB**
Women & Infants Hospital and the Alpert Medical School of Brown University, Providence, RI

Developed in cooperation with Endocrinology Division

INTENDED AUDIENCE: Laboratory directors, clinical chemists, pathologists, physicians, nurses, and IVD industry representatives especially those interested in assay development.

SESSION OVERVIEW: Polycystic ovarian syndrome (PCOS) is a heterogeneous condition and is largely a diagnosis of exclusion. Current diagnostic strategies focus on ovarian follicle counts, demonstration of androgen excess and/or menstrual abnormalities. Laboratory diagnostic tools are needed to define and monitor this common cause of infertility. This session will discuss current PCOS diagnostic strategies as well as promising new biomarkers, the foremost of which is anti-mullerian hormone (AMH). Newly developed automated AMH assays will increase testing availability and may more formally integrate the laboratory into PCOS diagnosis.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe current and potential future approaches to PCOS diagnosis; 2) explain the physiological role of AMH in patients with typical and atypical reproductive function; 3) describe the evolution of AMH measurement methods; and 4) list current and potential future applications of AMH measurement.

SPEAKERS

Current and Future Approaches to PCOS Diagnosis
#Rob Nerenz, PhD, DABCC
Dartmouth-Hitchcock Medical Center, Lebanon, NH

Medical and Technical Evolution of AMH Test Methods
#Mark Cervinski, PhD, DABCC
Dartmouth-Hitchcock Medical Center, Lebanon, NH

MONDAY AFTERNOON

SYMPOSIA 2:30PM - 4:00PM

Future Directions in Laboratory Utilization

32219
San Diego Convention Center - 28ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Ron Schifman, MD
Southern Arizona VA Healthcare System, Tucson, AZ

INTENDED AUDIENCE: Laboratory managers, pathologists, laboratory directors, healthcare system administrators, and health information managers.

SESSION OVERVIEW: This session will describe advanced concepts and emerging strategies for laboratory utilization that are intended to improve patient outcomes. Topics will include population health by use of registries, inter-institutional benchmarking, information system interoperability, business process management systems, and techniques for designing utilization studies aimed at interventions to reduce diagnostic errors.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) discuss emerging systems for test utilization that can improve outcome and reduce diagnostic errors; 2) describe how use of patient registries, benchmarking and business process management systems can be used to improve patient outcomes; 3) design utilization studies and know when and when not to conduct a study; and 4) describe an example of how interoperability of laboratory information systems can improve diagnosis and evidence based medical practice.

SPEAKERS

Emerging Laboratory Utilization Systems Aimed at Improving Outcomes
#Ron Schifman, MD
Southern Arizona VA Healthcare System, Tucson, AZ

Inter-Facility Benchmarking and Meaningful Design of Utilization Studies
*Robert Schmidt, MD, PhD, MBA
University of Utah, Salt Lake City, UT

SYMPOSIA 2:30PM - 4:00PM

Presenting Expert Testimony in the Courtroom

FXP TOUCH

32220
San Diego Convention Center - 29ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Saeed Jortani, PhD, DABCC, FACB
University of Louisville, Louisville, KY

INTENDED AUDIENCE: Pathologists, toxicologists, medical technologists, lab directors, clinical chemists, and any laboratory professional interested in serving as an expert witness.

SESSION OVERVIEW: In this session, a courtroom setting will be used to demonstrate the importance of expert witness testimony in resolving toxicology and clinical chemistry related litigation. Attorneys and the expert witness, who worked on two recent trials, will provide arguments and evidence used to litigate these cases. The first case is a murder trial in which the expert witness was called to testify about the role of psychoactive drugs in the manner of death. The second case is a medical malpractice lawsuit where the plaintiff contends improper specimen collection eventually led to severe brain injury.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) prepare as an expert witness in criminal and civil cases; 2) describe the types of questions asked of an expert witness in court proceedings; and 3) formulate appropriate responses to the type of direct and cross examination questions posed in the courtroom.

SPEAKERS

#Eric Haner, Judge
Kentucky Administrative Office of the Courts, Louisville, KY

#Saeed Jortani, PhD, DABCC, FACB
University of Louisville, Louisville, KY

#David Mejia, Esq., JD
Mejia Law Office, Louisville, KY

#Robert Shelton, Esq., JD
Shelton Law Group, Louisville, KY

The Role of the Laboratorian and Clinician in the Diagnosis and Management of Tuberculosis

32221
San Diego Convention Center - 28DE

Level: Intermediate
CE Credit: 1.5*

MODERATOR
#Steven Cotten, PhD, DABCC
The Ohio State University Wexner Medical Center, Columbus, OH

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: Pathologists, lab directors, clinical chemists, technologists, IVD industry scientists, and those interested in the diagnosis and management of tuberculosis in the USA and developing countries.

SESSION OVERVIEW: Early diagnosis and treatment initiation of tuberculosis (TB) is critical for patient survival, and ultimately ending the TB epidemic. Laboratory tests must be sufficiently sensitive and specific for TB detection, and must be amenable to both developed and resource-limited countries. This session will review the clinical epidemiology of TB, as well as highlight current laboratory tests used for TB diagnosis, and the barriers of implementing rapid testing in resource-limited areas through clinical research trials experience.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain the different technologies available for TB diagnosis; 2) recognize treatment options for infected individuals; and 3) contrast testing and management workflows in developed and resource-limited countries.

SPEAKERS

Why and When: Selecting the Best Tuberculosis Diagnostic Test
*Joan-Miquel Balada-Llasat, PharmD, PhD, ABMM
The Ohio State University Wexner Medical Center, Columbus, OH

Combating Tuberculosis in the US and Developing Countries
#Shu-Hua Wang, MD, MPH, PharmD
The Ohio State University Wexner Medical Center, Columbus, OH

SYMPOSIA 2:30PM - 4:00PM

Invited Oral Abstracts:
Emerging Technologies

32222
San Diego Convention Center - 30C

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Dana Bailey, PhD, FACB
Dynacare, London, ON, Canada

INTENDED AUDIENCE: Postdoctoral fellows, pathologists, laboratory directors, clinical chemists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: AACC is dedicated to advancing the science and practice of laboratory medicine. A select group of members has reviewed and ranked the abstracts submitted for the AACC annual scientific meeting. The Annual Meeting Organizing Committee has reviewed the accepted abstracts in the area of emerging technologies and has chosen five authors to present their research as oral presentations. Each 15-minute presentation will be followed by a 3-minute question-and-answer session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe and evaluate the latest advances in emerging technologies; 2) compare and contrast the research in emerging technologies to the practice of pathology and laboratory medicine; and 3) integrate and translate state of the art knowledge in emerging technologies into the roles and responsibilities of the clinical laboratory professional.

SPEAKERS

Adapting High Resolution Mass Spectrometry for Clinical Toxicology: Comparison and Optimization of SWATH to Data-Dependent Acquisition for Drug Screening
#Jeffrey Whitman, PhD
University of California San Francisco, San Francisco, CA

Breaking Free From the ratio: Analytical Performance of an Immunoenrichment-coupled MALDI-TOF MS Detection Method for Monoclonal Immunoglobuin Free Light Chains
#Luisa Sepiashvili, PhD
Mayo Clinic, Rochester, MN

Evaluation of Quantitative Microsampling for Immunosuppressant Drug Monitoring
#Valentinas Gruzdys
ARUP Laboratories, Salt Lake City, UT

Urinary Biomarkers of Idiopathic Membranous Nephropathy Identified by High Resolution Mass Spectrometry Coupled with Liquid Chromatography
#Lu Pang, MBA
Peking University First Hospital, Beijing, China

Improving the Measurement of L-Asparaginase: A Standard-of-Care Drug Used in Pediatric Oncology
#Angela Fung, PhD
University of Toronto, ON, Canada

Current Perspectives on Alzheimer's Disease

32226
San Diego Convention Center - 32AB

Level: Intermediate
CE Credit: 1.5

MODERATOR
***Leslie Shaw, PhD, DABCC**
Hospital of University of Pennsylvania, Philadelphia, PA

INTENDED AUDIENCE: Neurologists, pathologists, laboratory directors, clinical chemists, technologists, and IVD Industry Scientists.

SESSION OVERVIEW: Alzheimer's Disease (AD) is a major cause of dementia in the elderly population. Though no cure has been discovered, significant efforts are being made to find one. To provide a better understanding of AD, this session will discuss National Institute on Aging's strategic approach towards conquering AD, ongoing clinical trials for diagnosis and treatment, and current and potential biomarkers for AD.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) discuss the strategic approach the National Institute of Aging, Division of Neurosciences is taking to address AD; 2) explain the focus of some of the ongoing clinical trials addressing diagnosis and treatment of AD; and 3) describe biomarkers used in the diagnosis and monitoring of AD.

SPEAKERS

NIA's Approach to Alzheimer's Disease
#Eliezer Masliah, MD
National Institute of Aging, Bethesda, MD

Current Clinical Trials to Diagnose, Treat and Prevent Alzheimer's Disease
*Douglas Galasko, MD
University of California San Diego, La Jolla, CA

Current and Potential Biomarkers for Diagnosing and Monitoring Alzheimer's Disease
#Robert Rissman, PhD
University of California San Diego, La Jolla, CA

SHORT COURSES 2:30PM - 4:00PM

Liquid Biopsy as an Emerging Noninvasive Clinical Tool for Cancer Patient Management

72217
San Diego Convention Center - 30AB

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Qing Meng, MD, PhD, DABCC, FCACB
The University of Texas MD Anderson Cancer Center, Houston, TX

Developed in cooperation with Molecular Pathology Division, Personalized Medicine Division

INTENDED AUDIENCE: Pathologists, lab directors, clinical chemists, technologists, and IVD industry scientists.

SESSION OVERVIEW: This session will discuss pre-analytical, technical and bioinformatic challenges associated with the implementation of liquid biopsy. Significant advances have been made in the analysis of circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) though liquid biopsy. This testing allows for cancer patient stratification and the monitoring of therapeutic response.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify the applications and limitations of current technologies for molecular liquid biopsy profiling; 2) list key pre-analytical and analytical variables that may affect the implementation of liquid biopsy in a clinical setting; and 3) describe the clinical utility of these new approaches in guiding personalized cancer treatment.

SPEAKERS

Using New Technology for Circulating Tumor Cell Detection in Cancer Therapy
#Qing Meng, MD, PhD, DABCC, FCACB
The University of Texas MD Anderson Cancer Center, Houston, TX

Liquid Biopsy (ctDNA) Assay Development and Validation: Pre-Analytical and Analytical Considerations
#Rajyalakshmi Luthra, PhD
The University of Texas MD Anderson Cancer Center, Houston, TX

Molecular Profiling: From Tumor to Blood
*Dana Tsui, PhD
Memorial Sloan Kettering Cancer Center, New York, NY

A Roadmap to Alternative Body Fluid Testing for Disease Diagnosis

72218
San Diego Convention Center - 30DE

Level: Intermediate
CE Credit: 1.5

MODERATOR
***Lakshmi Ramanathan, PhD**
Memorial Sloan-Kettering Cancer Center, New York, NY

INTENDED AUDIENCE: Clinical chemists, pathologists, laboratory directors, lab technologists, lab supervisors, fellows, residents, and scientists.

SESSION OVERVIEW: Collection and testing of non-invasive body fluids show promise in population-based screening studies and point-of-care, decentralized testing. Tests in saliva, cerebral spinal and body fluids have the potential to significantly improve diagnostic interpretation and permit biomarker analysis for novel management and treatment decisions.This session will present data on emerging markers in urine (cfDNA, miRNA, exosomes), CSF (CTC), saliva, stool (new genomic tests for colon cancer), and lavage from various organs, providing a road map to non-invasive clinical testing (NIT).

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list the advantages of noninvasive testing; 2) identify the performance characteristic required for assays in body fluids; and 3) discuss biomarkers that are used in blood and how these are measured in saliva and body fluids after proper validation.

SPEAKERS

Performance Characteristics and Validation in Non-Blood Analysis
*Lakshmi Ramanathan, PhD
Memorial Sloan-Kettering Cancer Center, New York, NY

New Biomarker Analysis in CSF and Lavage Fluid Collections
#Martin Fleisher, PhD, FACB
Memorial-Sloan Kettering Cancer Center, New York, NY

Current and New 0pportunities in Saliva Analysis
*Chamindie Punyadeera, PhD
Queensland University of Technology Institute of Health and Biomedical Innovation, Brisbane, QLD, Australia

SPECIAL SESSION 4:30PM - 6:00PM

Q&A with Qualcomm Tricorder XPRIZE Finalists

32227
San Diego Convention Center - Ballroom 20

Level: Basic

MODERATORS

#Shannon Haymond, PhD, DABCC
Lurie Children's Hospital of Chicago, Chicago, IL

#Stephen Master, MD, PhD, FCAP, FACB
Weill Cornell Medical College, New York, NY

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, and IVD industry scientists.

SESSION OVERVIEW: The Qualcomm Tricorder XPRIZE is a $10 million dollar global competition to stimulate innovation and integration of advanced technologies, enabling reliable health diagnoses anywhere, anytime. The winning team will develop a device weighing no more than five pounds that will diagnose 13 health conditions and capture five real-time health vital signs. Devices are judged for their diagnostic accuracy and user experience. In this session, the audience will hear from the Tricorder competition winner, as well as a finalist and semi-finalist.

The speakers will discuss the technology they have developed, share the inspiration for their devices, the hurdles encountered, and the potential future for their technology. This is an opportunity to learn more about the drivers and status of the digital health revolution and the breakthroughs needed for this model, once relegated to science fiction, to become a reality. This includes the emergence of precision diagnostics that utilize novel sensing technologies with advanced technological integration, requiring new regulatory pathways and healthcare industry acceptance.

Following the presentation, there will be a moderator-led Q&A session featuring questions from the audience. The moderators will include Drs. Shannon Haymond, PhD and Stephen Master, MD, PhD. This is an interactive session highlighting commercial products, and as such will not receive Continuing Medical Education or ACCENT credit.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the principles behind the winning Tricorder device and two of the finalist devices; 2) explain the hurdles encountered by the Tricorder finalists; and 3) identify the potential utility of this new technology.

SPEAKERS

#Jessica Ching
XPRIZE, Culver City, CA

#Eugene Chan, PhD
DNA Medicine Institute, Cambridge, MA

#Chung-Kang Peng, PhD
Beth Israel Deaconess Medical Center, Boston, MA

#Philip Charron
Basil Leaf Technologies, Paoli, PA

TUESDAY AUGUST 1

PLENARY & EDUCATION SESSIONS

PLENARY SESSION 13001

BEYOND SEQUENCING: NEW FRONTIERS IN GENOMICS

#JAY SHENDURE, MD, PhD
University of Washington,
Seattle, WA

TUESDAY, AUGUST 1
8:45am - 10:15am
San Diego Convention Center - Ballroom 20
Level: Basic **CE Credit:** 1

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, immunologists, molecular biologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: Over the past decade, massively parallel or next-generation DNA sequencing has emerged as a broadly enabling 21st century "microscope" for the measurement of diverse biological phenomena. In the clinic, the utility of sequence data is being intensively evaluated in diverse contexts, including reproductive medicine, oncology and infectious disease, and sequencing is increasingly being used in unanticipated ways that reach beyond conventional human genetics. This presentation will focus on efforts to develop new applications for DNA sequencing in clinical medicine, including for non-invasive diagnostics and for decomposing complex cell populations.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the current and anticipated applications of massively parallel DNA sequencing in clinical medicine; 2) define the basis for inferring cell types contributing to cell-free DNA based on epigenetic characteristics of sequenced DNA fragments; and 3) explain the motivations and methods for decomposing complex cell populations into constituent cell types based on single cell transcriptome or epigenome profiling.

PLEASE REFER TO THIS GUIDE WHEN MAKING YOUR SESSION SELECTIONS

Each session is identified by a five- or six-digit session number.

EXAMPLE
Session **72105** is a:
A. Short Course
B. On Monday
C. In the Morning

SESSION TYPE
A. FIRST DIGIT
1 =Plenary Sessions
3 =Symposia
4 =AM Brown Bag Sessions
5 =PM Brown Bag Sessions
6 =Meet the Expert Session
7 =Short Courses
19 = Sunday AACC University Sessions

SESSION DAY
B. SECOND DIGIT
1 = Sunday
2 = Monday
3 = Tuesday
4 = Wednesday
5 = Thursday

SESSION TIME
C. THIRD DIGIT
1 = am
2 = pm
4 = Mid-day

The last two digits are AACC internal numbers.

BROWN BAG SESSIONS 7:30AM - 8:30AM & 12:30PM - 1:30PM

TICKET

Brown Bag Sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. AACC does not provide meals for these sessions. You will be able to purchase your own food in the Convention Center prior to the session.

CE Credit: 1.0 (per Brown Bag Session) unless otherwise noted San Diego Convention Center - 6A/6B

TITLE	SESSION NUMBER AM	PM	LEVEL	SPEAKERS
Rule-Based Strategies for Taming Wasteful Testing	43101	53201	Intermediate	**#Ron Schifman, MD** Southern Arizona VA Healthcare System, Tucson, AZ
MALDI-TOF Mass Spectrometry and its Applications in Laboratory Medicine	43102	53202	Intermediate	**#Yusheng Zhu, PhD, DABCC, FACB** Penn State University Hershey Medical Center, Hershey, PA
Challenges of Quality Control in Modern Analytical Systems	43103	53203	Basic	***Oswald Sonntag, PhD** Bio-Rad Laboratories, Munchen, Germany
Laboratory Tests Related to Calcium and Bone Metabolism	43104	53204	Intermediate	***Lu Song, PhD, DABCC** University of California, Los Angeles Medical Center, Los Angeles, CA
How to Design and Execute a Clinical Outcomes Study	43105	53205	Intermediate	**#Stacy Beal, MD** University of Florida College of Medicine, Gainesville, FL
Was That the Right Decision? A Post-Mortem Analysis of a Multi-Year Quality Improvement Process	43106	53206	Intermediate	**#Valentinas Gruzdys, PhD** University of Utah, Salt Lake City, UT
Laboratory Assessment of Pediatric Metabolic Syndrome	43108	53208	Basic	**#Victoria Higgins, PhD Candidate** The Hospital for Sick Children, Toronto, ON, Canada
Serum Free Light Chains (sFLC): Advantages and Disadvantages of Currently Available Assays	43109	53209	Basic	**#Nicole White-Al Habeeb, PhD** University of Toronto, Toronto, ON, Canada
It's Not Just 'My Way or The Highway:' Navigating the Standardization of Clinical Laboratory Operations Across Hospital Enterprises	43110	53210	Basic	**#Allison Chambliss, PhD, DABCC** University of Southern California, Los Angeles, CA
Harmonizing Reference Intervals—A Provincial Example	43111	53211	Intermediate	**#Janet Simons, MD, FRCPC** McMaster University, Hamilton, ON, Canada
Abnormal Routine Laboratory Results and Interpretation in Cancer Patients	43112	53212	Intermediate	**#Qing Meng, MD, PhD, DABCC, FCACB** The University of Texas MD Anderson Cancer Center, Houston, TX
The CDC Hormone Standardization (HoSt) Program: Improving Clinical Measurements of Testosterone and Estradiol	43113	53213	Intermediate	**#Krista Poynter, BS** Centers for Disease Control & Prevention, Atlanta, GA
Optimizing Accuracy and Precision for POCT in Specific Clinical Settings	43114	53214	Intermediate	**#Anthony Okorodudu, PhD, MBA, DABCC** University of Texas Medical Branch, Galveston, TX
Inferior Petrosal Sinus Sampling (IPSS): The Challenges in Performing This Diagnostic Procedure for Patients with Cushing's Disease	43115	53215	Intermediate	**#Siaw Li Chan, PhD** University of Chicago, Chicago, IL

TITLE	SESSION NUMBER AM	PM	LEVEL	SPEAKERS
Recent Updates on Celiac Disease Testing and Utilization of Laboratory Testing Algorithms	43116	53216	Intermediate	**#Mahesheema Ali, PhD** Texas Children's Hospital, Houston, TX
The Journey in Obtaining POCT Education Documentation within a Health System	43117	53217	Basic	**#Deborah Bozek, MLS (ASCP)cm** Baystate Medical Center, Springfield, MA
Data-Driven Optimization of Result Autoverification in an Automated Chemistry Laboratory	43118	53218	Basic	**#Anna Merrill, PhD** University of Washington, Seattle, WA
Biomarkers to Detect Alcohol Exposure	43119	53219	Intermediate	**#Kamisha Johnson-Davis, PhD, DABCC, FACB** University of Utah/ARUP Laboratories, Salt Lake City, UT
Decreasing Barriers to Testing: HIV Point-of-Care Testing	43120	53220	Basic	**#Dorothy Truong, PhD** University of Toronto, Toronto, ON, Canada
Minimum Retesting Intervals (MRI): Importance, Determination, Advantages, Challenges of Enforcement	43121	53221	Intermediate	**#Asmita Hazra, MBBS, MD** Dr. Sampurnanand Medical College, Jodhpur, Rajasthan, India
Small Blood Samples, Challenges for the Lab	43122	53222	Basic	**#Khushbu Patel, PhD, DABCC** UT Southwestern, Dallas, TX
Screening for Cancer: Recommendations and Controversies	43123	53223	Intermediate	**#Shahram Shahangian, PhD, MS, DABCC, FACB** US Centers for Disease Control and Prevention (CDC), Atlanta, GA
Strategies for Streamlining Analytical and Post-Analytical Processes in Clinical Urine Multi-Target Drug Testing Using LC-MS/MS Technology	43124	53224	Intermediate	**#Danijela Konforte, PhD, FCACB** Lifelabs, Toronto, ON, Canada
A Case-Based Discussion: Therapeutic Drug Monitoring for Reduction of Adverse Drug Reactions	43125	53225	Basic	**#Claire Knezevic, PhD** Johns Hopkins Medical Institutes, Baltimore, MD
Use of Frequency Distribution Curves to Determine Drug Cutoffs*	43126	53226	Intermediate	***Amadeo Pesce, PhD, ABCC, FACB** Precision Diagnostics LLC, San Diego, CA
Serum vs. Plasma: Which Specimen Should You Use?	43127	53227	Basic	***Jeffrey Chance, PhD** BD Life Sciences - Preanalytical Systems, Franklin Lakes, NJ
Controversies and Solutions to Establishing and Maintaining a Compliant Body Fluid Testing Program	43128	53228	Basic	***Darci Block, PhD** Mayo Clinic, Rochester, MN
Negotiating a Job Contract That Meets Everyone's Needs *Developed in cooperation with Society for Young Clinical Laboratorians, Management Sciences and Patient Safety Division*	43129	53229	Basic	**#Joe El-Khoury, PhD, DABCC, FACB** Yale University, New Haven, CT
A Case Based Approach to Understanding the Role of the Laboratory in Transgender Care	43130	53230	Basic	**#Dina Greene, PhD, DABCC** University of Washington, Seattle, WA
The Evolution of Next Generation Clinical Mass Spectrometry	43131	53231	Basic	***Steven Wong, PhD, DABCC (TC), FACB** Wake Forest University School of Medicine, Winston-Salem, NC
The Impact of the National Glycohemoglobin Standardization Program (NGSP) on HbA1c Measurement in the Clinical Laboratory	43132	53232	Intermediate	***Randie Little, PhD** University of Missouri at Columbia, Columbia, MO
Leveraging CLSI Guidelines for Validation of Mass Spectrometry Assays	43133	53233	Basic	**#Hema Ketha, PhD** University of Michigan, Ann Arbor, MI

** Credits for these sessions are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

MEET THE EXPERT 10:30AM - 11:30AM

Beyond Sequencing: New Frontiers in Genomics

63101
San Diego Convention Center - 33A

Level: Basic
CE Credit: 1

MODERATOR
#Ann Gronowski, PhD, DABCC, FACB
Washington University School of Medicine, St. Louis, MO

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, immunologists, molecular biologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: This session provides an excellent opportunity for a limited number of attendees to meet with Dr. Jay Shendure, a renowned human geneticist. Dr. Shendure's research group pioneered exome sequencing and its application to Mendelian disorders, a strategy that has been applied to identify hundreds of disease-causing genes. Dr. Shendure will discuss efforts to develop new applications for DNA sequencing in clinical medicine, including for non-invasive diagnostics and for decomposing complex cell populations.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the current and anticipated applications of massively parallel DNA sequencing in clinical medicine; 2) define the basis for inferring cell types contributing to cell-free DNA based on epigenetic characteristics of sequenced DNA fragments; and 3) explain the motivations and methods for decomposing complex cell populations into constituent cell types based on single cell transcriptome or epigenome profiling.

SPEAKER
#Jay Shendure, MD, PhD
University of Washington, Seattle, WA

Q&A with Qualcomm Tricorder XPRIZE Finalists

63102
San Diego Convention Center - 29D

Level: Basic

MODERATORS
#Shannon Haymond, PhD, DABCC
Lurie Children's Hospital of Chicago, IL

#Stephen Master, MD, PhD, FCAP, FACB
Weill Cornell Medical College, New York, NY

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, and IVD industry scientists.

SESSION OVERVIEW: The Qualcomm Tricorder XPRIZE is a $10 million dollar global competition to stimulate innovation and integration of advanced technologies, enabling reliable health diagnoses anywhere, anytime. The winning team will develop a device weighing no more than five pounds that will diagnose 13 health conditions and capture five real-time health vital signs. Devices are judged for their diagnostic accuracy and user experience. In this session, the audience will hear from the Tricorder competition winner, as well as a finalist and semi-finalist.

The speakers will discuss the technology they have developed, share the inspiration for their devices, the hurdles encountered, and the potential future for their technology. This is an opportunity to learn more about the drivers and status of the digital health revolution and the breakthroughs needed for this model, once relegated to science fiction, to become a reality. This includes the emergence of precision diagnostics that utilize novel sensing technologies with advanced technological integration, requiring new regulatory pathways and healthcare industry acceptance.

Following the presentation, there will be a moderator-led Q&A session featuring questions from the audience. The moderators will include Drs. Shannon Haymond, PhD and Stephen Master, MD, PhD. This is an interactive session highlighting commercial products, and as such will not receive Continuing Medical Education or ACCENT credit.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the principles behind the winning Tricorder device and two of the finalist devices; 2) explain the hurdles encountered by the Tricorder finalists; and 3) identify the potential utility of this new technology.

SPEAKERS
#Jessica Ching
XPRIZE, Culver City, CA

#Eugene Chan, PhD
DNA Medicine Institute, Cambridge, MA

#Chung-Kang Peng, PhD
Beth Israel Deaconess Medical Center, Boston, MA

#Philip Charron
Basil Leaf Technologies, Paoli, PA

SYMPOSIA 10:30AM - NOON

Integrating TDM in the Health Care Environment: Team-Based Care with Pharmacists

33103
San Diego Convention Center - 30DE

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Amitava Dasgupta, PhD, DABCC, NRCC
University of Texas at Houston Medical School, Houston, TX

INTENDED AUDIENCE: Laboratory medicine physicians, laboratory directors, pathologists, toxicologists, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals who participate in patient care.

SESSION OVERVIEW: Pharmacists play an important role in bridging the gap between clinicians and the clinical laboratory for proper utilization of TDM results. The responsibility of laboratory scientists is to provide accurate and timely results to the providers. This session will discuss how pharmacists and laboratorians can collaborate for optimal patient care.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) eliminate pre-analytical and analytical errors in therapeutic drug monitoring; 2) detail the process of integrating pharmacists with laboratory scientists for improving patient safety and optimizing care; and 3) implement measures for improved communications between the pharmacy and clinical laboratory in order to enhance TDM services.

SPEAKERS

Implementation of Team-Based Delivery of TDM Services in a Modern Healthcare Environment
*William Clarke, PhD, MBA, DABCC
Johns Hopkins Medical Institutions, Baltimore, MD

TDM For Optimal Patient Care: A Pharmacist's Perspective
#Annette Rowden, PharmD, BCPS
Johns Hopkins Hospital, Baltimore, MD

Invited Oral Abstracts:
Precision Medicine and Therapeutics

33104
San Diego Convention Center - 29ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Mathew Estey, PhD
DynaLIFEDx, Edmonton, AB, Canada

INTENDED AUDIENCE: Postdoctoral fellows, pathologists, laboratory directors, clinical chemists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: AACC is dedicated to advancing the science and practice of laboratory medicine. A select group of members has reviewed and ranked the abstracts submitted for the AACC annual scientific meeting. The Annual Meeting Organizing Committee has reviewed the accepted abstracts in the area of precision medicine and therapeutics and has chosen five authors to present their research as oral presentations. Each 15-minute presentation will be followed by a 3-minute question-and-answer session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe and evaluate the latest advances in precision medicine and therapeutics; 2) compare and contrast the research in precision medicine and therapeutics to the practice of pathology and laboratory medicine; and 3) integrate and translate state of the art knowledge in precision medicine and therapeutics into the roles and responsibilities of the clinical laboratory professional.

SPEAKERS

Sensitive and Specific Detection of Variants in Circulating Tumor DNA by Anchored Multiplex PCR and Next-Generation Sequencing
*Brady Culver, PhD
Archer Dx, Boulder, CO

Comparison of the Traditional and Reverse Syphilis Screening Algorithms in Medical Health Checkups
#Eunhee Nah, MD
Korea Association of Health Promotion, Seoul, Korea

Increased Disialotransferrin Evident with Chronic Alcohol Consumption
#Dorothy Truong, PhD
University of Toronto, Toronto, ON, Canada

Measurement of Intact Fibroblast Growth Factor 23 in Patients with Heart Failure with Reduced Ejection Fraction
#Damien Gruson, PhD
Cliniques Universitaires St-Luc, Bruxelles, Belgium

miRNAs as Potential Biomarkers for New-Onset Fibrillation: In Silico and in Vivo Analysis
#Vivian Silbiger, MAS
Universidade Federal do Rio Grande do Norte, Parnamirim, Brazil

SYMPOSIA 10:30AM - NOON

Continuous Improvement of Your POCT Program: Patient-Centered Care, Reducing Overall Healthcare Costs, and Helping Meet the Goals of Healthcare Reform

FXP TOUCH

33105
San Diego Convention Center - 28ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Brenda Suh-Lailam, PhD, DABCC
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

Developed in cooperation with SYCL, Critical and Point-of-Care Testing Division

Supported by Radiometer America

INTENDED AUDIENCE: Pathologists, laboratory directors, physicians, nurses, clinical chemists, point-of-care coordinators, and technologists.

SESSION OVERVIEW: In the current climate of healthcare reform, there is a requirement to provide patient-centered care, while reducing overall costs. Point-of-Care Testing (POCT) is increasingly playing an important role as it has the potential to improve operational efficiency and patient care, when implemented appropriately. This session will focus on current and future changes in POCT and how to help meet the goals of healthcare reform in accountable care organizations.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe how POCT is changing in light of the current healthcare reform; 2) discuss two ways by which they can demonstrate the value of their POCT program; 3) summarize changes in POCT technology and possible impact on current POCT structure; and 4) explain the advantages and challenges of multidisciplinary collaborations, and how to navigate such collaborations.

SPEAKERS

Multidisciplinary Collaborations to Evaluate the Use of POCT
#Rob Nerenz, PhD, DABCC
Dartmouth-Hitchcock Medical Center, Lebanon, NH

Demonstrating the Value of Your POCT Program
#Brenda Suh-Lailam, PhD, DABCC
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

Trends in POCT Technology and Assessing Their Value
#Nicole Tolan, PhD, DABCC
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

CDC/APHL HIV Diagnostic Testing Algorithm: Incorporating New HIV Testing Technologies and Managing Common HIV Testing Dilemmas

33106
San Diego Convention Center - 28DE

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Philip Peters, MD
Centers for Disease Control and Prevention, Atlanta, GA

Supported by Radiometer America

INTENDED AUDIENCE: Clinical laboratory scientists, physicians, administrators, technologists, and laboratory directors who specialize in healthcare diagnostics and are either implementing or are interested in advances in HIV testing.

SESSION OVERVIEW: This session will present an overview of the CDC/APHL HIV Diagnostic Testing Algorithm with the goal to educate persons involved in HIV-testing programs on 1) the most current HIV-testing technologies; 2) incorporating HIV tests into laboratory practice; and 3) best practices on managing HIV-testing dilemmas.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the CDC/APHL HIV Diagnostic Testing Algorithm; 2) identify the impact of three new HIV diagnostic assays on HIV testing recommendations; and 3) apply learned information to answer common questions from clinicians.

SPEAKERS

Managing Common HIV Testing Dilemmas
#Philip Peters, MD
Centers for Disease Control and Prevention, Atlanta, GA

New HIV Testing Technologies and Their Impact on the Laboratory
#Silvina Masciotra, MBS
Centers for Disease Control and Prevention, Atlanta, GA

Overview of the CDC/APHL HIV Diagnostic Testing Algorithm
#Laura Wesolowski, PhD
Centers for Disease Control and Prevention, Atlanta, GA

SYMPOSIA 10:30AM - NOON

Changing the Rules of the Game: Multi-Disciplinary Stakeholder Perspectives on the New 2017 Federal Regulations for Research

33107
San Diego Convention Center - 33B

Level: Basic
CE Credit: 1.5

MODERATOR
***Erin Paquette, MD, JD**
Northwestern University, Chicago, IL

INTENDED AUDIENCE: Pathologists, laboratory directors, laboratory administrators, policy makers, and scientists with an interest in learning how changes to the Common Rule may impact use of biospecimens for research.

SESSION OVERVIEW: This session will focus on the changes to the Common Rule in the Federal Regulations Governing Research. Through lecture and examples, the presenters will discuss regulatory, ethical, and practical changes to the Common Rule. Specifically, the session will describe the ethical and regulatory context for the changes that were proposed, review the final changes adopted in January 2017, and will explore the impact on research for investigators, laboratory medicine, and IVD industry.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) discuss the proposed changes to the Common Rule and the changes that became part of the final rule; 2) describe the ethical and regulatory frameworks motivating the changes to the Common Rule; and 3) evaluate the impact of the Common Rule changes on laboratory medicine, investigators, and industry.

SPEAKERS

The Common Rule After a Quarter Century: Ethical and Regulatory Changes in an Age of Population Medicine
*Erin Paquette, MD, JD
Northwestern University, Chicago, IL

Proposed Changes to the Common Rule: Industry Perspective
*Danelle Miller, JD
Roche Diagnostics, Indianapolis, IN

Regulatory Threats to Research and Diagnostic Laboratories
#Mark Sobel, PhD, MD
American Society for Investigative Pathology, Bethesda, MD

Clinical Biochemistry Hot Topics of 2017

33122
San Diego Convention Center - 32AB

Level: Intermediate
CE Credit: 1.5

MODERATOR
***Pete Kavsak, PhD**
Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, molecular diagnostics specialists, technologists, and IVD industry scientists

SESSION OVERVIEW: This session highlights two speakers that have achieved significant interest from the readership of *Clinical Biochemistry*. One presentation will discuss the release mechanisms, utility, and quality of cardiac biomarkers in *Clinical Biochemistry* and other top-tiered clinical journals. The second presentation will discuss the use of EQA data to establish quality and novel approaches to manage laboratory testing.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) discuss the strengths and weaknesses when interpreting cardiac troponin and other cardiac biomarkers, especially with respect to renal disease and release mechanics/clearance; and 2) explain how quality can be managed by the laboratory professionals to provide accurate results.

SPEAKERS

High-Sensitive Cardiac Troponin, NT-proBNP, hFABP and Copeptin Levels in Relation to Glomerular Filtration Rates and a Medical Record of Cardiovascular Disease
#Ola Hammarsten, MD
Sahlgrensk Academy at the University of Gothenburg, Gothenburg, Sweden

A Simple Matrix of Analytical Performance to Identify Assays That Risk Patients Using External Quality Assurance Program Data
#Tony Badrick, PhD, FACB
RCPAQAP, Sydney, Australia

SYMPOSIA 10:30AM - NOON

New Harmonized Reference Ranges for Circulating Testosterone Levels in Men

33123
San Diego Convention Center - 31ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Hubert Vesper, PhD
Centers for Disease Control and Prevention, Atlanta, GA

Developed in cooperation with Partnership for the Accurate Testing of Hormones (PATH)

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, and IVD industry scientists.

SESSION OVERVIEW: Reference intervals for testosterone are essential for diagnosis of hypogonadism in men. New reference intervals were determined using n=9054 men from four major cohort studies. Access to these revised reference intervals should improve the diagnosis of hypogonadism by having tests and reference intervals standardized to the same accuracy.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the benefits of accurate reference intervals in patient care; 2) discuss the revised reference intervals for testosterone in men; and 3) explain how reference intervals can be derived from multiple study cohorts.

SPEAKERS

Standardized Mass Spectrometry-Based Method for Establishing Reference Ranges for Testosterone in Men
#Hubert Vesper, PhD
Centers for Disease Control and Prevention, Atlanta, GA

Statistical Design and Derivation of Testosterone Reference Ranges Using Multiple Study Cohorts
#Thomas Travison, PhD
Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Reference Ranges for Testosterone in Men and Their Clinical Impact
*Shalender Bhasin, MD
Harvard Medical School, Boston, MA

SHORT COURSE 10:30AM - NOON

Multi-Marker Testing Strategies in Women's Health

73102
San Diego Convention Center - 6C/6D

Level: Basic
CE Credit: 1.5

MODERATOR
***David Grenache, PhD, MT(ASCP), DABCC, FACB**
University of Utah & ARUP Laboratories, Salt Lake City, UT

INTENDED AUDIENCE: Laboratory directors, pathologists, clinicians, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals who participate in patient care.

SESSION OVERVIEW: Multi-marker testing strategies have been used for decades to improve the diagnostic performance of laboratory tests. These strategies are extremely relevant in women's health, particularly in the background of pregnancy and cancer. Therefore, this session will focus on clinically established and developing multi-marker testing strategies that are of importance in women's health, including those for fetal aneuploidy, preeclampsia, preterm labor, and ovarian cancer.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the established multi-marker prenatal screening program for aneuploidy; 2) compare developing strategies for ectopic pregnancy, preeclampsia and preterm labor; and 3) list the strengths and weaknesses of multi-marker test strategies for ovarian cancer risk assessment.

SPEAKERS

Multi-Marker Strategies to Predict Maternal Complications of Pregnancy
*Geralyn Lambert-Messerlian, PhD, FACB
Women & Infants Hospital and the Alpert Medical School of Brown University, Providence, RI

Multi-Marker Strategies for Ovarian Cancer Risk Assessment
*David Grenache, PhD, MT(ASCP), DABCC, FACB
University of Utah & ARUP Laboratories, Salt Lake City, UT

SYMPOSIA 2:30PM - 4:00PM

Invited Oral Abstracts:
Hot Topics in Lab Medicine

FXP TOUCH

33218
San Diego Convention Center - 28ABC

Level: Intermediate
CE Credit: 1.5*

MODERATOR
#Anna Fuezery, PhD, DABCC, FACB
Royal Alexandra Hospital Core Laboratory, Edmonton, AB, Canada

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: Postdoctoral fellows, pathologists, laboratory directors, clinical chemists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: AACC is dedicated to advancing the science and practice of laboratory medicine. A select group of members has reviewed and ranked the abstracts submitted for the AACC annual scientific meeting. The Annual Meeting Organizing Committee has reviewed the accepted abstracts focusing on hot topics in laboratory medicine and has chosen five authors to present their research as oral presentations. Each 15-minute presentation will be followed by a 3-minute question-and-answer session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe and evaluate the latest advances in laboratory medicine; 2) compare and contrast cutting edge laboratory medicine research to the practice of pathology and laboratory medicine; and 3) integrate and translate state of the art knowledge in lab medicine into the roles and responsibilities of the clinical laboratory professional.

SPEAKERS

Sex-Specific 99th Percentiles Derived from the AACC Universal Sample Bank for the Roche Gen 5 cTnT assay
*Fred Apple, PhD, DABCC
Hennepin County Medical Center, Minneapolis, MN

Frequency of Instrument, Environment and Laboratory Technologist Contamination During Routine Diagnostic Testing of Infectious Specimens
#Melanie Yarbrough, PhD
Washington University School of Medicine, St. Louis, MO

Development of Mulitplexed Mass Spectrometry-Based Assays for Urine Biomarkers of Aggressive Prostate Cancer
#Claire Knezevic, PhD
Johns Hopkins Medical Institutes, Baltimore, MD

Evaluation of the Utility of CMS Claim Data for Early Detection of Increasing Influenza Activity
#Rex Astles
Centers For Disease Control and Prevention, Atlanta, GA

Genetic Variants in the Vascular Endothelial Growth Factor Pathway as Potential Markers of Ovarian Cancer Risk, Therapeutic Response, and Clinical Outcome
#Liyun Cao
MD Anderson Cancer Center, Houston, TX

The Role and Utility of Glycated Proteins: Beyond Hemoglobin A1c

33221
San Diego Convention Center - 30DE

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Mitchell Scott, PhD, DABCC
Washington University School of Medicine, Saint Louis, MO

Developed in cooperation with American Diabetes Association (ADA), Clinical Society Collaboration Committee

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, IVD industry scientists, students, trainees, and endocrinologists.

SESSION OVERVIEW: HbA1c does not always reflect average glucose. Assays have been developed to measure other glycated proteins including fructosamine, glycated albumin and advanced glycation end-products. These markers are not altered by erythrocyte turnover but many laboratorians have limited knowledge of these markers. This session will review the role of these biomarkers and evaluate whether they provide useful information beyond HbA1c.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) summarize challenges and progress in the measurement of chronic glycemia by fructosamine, glycated albumin and advanced glycation end products; 2) describe the evidence for the clinical role of these markers in diabetes; and 3) discuss studies that are necessary to enhance the value of these markers in the management of diabetes.

SPEAKERS

Technical Challenges and Progress in the Measurement of Chronic Glycemia
#David Sacks, MD, MB, ChB, FRCPath
NIH, Bethesda, MD

Is There a Clinical Need for Fructosamine or Glycated Albumin?
*Cyrus Desouza, MBBS
University of Nebraska Medical Center, Omaha, NE

Advanced Glycation End-Products: Do They Have a Role in Diabetes?
*Paul Thornalley, PhD
University of Warwick, Coventry, United Kingdom

SYMPOSIA 2:30PM - 5:00PM

MALDI-TOF Mass Spectrometry: Not Just for Clinical Microbiology Labs Anymore

33212
San Diego Convention Center - 33A

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Mari DeMarco, PhD, DABCC, FACB
University of British Columbia and St Paul's Hospital, Vancouver, BC, Canada

Developed in cooperation with Proteomics & Metabolomics Division

INTENDED AUDIENCE: Students, residents, fellows, clinical laboratory technicians, IVD industry scientists, pathologists, laboratory directors, and technologists.

SESSION OVERVIEW: This session will provide an introduction to MALDI-TOF mass spectrometry applications in clinical chemistry laboratories. This session uses an interactive approach to discuss the application of MALDI-TOF MS, combined with emerging technologies, for qualitative and quantitative investigation of biomarkers (peptides, proteins, DNA) and drugs of abuse.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the principles of MALDI-TOF MS; 2) discuss applications of MALDI-TOF MS for qualitative and quantitative analyses; and 3) explain the strengths and weaknesses of MALDI-TOF MS.

SPEAKERS

Leveraging the Simplicity of MALDI-TOF MS: Rapid Characterization of Endogenous Peptide and Protein Isoforms
#Mari DeMarco, PhD, DABCC, FACB
University of British Columbia and St Paul's Hospital, Vancouver, BC, Canada

Leveraging the Power of MALDI-TOF MS: Quantitation of Protein Biomarkers Using Nanoparticles
#Tony Hu, PhD
Arizona State University, Tempe, AZ

Leveraging the Flexibility of MALDI-TOF MS: Application to Molecular Genetics and Toxicology
#Yusheng Zhu, PhD
Pennsylvania State University, Hershey Medical Center, Hershey PA

Diseases of the Gastrointestinal System: Immune-Mediated and Infectious

33213
San Diego Convention Center - 22

Level: Intermediate
CE Credit: 2.5

MODERATOR
***Melissa Snyder, PhD, DABCC**
Mayo Clinic, Rochester, MN

Developed in cooperation with Clinical & Diagnostic Immunology Division

INTENDED AUDIENCE: Clinical laboratory directors, pathologists, clinical technologists, IVD manufacturers, pharmaceutical scientists, and anyone interested in immunologically-related gastrointestinal diseases.

SESSION OVERVIEW: Many gastrointestinal disorders have an underlying immunological pathology, including autoimmune, infectious, and allergic diseases. The clinical symptoms associated with these various diseases may overlap, making for a challenging diagnosis. This session will show how laboratory testing plays a key role in helping to establish the correct diagnosis, allowing for an appropriate treatment strategy.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify testing that is useful for assessing the degree of inflammation within the gastrointestinal system and as an aid in the diagnosis of immune-mediated diseases such as inflammatory bowel disease; 2) describe the epidemiology of infectious gastroenteritis and identify the current standard and newer testing available within the clinical laboratory; 3) list the gastrointestinal manifestations of food allergy, distinguishing between likely and unlikely food allergens; and 4) discuss the limitations of current testing methods.

SPEAKERS

Autoimmune Gastrointestinal Diseases
*Melissa Snyder, PhD, DABCC
Mayo Clinic, Rochester, MN

Infections of the Gastrointestinal System
*Amy Leber, PhD, D(ABMM)
Nationwide Children's Hospital, Columbus, OH

Diagnostic Challenges for Food Allergies
*Bruce Lanser, MD
National Jewish Health, Denver, CO

SYMPOSIA 2:30PM - 5:00PM

Cannabis Impaired Driving: Biological Markers and Behavioral Indicators of Recent Cannabis Intake

FXP TOUCH

33215
San Diego Convention Center - 30ABC

Level: Basic
CE Credit: 2.5*

MODERATOR
***Marilyn Huestis, PhD**
NMS Labs, Inc., Willow Grove, PA

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, toxicologists, and industry scientists.

SESSION OVERVIEW: The short-term adverse consequence of cannabis legalization is cannabis-impaired driving. New blood cannabinoid markers and roadside oral fluid screening devices, and new Drug Evaluation and Classification Program data from cannabis-impaired drivers and following controlled cannabis administration are shared. Cannabis-impaired driving is an important public health and safety issue that affects all of us. Laboratorians may want to incorporate new analytical methods for the measurement of cannabinoid markers in blood and oral fluid. Clinical scientists need to be fully aware of the advantages and disadvantages of cannabinoid concentration laws and documentation of impairment by law enforcement to deter cannabis-impaired driving and to be upheld in court. This session will debate the most effective measures to document cannabis-impaired driving.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list new recent cannabis intake blood markers; 2) compare onsite oral fluid screening device performance; 3) discuss the best cannabis indicators of the Drug Evaluation and Classification Program; and 4) describe performance on divided attention psychophysical tasks and eye examinations following cannabis.

SPEAKERS

Participant Performance on Divided Attention Psychophysical Tasks and Eye Examinations from DECP Following Controlled Administration of Placebo, Smoked, Vaporized, and Oral Cannabis to Frequent and Occasional Smokers
*Madeleine Swortwood, PhD
Sam Houston State University, Huntsville, TX

Cannabinoid Pharmacology, Blood Cannabinoids and Recent Cannabis Markers in Occasional and Chronic Frequent Cannabis Smokers After Controlled Smoked, Inhaled and Oral Cannabis
*Marilyn Huestis, PhD
NMS Labs, Inc., Willow Grove, PA

Cannabis and Driving, National Advanced Driving Simulator, Drug Recognition Expert (DRE) Examination Characteristics of Cannabis Impairment
#Rebecca Hartman, PhD
Monroe County Medical Examiners' Office, Rochester, NY

Cannabis Per Se Levels and Oral Fluid Testing Performance of the Alere™ DDS®2 Mobile Test System in Identifying Cannabis Intake in Oral Fluid Samples Collected from Human Subjects at a Music Festival
*Barry Logan, PhD, D-ABFT
Fredric Rieders Family Renaissance Foundation, Willow Grove, PA

SYMPOSIA 2:30PM - 5:00PM

Determining What Works: Clinical Effectiveness and Value Based Laboratory Testing

33216
San Diego Convention Center - 28DE

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Alex Chin, PhD, DABCC, FACB, FCACB
Calgary Laboratory Services/University of Calgary, Calgary, AB, Canada

INTENDED AUDIENCE: Clinical chemists, pathologists, laboratory directors, technologists, IVD industry scientists, and regulators.

SESSION OVERVIEW: This session will discuss the role of evidence-based laboratory medicine and how it can significantly add value to the patient-focused care pathway by addressing both analytical and clinical performance as they relate to cost and clinical effectiveness in terms of direct patient benefits and safety.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list key principles in developing evidence-based biomarker evaluations; 2) explain what clinical performance criteria should be used to assess biomarker testing effectiveness; 3) describe how to assess the impact of biomarker assay performance on patient outcomes; and 4) discuss the value of evidence-based laboratory medicine in the patient care pathway.

SPEAKERS

Transforming Laboratory Medicine from Volume to Value: Shifting the Focus to Outcomes and a Value Proposition
*Brian Jackson, MD, MS, FCAP
ARUP Laboratories and University of Utah, Salt Lake City, UT

Solutions to Achieve More Effective and Efficient Lab Testing That Avoids Harms and Adds Value for Clinical and Patient Needs
#Alex Chin, PhD, DABCC, FACB, FCACB
Calgary Laboratory Services/University of Calgary, Calgary, AB, Canada

Framework for Evaluating Clinical Effectiveness
#Andrea Horvath, MD, PhD
NSW Healthy Pathology, Sydney, NSW, Australia

Clinical Performance Criteria and Clinical Effectiveness of Biomarker Testing
#Patrick Bossuyt, PhD
University of Amsterdam, Amsterdam, Netherlands

Patient-Centered Laboratory Medicine—How Laboratory Testing Impacts on Outcomes
*Mike Hallworth, MA, MSc, MCB, FRCPath
Retired, Shrewsbury, United Kingdom

SYMPOSIA 2:30PM - 5:00PM

Serum Protein Electrophoresis Reporting: New Consensus Guidelines, Interactive Cases, and Interferences

33217
San Diego Convention Center - 33B

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Ronald Booth, PhD, FCACB, FACB
The Ottawa Hospital, Ottawa, ON, Canada

Developed in cooperation with Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group, Clinical & Diagnostic Immunology Division

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical biochemists, and technologists involved in performing and interpreting serum and/or urine protein electrophoresis.

SESSION OVERVIEW: SPE reporting varies significantly between laboratories and individuals. This session will present new consensus recommendations jointly developed by laboratorians and myeloma clinicians focused on synoptic reporting. This will be followed by interactive case presentations using standardized approaches and a practical discussion of interferences, such as monoclonal therapies.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify the need for standardization of protein electrophoresis reporting; 2) apply the new consensus recommendations for serum protein electrophoresis reporting; and 3) identify and manage both common and rare interferences encountered when interpreting protein electrophoresis.

SPEAKERS

2017 Consensus Recommendations for Protein Electrophoresis Reporting
#Ronald Booth, PhD, FCACB, FACB
The Ottawa Hospital, Ottawa, ON, Canada

Interactive Serum Protein Electrophoresis Case Reporting: A Step Towards Standardization and Synoptic Reporting
#Chris McCudden, PhD, DABCC, FCACB, FACB
The Ottawa Hospital, Ottawa, ON, Canada

Challenges in Measuring Monoclonal Proteins
#David Keren, MD
The University of Michigan Medical School, Ann Arbor, MI

SPEAKER DISCLOSURE (*) (+) (#)

* Speakers whose names are preceded by an asterisk (*) have disclosed, in accordance with ACCME Standards and the policy of the AACC, that they have a relationship that, in the context of their presentation, could be perceived by some people as a real or potential conflict of interest (e.g., ownership of stock, research grants, or consulting fees). The speakers do not consider their presentations to be influenced by these relationships.

Speakers who disclose that they have no relationships that could be perceived as a conflict of interest are noted with a (#). Disclosure forms are on file in the AACC office.

+ Speakers who had not returned a disclosure form by the time of printing are noted with a (+).

All speakers will have completed forms prior to the start of the Annual Scientific Meeting. A detailed handout on speaker disclosure will be distributed at the Annual Scientific Meeting.

SYMPOSIA 2:30PM - 5:00PM

Not Out for Blood: Clinical Evaluations of Emerging Samples, Sensors, and Devices

33219
San Diego Convention Center - 32AB

Level: Basic
CE Credit: 2.5*

MODERATOR
***Jerry Cangelosi, PhD**
University of Washington, Seattle, WA

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, medical technologists, laboratory administrators, academic researchers, and IVD industry scientists with an interest in learning about emerging technologies poised to be the future of diagnostics.

SESSION OVERVIEW: Recent technological and scientific advances have enabled diagnostic approaches previously described only in science fiction, including non-invasive sampling, wearable devices, and implantable sensors. These technologies, when coupled with increased mobile connectivity, have the potential to expand access to real-time, near-patient clinical testing. This session highlights selected emerging diagnostic strategies of this type, which have shown promise in early studies in the clinic or on human volunteers.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) define and describe cutting-edge advances in non-invasive sampling, wearable devices, and implantable sensors; 2) discuss the unique challenges of clinically evaluating emerging diagnostics that utilize novel sampling and analytical strategies; and 3) summarize emerging diagnostic paradigms that have demonstrated promise in clinical evaluations and field trials.

SPEAKERS

Development of Point-Of-Care Diagnostics for Infectious Diseases: From Bench to Consumer
#Samiksha Nayak, MS
Columbia University, New York, NY

Wearable Electrochemical Sensors
#Joseph Wang, DSc, MSc
University of California San Diego, La Jolla, CA

Micro Nanotechnologies for the Clinical Applications of Circulating Tumor Cells: Implementing Liquid Biopsy
#Sunitha Nagrath, MS, PhD
University of Michigan, Ann Arbor, MI

Biomedical Applications of Single Walled Carbon Nanotube Biosensors
#Michael Strano, PhD
MIT, Cambridge, MA

Non-Invasive Infectious Disease Sampling and Viability Testing
*****Jerry Cangelosi, PhD
University of Washington, Seattle, WA

SYMPOSIA 2:30PM - 5:00PM

Biomarkers of Heart Failure with Preserved Ejection Fraction

33220
San Diego Convention Center - 31ABC

Level: Intermediate
CE Credit: 2.5

MODERATOR
***Petr Jarolim, MD, PhD**
Brigham and Women's Hospital, Harvard Medical School, Boston, MA

INTENDED AUDIENCE: Laboratory directors, clinical chemists, pathologists, medical technologists as well as IVD industry scientists.

SESSION OVERVIEW: The prevalence of heart failure with preserved ejection fraction will soon exceed that of the well-established and better understood heart failure with reduced ejection fraction. This session will cover pathophysiology of heart failure with preserved ejection fraction and biomarkers that can be used for its diagnosis, monitoring and therapeutic guidance.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) summarize the differences between heart failure with reduced and preserved ejection fraction; 2) describe reasons for different performance of established and novel biomarkers of heart failure in these two heart failure subtypes; and 3) identify promising clinical assays for the diagnosis and monitoring of patients with heart failure with preserved ejection fraction.

SPEAKERS

Heart Failure with Preserved Ejection Fraction: Pathophysiology of an Emerging Epidemic
#Garrick Stewart, MD MPH
Brigham and Women's Hospital, Harvard Medical School, Boston, MA

What Do Natriuretic Peptides Tell Us in Heart Failure with Preserved Ejection Fraction
*Petr Jarolim, MD, PhD
Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Beyond BNP: Biomarkers in HFpEF and the Pursuit of Personalized Medicine
*David Morrow, MD, MPH
Brigham and Women's Hospital, Harvard Medical School, Boston, MA

SHORT COURSES 2:30PM - 5:00PM

Genomics 101: An Interactive Workshop

73210
San Diego Convention Center - 6C/6D

Level: Basic
CE Credit: 2.5

MODERATOR
#Helen Fernandes, PhD
Columbia University Medical Center, New York, NY

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, laboratory supervisors, residents/fellows, medical technologists, IVD industry scientists, and those interested in clinical chemistry and molecular diagnostics.

SESSION OVERVIEW: Genomic medicine is transforming healthcare. Using a case-based, interactive small-group approach, participants will learn introductory principles related to developing genomic assays and interpreting results. The workshop includes practical hands-on instruction with online genomics tools. Workshop material is based on the Training Residents in Genomics (TRIG) curriculum (www.pathologylearning.org/trig).

Workshop requirements: Participants must bring a laptop for this course.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify central applications and interpretive considerations of genomic oncology tests; 2) determine the clinical significance of genomic variants using online tools; 3) evaluate critically the benefits and limitations of genomic testing in the context of patient care; and 4) recognize the significance of incidental findings that may arise from genomic testing.

SPEAKERS

An Innovative Approach to Teaching Genomic Medicine
#Richard Haspel, MD, PhD
Beth Israel Deaconess Medical Center, Boston, MA

Designing a Multiplex Genetic Assay Case Example
#John Howe, PhD, DABCC
Yale University School of Medicine, New Haven, CT

Exploring Exome Sequencing with a Case Example
*Jason Park, MD, PhD
UT Southwestern and Children's Medical Center, Dallas, TX

SHORT COURSES 2:30PM - 5:00PM

Enhancing the Diagnostic Value of Clinical Laboratory Testing Using Data Mining, Machine Learning, Informatics and Clinical Decision Support

73211
San Diego Convention Center - 29D

Level: Intermediate
CE Credit: 2.5

MODERATOR
***Jason Baron, MD**
Massachusetts General Hospital, Boston, MA

INTENDED AUDIENCE: Laboratory medicine physicians, laboratory directors, pathologists, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals interested in bioinformatics.

SESSION OVERVIEW: From GPS navigation to weather forecasting, artificially intelligent systems have become ubiquitous and are now looking to transform health care. Computational Pathology draws on machine learning and data analytic strategies to allow the fields of pathology and laboratory medicine to increasingly report integrative, predictive and prescriptive information. This session will use a series of cases studies and practical synopses to illustrate key concepts related to clinical data mining, EHR optimization, machine learning and intelligent clinical decision support.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain the basics of machine learning; 2) identify opportunities to optimize health information systems; 3) detail strategies to apply clinical decision support within existing health information technology; and 4) design projects to use data mining to uncover encoded data in test panels and to monitor clinical quality.

SPEAKERS

Machine Learning, Data Mining and Intelligent Clinical Decision Support: An Overview and Applications to the Clinical Laboratory
*Jason Baron, MD
Massachusetts General Hospital, Boston, MA

Intelligent Clinical Decision Support and Image Analysis in Anatomic Pathology
*Christopher Garcia, MD
Medical College of Wisconsin, Milwaukee, WI

Technical and Cost Analysis for Clinical Decision Support for Genomic and Molecular Pathology
#Brian Shirts, PhD
University of Washington, Seattle, WA

Mining the Electronic Health Record to Derive New Clinical Laboratory Knowledge
#Lee Schroeder, MD, PhD
University of Michigan, Ann Arbor, MI

SYMPOSIUM 4:00PM - 5:00PM

Laboratory Medicine Family Feud: AACC Leadership vs. SYCL

FXP TOUCH

33214
San Diego Convention Center - 29ABC

Level: Basic
CE Credit: 1

MODERATOR
***Paul Jannetto, PhD, DABCC, FACB, MT(ASCP)**
Mayo Clinic, Rochester, MN

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, fellows/residents, and IVD industry scientists.

SESSION OVERVIEW: This session will cover various areas of laboratory medicine including biomarkers (oncology/cardiovascular), molecular testing, POCT, TDM/Toxicology and over utilized or outdated tests. These topics will be covered using the Family Feud style game pitting AACC leadership against SYCL members.

EXPECTED OUTCOMES: After this session, the participants will be able to: 1) list various tumor markers and their clinical utility; 2) identify new and current cardiovascular biomarkers; 3) discuss the most commonly used/abused drugs; 4) recognize outdated and over-utilized tests; and 5) list common factors that can affect laboratory test results.

SPEAKERS

AACC LEADERSHIP

#Michael Bennett, PhD, DABCC, FACB
University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA

#Steven Cotten, PhD, DABCC
The Ohio State University Wexner Medical Center, Columbus, OH

#Dennis Dietzen, PhD, DABCC
Washington University School of Medicine, St. Louis, MO

#Patricia Jones, PhD, DABCC, FACB
Children's Medical Center, Dallas, TX

#Anthony Killeen, MD, PhD
University of Minnesota, Minneapolis, MN

SYCL

#Linnea Baudhuin, PhD
Mayo Clinic, Rochester, MN

#Deborah French, PhD, DABCC, FACB
University of California San Francisco, San Francisco, CA

#T. Scott Isbell, PhD, DABCC
Saint Louis University School of Medicine, St. Louis, MO

*Nichole Korpi-Steiner, PhD, DABCC, FACB
University of North Carolina, Chapel Hill, NC

#Jeff Meeusen, PhD
Mayo Clinic, Rochester, MN

WEDNESDAY AUGUST 2

PLENARY & EDUCATION SESSIONS

PLENARY SESSION 14001

ANTIBIOTIC RESISTANCE: A PUBLIC HEALTH CRISIS

***VICTORIA J. FRASER, MD**
Washington University School of Medicine,
St. Louis, MO

WEDNESDAY, AUGUST 2
8:45am - 10:15am
San Diego Convention Center - Ballroom 20
Level: Basic **CE Credit:** 1

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, microbiologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: Infections with antibiotic resistant bacteria have become a major problem in the United States and throughout the world with a significant effect on morbidity and mortality. In this presentation, the major challenges in antimicrobial resistance nationwide as well as the evolving diagnostic tools and strategies for prevention and control of antimicrobial resistance in hospitals will be discussed. In addition, the important role of the clinical pathology laboratory in infection prevention and antimicrobial stewardship will be reviewed.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the changing epidemiology of antibiotic resistance; 2) explain the key elements needed to combat antibiotic resistance; and 3) discuss the role of antimicrobial stewardship and infection prevention to limit the spread of antibiotic resistance.

PLEASE REFER TO THIS GUIDE WHEN MAKING YOUR SESSION SELECTIONS

Each session is identified by a five- or six-digit session number.

EXAMPLE
Session **72105** is a:
A. Short Course
B. On Monday
C. In the Morning

SESSION TYPE
A. FIRST DIGIT
1 =Plenary Sessions
3 =Symposia
4 =AM Brown Bag Sessions
5 =PM Brown Bag Sessions
6 =Meet the Expert Session
7 =Short Courses
19 = Sunday AACC University Sessions

SESSION DAY
B. SECOND DIGIT
1 = Sunday
2 = Monday
3 = Tuesday
4 = Wednesday
5 = Thursday

SESSION TIME
C. THIRD DIGIT
1 = am
2 = pm
4 = Mid-day

The last two digits are AACC internal numbers.

BROWN BAG SESSIONS 7:30AM - 8:30AM & 12:30PM - 1:30PM

TICKET

Brown Bag Sessions are presented twice daily. Attendance is limited to 10 participants per session. Advance registration and session fees are required. AACC does not provide meals for these sessions. You will be able to purchase your own food in the Convention Center prior to the session.

CE Credit: 1.0 (per Brown Bag Session) unless otherwise noted San Diego Convention Center - 6A/6B

TITLE	SESSION NUMBER AM	PM	LEVEL	SPEAKERS
Thyroid Function and Laboratory Assessment of Thyroid Disease	44101	54201	Intermediate	#David Kemble, PhD Dartmouth-Hitchcock Medical Center, Lebanon, NH
Innovative Applications in the Work-up of Primary Aldosteronism: Assays and Diagnostic Management Teams	44102	54202	Intermediate	*Joesph Wiencek, PhD Vanderbilt University School of Medicine, Nashville, TN
Syphilis Testing Triple-A: Advancements, Automation, Algorithms	44103	54203	Basic	#Vera Tesic, MD University of Chicago, Chicago, IL
How Statistics Influence Our Clinical Decisions	44104	54204	Basic	*Oswald Sonntag, PhD Bio-Rad Laboratories, Munchen, Germany
What's THAT?—Real World Troubleshooting	44105	54205	Intermediate	#Danyel Tacker, PhD, FACB, DABCC West Virginia University, Morgantown, WV
Overview of Marijuana Metabolites, Pharmacokinetics, and the Utility of Potential Biomarkers	44106	54206	Basic	#Breland Smith, PhD, ASCP University of California, San Diego, San Diego, CA
Implementing a Test Utilization Program	44107	54207	Basic	#Michele Koester North Memorial Health, Robbinsdale, MN
Evaluation of MALDI-TOF Mass Spectrometry for Pharmacogenetic Testing in Clinical Laboratories	44108	54208	Basic	#Fang Wu, PhD University of Utah and ARUP Laboratories, Salt Lake City, UT
Procalcitonin and Lactate—The Community Hospital Example	44109	54209	Basic	#Maria Gauthreaux, MSHSA, MT(ASCP) West Kendall Baptist Hospital, Miami, FL
Natriuretic Peptides: Testing BNP and NT-proBNP with Neprilysin Inhibitors	44110	54210	Basic	#Sean Campbell, PhD University of Virginia Health System, Charlottesville, VA
The CDC Vitamin D Standardization-Certification Program (VDSCP): Improving the Clinical Measurement of Total 25-Hydroxyvitamin D	44111	54211	Intermediate	#Otoe Sugahara, BS Centers for Disease Control and Prevention, Atlanta, GA
Minimal Residual Disease in Multiple Myeloma: The Need for More Sensitive Assays?	44112	54212	Basic	#Dorothy Truong, PhD University of Toronto, Richmond Hill, ON, Canada
Sepsis Biomarkers and the Role of the Laboratory	44114	54214	Basic	#Angela Fung, PhD University of Toronto, Toronto, ON, Canada
Liquid Biopsy: A New Trend in Clinical Testing	44115	54215	Basic	#Ventzi Hristova, PhD Johns Hopkins School of Medicine, Baltimore, MD

TITLE	SESSION NUMBER AM	PM	LEVEL	SPEAKERS
A Dirty Assay: Challenges of PTH Estimation and Progress in PTH Harmonization	44116	54216	Intermediate	**#Asmita Hazra, MBBS, MD** Assistant Professor, Jodhpur, Rajasthan, India
Emerging Trends in Vitamin Supplementation	44117	54217	Intermediate	**#Carmen Gherasim, PhD** ARUP Laboratories, Salt Lake City, UT
Drug Screens: Basic Principles, Principle Problems, and Future Approaches	44118	54218	Basic	**#Mitchell McGill, PhD** Washington University School of Medicine, St. Louis, MO
Case Studies: Acceptability of Patient Risk at Monthly/Regular QC Review	44119	54219	Intermediate	***Zoe Brooks, ART, CSMLS** AWEsome Numbers Inc., Worthington, ON, Canada
Strategy for Provider-Performed Microscopy Testing Competency Management	44120	54220	Basic	**#Hoi-Ying (Elsie) Yu, PhD, DABCC, FACB** Geisinger Health System, Danville, PA
Designing a Successful Point-of-Care Testing Program: Survival Guide for New Laboratory Directors *Developed in cooperation with SYCL*	44121	54221	Basic	**#Rob Nerenz, PhD, DABCC** Dartmouth-Hitchcock Medical Center, Lebanon, NH
Methods to Detect Circulating MicroRNAs (miRNAs) in the Clinical Laboratory	44122	54222	Basic	**#Nicole White-Al Habeeb, PhD** Hospital for Sick Children, Toronto, ON, Canada
Testing for Alpha 1-Antitrypsin Deficiency	44123	54223	Intermediate	**#Joshua Bornhorst, PhD, DABCC** Mayo Clinic, Rochester MN
Discrepancies in HIV Screening and Confirmation Results	44124	54224	Intermediate	**#Anthony Okorodudu, PhD, MBA, DABCC** University of Texas Medical Branch, Galveston, TX
Counting on AMH Immunoassays	44125	54225	Intermediate	***Geralyn Lambert-Messerlian, PhD, FACB** Women & Infants Hospital and the Alpert Medical School of Brown University, Providence, RI
Biotin-Related Interference with Immunoassay Methodologies *(ACCENT® credit only)*	44126	54226	Intermediate	***Randal Schneider, PhD** Abbott Diagnostics, Waterford, WI
Digging Deep: Tackling Difficult Lab Safety Issues	44127	54227	Intermediate	***Dan Scungio, MT(ASCP), SLS, CQA (ASQ)** Sentara Healthcare, Hampton, VA
Management of Incidental Laboratory Findings	44128	54228	Intermediate	**#Michael Lewis, MD, MBA** University of Vermont Medical Center, Burlington, VT
Case Studies in Clinical Toxicology—How to Make Sense of Urine Drug Screen Results	44129	54229	Basic	**#Hema Ketha, PhD** University of Michigan, Ann Arbor, MI
C. difficile Testing—A Wealth of Opportunity	44130	54230	Intermediate	**#Stacy Beal, MD** University of Florida College of Medicine, Gainesville, FL

MEET THE EXPERT 10:30AM - 11:30AM

Antibiotic Resistance: A Public Health Crisis

64101
San Diego Convention Center - 29D

Level: Basic
CE Credit: 1

MODERATOR
#Ann Gronowski, PhD, DABCC, FACB
Washington University School of Medicine, St. Louis, MO

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, microbiologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: This session provides an excellent opportunity for a limited number of attendees to meet with Dr. Victoria Fraser, a distinguished infectious disease physician who studies the epidemiology of nosocomial infections including surgical site infections, blood stream infections and ventilator-associated pneumonia. Dr. Fraser will discuss the evolving diagnostic tools and strategies for prevention and control of antimicrobial resistance in hospitals. In addition, the important role of the clinical pathology laboratory in infection prevention and antimicrobial stewardship will be reviewed.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the changing epidemiology of antibiotic resistance; 2) explain the key elements needed to combat antibiotic resistance; and 3) discuss the role of antimicrobial stewardship and infection prevention to limit the spread of antibiotic resistance.

SPEAKER
Antibiotic Resistance: A Public Health Crisis
*Victoria J. Fraser, MD
Washington University School of Medicine, St Louis, MO

SYMPOSIA 10:30AM - NOON

The Role of the Clinical Laboratory in Antimicrobial Stewardship

34103
San Diego Convention Center - 31ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
***Carey-Ann Burnham, PhD**
Washington University School of Medicine, St. Louis, MO

INTENDED AUDIENCE: Laboratory medicine physicians, laboratory directors, pathologists, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals who participate in patient care.

SESSION OVERVIEW: Although antibiotics have transformed the practice of medicine, up to half of antibiotic prescriptions are either unnecessary or inappropriate. Antimicrobial Stewardship programs facilitate optimal use of antimicrobial agents and are being required by regulatory agencies. This session will describe the role of the clinical laboratory in Antimicrobial Stewardship programs.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) summarize how laboratory reports can contribute to an institutional antimicrobial stewardship program; 2) explain the key elements of a cumulative antibiogram report; 3) discuss the role of rapid diagnostic testing in antibiotic selection; and 4) describe approaches to selective and cascade reporting of antimicrobial susceptibility results, and the impact on antimicrobial utilization.

SPEAKERS
Stewardship Overview and Rapid Diagnostic Methods
#Melanie Yarbrough, PhD
Washington University School of Medicine, St. Louis, MO

Antibiograms and Selective Reporting: Impact on Antibiotic Prescribing Practices
*Carey-Ann Burnham, PhD
Washington University School of Medicine, St. Louis, MO

Point-of-Care Technologies for Fighting Antimicrobial Resistance
#Gyorgy Abel, MD, PhD, DABCC, FACB
Lahey Hospital & Medical Center, Burlington, MA

SYMPOSIA 10:30AM - NOON

Practical Considerations for Realizing Precision Oncology in Clinical Laboratories

34104
San Diego Convention Center - 6F

Level: Advanced
CE Credit: 1.5

MODERATOR
#Helen Fernandes, PhD
Columbia University Medical Center, New York, NY

Developed in cooperation with Molecular Pathology Division

INTENDED AUDIENCE: Pathologists, laboratory directors, lab administrators, supervisors, clinical chemists, technologists, and IVD industry scientists. This session is meant to inform and update all clinical laboratory personnel who have developed or are planning to develop, validate and implement genomic testing in their respective facilities.

SESSION OVERVIEW: Precision Medicine is at the center of scientific, clinical and governmental meetings and publications. There are however, practical considerations that need to be addressed before venturing on to genomic testing. This session will discuss and debate the pros and cons of implementing Precision Oncology in a routine clinical laboratory.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify current and future technologies for genomic testing; 2) list the benefits and limitations of genomic testing of tumors in the context of patient care; and 3) discuss the pros and cons of the involvement federal agencies in the implementation of genomic testing in clinical laboratories.

SPEAKERS

The Past, the Present, and the Future of Genomics in the Clinical Laboratory
*Gregory Tsongalis, PhD, HCLD
Geisel School of Medicine at Dartmouth, Lebanon, NH

The Benefits and Challenges of Next Generation Sequencing in Routine Clinical Molecular Diagnostics
#Andrea Ferreira-Gonzalez, PhD
Virginia Commonwealth University, Richmond, VA

Pros and Cons of Federal Regulations—The Laboratorian's Perspective
#Anthony Sireci, MD, MSc
Columbia University, New York, NY

Antiphospholipid Syndrome: Clinical Presentation and Laboratory Investigation

34105
San Diego Convention Center - 28ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#John Mitsios, PhD
BioReference Laboratories, Elmwood Park, NJ

Developed in cooperation with Clinical & Diagnostic Immunology Division, Hematology & Coagulation Division

INTENDED AUDIENCE: Clinical chemists, laboratory technologists, residents, and pathologists.

SESSION OVERVIEW: This session will review the clinical presentation, laboratory diagnosis including specialized testing, and treatment of antiphospholipid syndrome (APS). The presentation will conclude with case scenarios that highlight the teaching points from the presentation.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list the variable clinical presentations of APS; 2) describe the laboratory tests needed to diagnose APS; 3) compare and contrast the detection of the lupus inhibitor (anticoagulant) versus the detection of APS-associated autoantibodies; and 4) list evidence-based guidelines for the treatment of arterial and venous complications as well as obstetric manifestations of APS.

SPEAKERS

Antiphospholipid Syndrome: Clinical Presentation and Treatment
#Anita Rajasekhar, MD, MS
Washington University School of Medicine, St. Louis, MO

Antiphospholipid Syndrome: Laboratory Investigation
#John Mitsios, PhD
BioReference Laboratories, Elmwood Park, NJ

SYMPOSIA 10:30AM - NOON

Non-Harmonized Results Cause Medical Errors—Unless We Prevent Them

34106
San Diego Convention Center - 30ABC

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Hubert Vesper, PhD
Centers for Disease Control and Prevention, Atlanta, GA

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, and IVD industry scientists.

SESSION OVERVIEW: Non-harmonized laboratory results can lead to misclassification of patients and inconsistent patient care decisions. This problem is minimized by correctly calibrating laboratory tests using appropriate commutable reference materials and have target values assigned with generally accepted reference procedures. To achieve harmonized and reliable laboratory test results, the clinical laboratory needs to collaborate with new and traditional stakeholders to inform them about the clinical needs and analytical requirements, and to promote programs to achieve harmonized, high quality laboratory test results.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list current approaches to harmonize laboratory test results; 2) explain how the laboratory is engaging the legislative system to improve the situation; 3) explain the importance of commutability and procedures to use commutability information; and 4) describe how stakeholders can inform the laboratory about clinical needs and collaborate with the laboratory to implement harmonized tests.

SPEAKERS

Problems with Non-Harmonized Results and How Do We Prevent Them
#Stephen Master, MD, PhD, FCAP, FACB
Weill Cornell Medical College, New York, NY

Addressing Commutability Limitations
*Greg Miller, PhD, DABCC
Virginia Commonwealth University, Richmond, VA

Benefits of Stakeholder Engagement and Support
#Hubert Vesper, PhD
Centers for Disease Control and Prevention, Atlanta, GA

Invited Oral Abstracts:

Point-of-Care Testing

34107
San Diego Convention Center - 30DE

Level: Intermediate
CE Credit: 1.5*

MODERATOR
***Martha Lyon, PhD**
Royal University Hospital, Saskatoon, SK, Canada

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: Postdoctoral fellows, pathologists, laboratory directors, clinical chemists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: AACC is dedicated to advancing the science and practice of laboratory medicine. A select group of members has reviewed and ranked the abstracts submitted for the AACC annual scientific meeting. The Annual Meeting Organizing Committee has reviewed the accepted abstracts in the area of point-of-care testing and has chosen five authors to present their research as oral presentations. Each 15-minute presentation will be followed by a 3-minute question-and-answer session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe and evaluate the latest advances in point-of-care testing; 2) compare and contrast the research in point-of-care testing to the practice of pathology and laboratory medicine; and 3) integrate and translate state of the art knowledge in point-of-care testing into the roles and responsibilities of the clinical laboratory professional.

SPEAKERS

Rapid Detection of Early Stage Mycoplasma Pneumonie Infection Using Single-Walled Carbon Nanotube/Colloidal Gold Based Immunochromatographic Strips
#Weizhuo Xu
Shenyang Pharmaceutical University, Shenyang, China

Evaluation of a POC INR Program in a Long-Term Care Setting: Comparison of the CoaguChex XS and Time in Therapeutic Range Versus Laboratory-Based Monitoring
*Dana Nyholt-Bailey, MSc, PhD, FCACB
DynaCare, London, ON, Canada

Comparison of Creatinine on the Alere Epoc Blood Analysis System Against Multiple Point-of-Care and Central laboratory Assays
#Albert KY Tsui, PhD
University of Alberta, Edmonton, AB, Canada

Analytical Evaluation of Blood Gas Syringes for Pneumatic Tube Systems
#Ben Collins, BS
Instrumentation Laboratory, Bedford, MA

Optimization of Lactate Measurements for Sepsis Guidelines Using Point of Care Testing
Lilah M. Evans, MT(ASCP)
Thomas Jefferson University Hospital, Philadelphia, PA

SYMPOSIA 10:30AM - NOON

Relevant, Practical and Novel Topics from the *Journal of Applied Laboratory Medicine*

34121
San Diego Convention Center - 28DE

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Robert Christenson, PhD, DABCC, FACB
University of Maryland School of Medicine, Baltimore, MD

Supported by Beckman Coulter, Inc.

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, molecular diagnostics specialists, technologists, regulatory personnel, and IVD industry scientists and managers.

SESSION OVERVIEW: This session showcases a collection of topics that were published and well received in the *Journal of Applied Laboratory Medicine*. Results from the ASSESS study; utilization of the AACC Universal Sample Bank; development of a LC MS\MS method for measuring atovaquone; and lipid recommendations from evidence-based laboratory medicine will be discussed.

EXPECTED OUTCOMES: After this session participants will be able to: 1) identify a troponin method comparison resource that includes high-sensitivity, POC and contemporary assays; 2) describe how a method for the anti-malaria Atovaquone will be beneficial; 3) list benefits and effect-sizes associated with inclusion of novel lipids to risk prediction; and 4) explain how to obtain a cohort of normal samples for determining a troponin 99th percentile.

SPEAKERS

The ASSESS Trial: A Multi-Instrument Evaluation of 13 Commercial Troponin Assays: Sample Analysis in a Common Cohort of Samples
#Robert Christenson, PhD, DABCC, FACB
University of Maryland School of Medicine, Baltimore, MD

An Ultra-Performance LC-MS/MS Method for the Quantification of the Antimalarial Atovaquone in Plasma
#Allison Chambliss, PhD, DABCC
Keck Medicine of University of Southern California, Los Angeles, CA

Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review
#Paramjit Sandhu, MPH, MD
Centers for Disease Control and Prevention, Atlanta, GA

Creation of a Universal Sample Bank for Determining the 99th Percentile for Cardiac Troponin Assays
*Alan Wu, PhD, DABCC, FACB
University of California/San Francisco General Hospital, San Francisco, CA

SHORT COURSE 10:30AM - NOON

Clinical and Laboratory Aspects of Monoclonal Antibody Therapeutics

74102
San Diego Convention Center - 6E

Level: Intermediate
CE Credit: 1.5

MODERATOR
#Melissa Snyder, PhD, DABCC
Mayo Clinic, Rochester, MN

Developed in cooperation with Clinical & Diagnostic Immunology Division

INTENDED AUDIENCE: Laboratory directors, pathologists, laboratory technologists, IVD manufacturers, pharmaceutical scientists, and anyone interested in the clinical or laboratory aspects of therapeutic monoclonal antibodies.

SESSION OVERVIEW: Monoclonal antibodies represent a unique class of therapeutic agents. These molecules are used to treat a variety of diseases, including solid-organ tumors, hematological malignancies, rheumatological disorders, and autoimmune gastrointestinal diseases. The clinical laboratory can make critical contributions to the management of patients receiving these treatments through quantitative measurement of the therapeutic antibodies and assessment of anti-drug antibodies. However, it is important to recognize that these drugs can also pose challenges through interference in some existing laboratory tests.

This session will provide laboratorians with information relevant to the utility of monoclonal antibodies as therapies. As more and more monoclonal antibodies are approved for clinical use, the role of the clinical laboratory will continue to expand, with two main perspectives: the quantitation of antibody therapeutics and detection of anti-drug antibodies with specialized testing, and the recognition of this new class of therapies as interferents in routine testing and their impact on patient care.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list the classes of monoclonal antibody therapeutics and their clinical applications; 2) explain the methods available for the measurement of monoclonal antibody therapeutics and assessment of anti-drug antibodies; and 3) discuss how the presence of monoclonal therapeutic antibodies can impact and/or interfere in existing clinical tests, such as protein electrophoresis and immunofixation.

SPEAKERS

Monoclonal Antibody Therapeutics as Potential Interferents on Protein Electrophoresis and Related Tests
#Maria Alice Willrich, PhD, DABCC, FACB
Mayo Clinic, Rochester, MN

Assessment of Monoclonal Antibody Therapeutics and Anti-Drug Antibodies
#Melissa Snyder, PhD, DABCC
Mayo Clinic, Rochester, MN

SYMPOSIUM 2:30PM - 4:00PM

Invited Oral Abstracts:
Global Health

34218
San Diego Convention Center - 31ABC

Level: Intermediate
CE Credit: 1.5*

MODERATOR
#Timothy Amukele, MD, PhD
Johns Hopkins University, Baltimore, MD

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: Postdoctoral fellows, pathologists, laboratory directors, clinical chemists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: AACC is dedicated to advancing the science and practice of laboratory medicine. A select group of members has reviewed and ranked the abstracts submitted for the AACC annual scientific meeting. The Annual Meeting Organizing Committee has reviewed the accepted abstracts in the area of global health and has chosen five authors to present their research as oral presentations. Each 15-minute presentation will be followed by a 3-minute question-and-answer session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe and evaluate the latest advances in global health; 2) compare and contrast the research in global health to the practice of pathology and laboratory medicine; and 3) integrate and translate state of the art knowledge in global health into the roles and responsibilities of the clinical laboratory professional.

SPEAKERS

The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozgous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25Ferritin Molar Ratio and with Markers of Hemolysis, Angiogenesis, Endothelial and Renal Dysfunction
#Ioannis Papassotiriou, PhD
Aghia Sophia Children's Hospital, Athens, Greece

Use of Urine Drug Screening Positivity Rates from Qualitative Liquid Chromatography Tandem Mass Spectrometry Definitive Testing to Identify Annual Trends in Drug Use
#Adam Ptolemy, PhD
Dynacare, London, ON, Canada

Report on a European and Two Korean Population Clinical Trials for Multiplex Detection of HIV and HCV
#Christian Oste
PCL Inc., Seoul, Korea

Effectiveness of Practices to Foster Quality Improvement Through Reaching Adequate Blood Volumes in Microbiological Tests in Taiwan: From Systematic Reviews to Validity Assessments
#Hsiao-Chen Ning, PhD
Chang-Gung Memorial Hospital, Tao-Yuan, Taiwan

RIG-I Enhances IGN-a Response by Promoting Antiviral Proteins Expression in patients with CHB
#Qishui Ou, PhD
The 1st Affiliated Hospital of Fujian Medical University, Fuzhou, China

SYMPOSIA 2:30PM - 5:00PM

Ethics in Laboratory Medicine

34207
San Diego Convention Center - 28DE

Level: Basic
CE Credit: 2.5

MODERATOR
***Kelly Dineen, JD, PhD**
Saint Louis University, St. Louis, MO

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, immunologists, molecular biologists, technologists, and IVD industry scientists.

SESSION OVERVIEW: This session will focus on ethical and legal issues surrounding evolving technologies and laboratory medicine. Through lecture and case studies, the presenters will discuss the legal and ethical considerations around screening and testing for drugs of abuse, the implications of CRISPR-CAS9 and mitochondrial replacement, the interaction of HIPAA and CLIA regulations, and the ethical limits of next generation sequencing and biospecimen banking.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain how the HIPAA Privacy Rule interacts with the Clinical Laboratory Improvements Amendments Act of 1988; 2) discuss the primary legal considerations and conflicting ethical norms often at issue in testing for drugs of abuse; 3) describe the legal implications of CRISPR-CAS9 and Mitochondrial Replacement; and 4) identify the evolving ethical issues surrounding next generation sequencing and biospecimen banking and practices.

SPEAKERS

Legal and Ethical Issues with Mitochondrial Replacement and CRISPR-cas9
#Seema Mohapatra, JD, MPH
Barry University Dwayne O. Andreas School of Law, Orlando, FL

The Ethics of Next Generation Sequencing and Biospecimen Banking
#Neil Haycocks, MD, PhD
UNLV School of Medicine, Las Vegas, NV

Legal and Ethical Challenges in Drug Testing
*Kelly Dineen, JD, PhD
Saint Louis University, St. Louis, MO

SPEAKER DISCLOSURE (*) (+) (#)

* Speakers whose names are preceded by an asterisk (*) have disclosed, in accordance with ACCME Standards and the policy of the AACC, that they have a relationship that, in the context of their presentation, could be perceived by some people as a real or potential conflict of interest (e.g., ownership of stock, research grants, or consulting fees). The speakers do not consider their presentations to be influenced by these relationships.

Speakers who disclose that they have no relationships that could be perceived as a conflict of interest are noted with a (#). Disclosure forms are on file in the AACC office.

+ Speakers who had not returned a disclosure form by the time of printing are noted with a (+).

All speakers will have completed forms prior to the start of the Annual Scientific Meeting. A detailed handout on speaker disclosure will be distributed at the Annual Scientific Meeting.

SYMPOSIA 2:30PM - 5:00PM

High-Sensitivity Cardiac Troponin: As with Every New Tool, There is a Learning Curve

34213
San Diego Convention Center - 32AB

Level: Intermediate
CE Credit: 2.5

MODERATOR
***Pete Kavsak, PhD**
Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada

INTENDED AUDIENCE: Physicians, pathologists, laboratory directors, clinical chemists, technologists, and IVD industry scientists.

SESSION OVERVIEW: This session will engage the audience in the latest guidelines, developments, and interactive sessions on how clinical chemistry tests can be best utilized for early decision making in the emergency department for patients presenting with chest pain. The session will lead off with a debate from the ED perspective on new guidelines, followed by case studies demonstrating use of cardiac troponin and new published algorithms in this evolving area.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify the strengths and weakness in approaches/algorithms used to rule-in and rule-out myocardial infarction in the emergency department; 2) explain how the selection of "healthy individuals" and statistical techniques can result in different 99th percentile concentration cutoffs; and 3) evaluate laboratory practices that can mitigate an incorrect cardiac troponin result from being reported.

SPEAKERS

Debate on European Society of Cardiology (ESC) New Guidelines to Rule-in and Rule-out Acute Myocardial Infarction (AMI) in the Emergency Department (ED)—European Point-of-View from the ED
*Richard Body, PhD
Manchester Royal Infirmary, Manchester, United Kingdom

Debate on European Society of Cardiology (ESC) New Guidelines to Rule-in and Rule-out Acute Myocardial Infarction (AMI) in the Emergency Department (ED)—Non European Point-of-View from the ED
*Martin Than, MBBS, FRCS (A&E Ed.), FRCEM, FACEM
Christchurch Public Hospital, Canterbury, New Zealand

Why Your Cardiac Troponin 99th Percentile Cutoff is Wrong
#Peter Hickman, PhD, MD
ACT Pathology, Woden, Australia

Why Your Cardiac Troponin Result is Wrong
*Pete Kavsak, PhD
Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada

SYMPOSIA 2:30PM - 5:00PM

AACC/ASCLS Healthcare Forum: Government Affairs Update

34214
San Diego Convention Center - 6F

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Vince Stine, PhD
AACC, Washington, DC

Developed in cooperation with ASCLS

INTENDED AUDIENCE: Laboratory directors, medical technologists, laboratory managers and other laboratory and industry personnel responsible for legislative, regulatory, payment and compliance issues.

SESSION OVERVIEW: This session will address FDA efforts to regulate laboratory developed tests; CMS implementation of a market-based laboratory fee schedule; an update on changes to the Clinical Laboratory Improvement Amendments program; and a big picture overview on future changes to the laboratory industry and how it operates.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) discuss FDA's current policy on LDT oversight; 2) describe changes to the CLIA program; 3) explain forthcoming changes in the clinical laboratory fee schedule; and 4) summarize potential changes in the healthcare industry and their impact on clinical laboratories.

SPEAKERS

The Future Direction of CLIA
#Karen Dyer, MT(ASCP), DLM
Centers for Medicare & Medicaid Services, Baltimore, MD

PAMA and the New Payment Paradigm
*Charles Root, PhD
CodeMap LLC, Schaumburg, IL

FDA's Regulatory Oversight of Next Generation Sequencing Diagnostic Tests
#Alberto Gutierrez, PhD
FDA/CDRH, Silver Spring, MD

The Changing Healthcare Environment and its Impact on Clinical Laboratories
#Elissa Passiment, EdM, CLS
EP Clinical Laboratory Consulting, Bluffton, SC

FOLLOW AACC @_AACC AND USE THE HASHTAG #2017AACC TO JOIN THE CONVERSATION.

SYMPOSIA 2:30PM - 5:00PM

Current Practices and New Innovations in Newborn Screening

FXP TOUCH

34215
San Diego Convention Center - 6E

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Ronald Whitley, PhD, DABCC, FACB
University of Kentucky, Lexington, KY

Developed in cooperation with CDC (Centers for Disease Control and Prevention), CLSI (Clinical Laboratory Standards Institute), Pediatric and Maternal-Fetal Division

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, clinical laboratory scientists, the pediatric provider community, public health professionals, and policy makers.

SESSION OVERVIEW: Newborn screening is widely known to improve health outcomes through early detection and treatment of a number of congenital disorders. However, there are many challenges with laboratory testing, communication of test results, treatment and follow-up. This session will provide an overview of newborn screening and discuss the aforementioned challenges in light of current practice and new innovations.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the process of newborn screening from sample collection to initial and follow-up testing and patient management; 2) identify major challenges encountered by laboratorians and clinicians in newborn screening; 3) summarize the current and future status of newborn screening; and 4) discuss quality assurance programs to support rapid and accurate test results.

SPEAKERS

CLSI Guidelines for Newborn Screening
#Ronald Whitley, PhD, DABCC, FACB
University of Kentucky, Lexington, KY

National Quality Efforts in Newborn Screening
#Carla Cuthbert, PhD, FACMG, FCCMG
Centers for Disease Control and Prevention, Atlanta, GA

Improved Performance of Newborn Screening Using Automated Adjustment of Results and Global Interpretive Tools
#Piero Rinaldo, MD, PhD
Mayo Clinic, Rochester, MN

The Laboratory's Role in Follow-up and Long-term Monitoring of Abnormal Newborn Screens
#Uttam Garg, PhD, DABCC, DABFT, FACB
Children's Mercy Hospital, Kansas City, MO

Clinical Aspects of Newborn Screening
#Jennifer Gannon, MD, FAAP, FACMG
Children's Mercy Hospital, Kansas City, MO

SYMPOSIA 2:30PM - 5:00PM

Precision Medicine Guided Pharmacotherapy in Cancer

34216
San Diego Convention Center - 28ABC

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Serge Cremers, PharmD, PhD, FCP
Columbia University and New York-Presbyterian Hospital, New York, NY

Developed in cooperation with Personalized Medicine Division, TDM & Toxicology Division

INTENDED AUDIENCE: Pathologists, clinical chemists, clinical pharmacologists, and clinicians.

SESSION OVERVIEW: This session will discuss Genomics, Transcriptomics and Systems Biology-based drug selection for the treatment of cancer patients. This will be followed by a clinician's perspective and experience in treating patients accordingly. The session will culminate with an overview of the potential roles of novel biomarkers and therapeutic drug monitoring in the treatment of cancer with off-label and experimental drugs.

EXPECTED OUTCOMES: At this session, participants will be able to: 1) describe the laboratory and interpretive components of genomics, transcriptomics and systems biology-based drug selection for the treatment of cancer patients; 2) list challenges associated with precision medicine-based drug selection and how such challenges lead to off-label and experimental drug use; 3) identify potential biochemical biomarkers that could be used to monitor therapeutic efficacy post-drug administrations; and 4) discuss the synergy of therapeutic drug monitoring of experimental drugs in supporting patient care and furthering drug development.

SPEAKERS

Pharmacotherapy of Cancer, Based on Clinical Whole Exome, Transcriptomic, and Large Panel Mutation Testing of Tumors
#Mahesh Mansukhani, MD
Columbia University Medical Center, New York, NY

Precision Medicine in the Pediatric Oncology Clinic: Where the Rubber Meets the Road
*Julia Glade Bender, MD
Columbia University Medical Center, New York, NY

Biomarkers for Precision Medicine Guided Therapy for Prostate Cancer
#Alex Rai, PhD, DABCC, FACB
Columbia University and New York-Presbyterian Hospital, New York, NY

TDM in the Era of Precision Medicine: Opportunities!
#Serge Cremers, PharmD, PhD, FCP
Columbia University and New York-Presbyterian Hospital, New York, NY

SYMPOSIA 2:30PM - 5:00PM

Beyond the Traditional Environments: Defining the Role of Laboratory Medicine in Pharmacy and Direct to Consumer Testing

FXP TOUCH

34219
San Diego Convention Center - 33B

Level: Intermediate
CE Credit: 2.5

MODERATOR
#T. Scott Isbell, PhD, DABCC, FACB
Saint Louis University School of Medicine, St. Louis, MO

Developed in cooperation with Critical and Point-of-Care Testing Division

INTENDED AUDIENCE: Clinical chemists, laboratory directors, pathologists, point-of-care coordinators, physicians, pharmacists, policy makers, and IVD industry scientists.

SESSION OVERVIEW: This interactive audience participation session will identify the current limitations of clinical testing in emerging models of patient-centered care and will outline a call to action for clinical laboratorians. Expert speakers will discuss the potential strengths, challenges, and opportunities associated with testing in retail pharmacy settings, integrating personal devices for at-home disease monitoring, and in direct to consumer (DTC) testing for facilitating patient engagement and improving outcomes.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) describe the current clinical testing challenges in the primary care setting; 2) list the benefits and challenges associated with lab testing in the pharmacy setting; 3) describe the role of personal connectivity devices and patient self-testing as an effective tool in the management of chronic disease; and 4) summarize the benefits and challenges of DTC testing, considering the critical assessment of methods.

SPEAKERS

Beyond the Laboratory, Time to Embrace a Paradigm Shift
#T. Scott Isbell, PhD, DABCC, FACB
Saint Louis University School of Medicine, St. Louis, MO

Clinical Testing Needs in the Primary Care Setting
#Augustine Sohn, MD
University of Illinois at Chicago, Chicago, IL

Advantages and Limitations of Direct to Consumer Testing
#Nicole Tolan, PhD, DABCC
Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

The Role of Pharmacists to Support Primary Care
*Donald Klepser, PhD
University of Nebraska Medical Center, Omaha, NE

Integration of At-Home Clinical Testing with Personal Connectivity Devices
#Christopher Longhurst, MD
University of California, San Diego Health System, San Diego, CA

SYMPOSIA 2:30PM - 5:00PM

Data Automation and Informatics with R: Application Showcase

34220
San Diego Convention Center - 33A

Level: Basic
CE Credit: 2.5

MODERATOR
#Daniel Holmes, BSc, MD, FRCPC
St Paul's Hospital, Vancouver, BC, Canada

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, medical technologists, and laboratory administrators with an interest in learning how laboratorians can use the R programming language to solve diverse but commonly encountered problems.

SESSION OVERVIEW: This session will demonstrate the versatility and power of the R statistical programming language in application to clinical laboratory medicine by showcasing tools that have been built and implemented by the speakers. Applications will range over topics of machine learning, method evaluation, automated report generation, and instrument interfacing. Laptops are not needed for this session.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) discuss features and benefits of using the R programming language in clinical laboratories; 2) describe ways the R programming language can be used to enhance clinical laboratory operations; and 3) evaluate and solve clinical laboratory problems using computational thinking.

SPEAKERS

Flat File Interfacing and Instrument with R. Application to the AB Sciex AP15000 LC-MS/MS
#Daniel Holmes, BSc, MD, FRCPC
St Paul's Hospital, Vancouver, BC, Canada

Using R to Build a Real Time Machine Learning Algorithm to Screen for Myelodysplastic Syndrome
#Stephen Master, MD, PhD, FCAP, FACB
Weill Cornell Medical College, New York, NY

RMarkdown: What is an Automated and Reproducible Report?
#Matthew Henderson, PhD, FCACB
Newborn Screening Ontario, Ottowa, ON, Canada

Using RMarkdown to Build Automated Physician Utilization Report Cards
#Patrick Mathias, MD, PhD
University of Washington, Seattle, WA

R Shiny: The Web App Builder for R: Application to Regression Analysis
#Burak Bahar, MD
Yale – New Haven Hospital, New Haven, CT

Simulations in R: Effects of Biological and Analytical Variation on Kidney Failure Risk Estimation
#Chris McCudden, PhD, DABCC, FCACB, FACB
The Ottawa Hospital, Ottowa, ON, Canada

SHORT COURSES 2:30PM - 5:00PM

Laboratory Medicine Steps Up to the Plate: The Role of the Laboratory Professional in Reducing Diagnostic Error and Improving Test Utilization and Interpretation

74210
San Diego Convention Center - 30ABC

Level: Intermediate
CE Credit: 2.5

MODERATOR
***Mike Hallworth, MA, MSc, MCB, FRCPath**
Retired, Shrewsbury, United Kingdom

INTENDED AUDIENCE: Laboratory medicine physicians, laboratory directors, pathologists, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals who participate in patient care.

SESSION OVERVIEW: Medical errors are the third leading cause of death in the United States; diagnostic errors are estimated to result in up to 80,000 deaths annually. In 2015, The National Academies of Sciences, Engineering and Medicine generated the Improving Diagnosis in Health Care report, which endorsed the facilitation of more effective teamwork in the diagnostic process. This session will provide tools to enable laboratorians to effectively participate in clinical teams through the identification of laboratory testing contributions to diagnostic errors, improvement of test utilization, and the delivery of clinically relevant interpretations of laboratory tests.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain the ways in which testing-related diagnostic errors arise; 2) outline effective strategies to improve test utilization and implement a utilization management program; 3) describe the recommendations of the 2017 CLSI guideline on test utilization; and 4) partner more effectively with clinicians and diagnostic colleagues to ensure effective interpretation, improved diagnosis and better patient outcomes.

SPEAKERS

Adding Value and Reducing Diagnostic Error—Delivering Patient-Centered Laboratory Medicine
*Mike Hallworth, MA, MSc, MCB, FRCPath
Retired, Shrewsbury, United Kingdom

Developing an Effective Test Utilization Management System
#Peter Perrotta, MD
West Virginia University, Morgantown, WV

Interacting with the Clinical Team—Providing Effective Interpretation of Laboratory Data Leading to Improved Clinical Outcomes
#Danielle Freedman, MB, ChB, FRCPath, MD
Luton & Dunstable Hospital NHS Trust, Luton, United Kingdom

SHORT COURSES 2:30PM - 5:00PM

New Definitions and Guidelines for Management of the Septic Patient— The Novel and Essential Role of the Laboratorian on the Clinical Team

FXP TOUCH

74211
San Diego Convention Center - 30DE

Level: Intermediate
CE Credit: 2.5

MODERATOR
#Khushbu Patel, PhD, DABCC
University of Texas Southwestern, Dallas, TX

INTENDED AUDIENCE: Laboratory directors, clinicians, pathologists, clinical chemists, supervisors, medical technologists, residents/fellows, IVD industry scientists, and other healthcare professionals who participate in patient care.

SESSION OVERVIEW: Sepsis remains a critical health problem and is the leading cause of death in non-cardiac intensive care units, requiring a need for early detection and intervention to reduce mortality. This session will highlight new guidelines in the diagnosis and monitoring of sepsis, and provide both the clinical laboratorian's and physician's perspectives on managing the septic patient. During this interactive session, the audience will debate the merits and applicability of the new guidelines as well the potential contributions of biomarkers, including lactate and procalcitonin, in sepsis management.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) define recent definitions and guidelines for sepsis management; 2) recognize the role of the laboratorian on the sepsis care team; 3) discuss the role of the laboratorian in antibiotic stewardship programs; 4) identify special considerations in the recognition and management of sepsis in pediatric populations; and 5) evaluate the potential utility of biomarkers such as lactate and procalcitonin in sepsis management.

SPEAKERS

Managing the New Definition and Regulations for the Septic Patients—The Clinical Perspective
#Todd Rice, MD, MSc
Vanderbilt University Medical Center, Nashville, TN

The Role of the Laboratorian on the Sepsis Management Team—Assessment of Current and Novel Diagnostic Approaches
*Alison Woodworth, PhD, DABCC
University of Kentucky, Lexington, KY

The Role of the Laboratorian in Antibiotic Stewardship Programs
#Allison Chambliss, PhD, DABCC
Keck Medicine of USC, Los Angeles, CA

Special Considerations with Pediatric Sepsis and Septic Shock
#Khushbu Patel, PhD, DABCC
UT Southwestern, Dallas, TX

SYMPOSIUM 4:00PM - 5:00PM

Infectious Disease Quiz Show

FXP TOUCH

34212
San Diego Convention Center - 29ABC

Level: Intermediate
CE Credit: 1

MODERATOR
***Carey-Ann Burnham, PhD**
Washington University School of Medicine, St. Louis, MO

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, fellows, residents, medical technologists, and IVD industry scientists.

SESSION OVERVIEW: This case-based session will highlight advancements in the diagnosis of infectious disease of interest to a broad laboratory medicine audience. Using a "Quiz Show" format, audience members will participate via an audience response system. Topics will include Zika virus, mass spectrometry, antimicrobial resistance, and more.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain the advantages of MALDI-TOF mass spectrometry for pathogen identification; 2) discuss and summarize emerging issues in infectious diseases relevant to the clinical laboratory; and 3) contrast the utility of serologic testing to molecular diagnostics for infectious diseases.

SPEAKERS

*Carey-Ann Burnham, PhD
Washington University School of Medicine, St. Louis, MO

#Melanie Yarbrough, PhD
Washington University School of Medicine, St. Louis, MO

FOLLOW AACC @_AACC AND USE THE HASHTAG #2017AACC TO JOIN THE CONVERSATION.

THURSDAY AUGUST 3

PLENARY & EDUCATION SESSIONS

PLENARY SESSION 15001

MODERN, EFFECTIVE CARE FOR SUBSTANCE USE DISORDERS: FINDINGS FROM THE 2016 SURGEON GENERAL'S FACING ADDICTION REPORT

***A. THOMAS McLELLAN, PhD**
Treatment Research Institute,
Philadelphia, PA

THURSDAY, AUGUST 3
8:45am - 10:15am
San Diego Convention Center - Ballroom 20
Level: Basic **CE Credit:** 1

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, toxicologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: Over 22 million Americans meet medical diagnostic criteria for "addiction" to alcohol and/or other drugs. Substance misuse and addiction cost our country over $400 billion annually and are implicated in over 70% of deaths among adolescents. Overall prevalence rates and costs have not declined over the decades leading to the view that substance misuse and addiction may simply be an intractable part of our culture. But there is one exception—cigarette use. The prevalence, health harms and costs associated with cigarette use have been dramatically reduced over the past four decades as a direct result of broadly applied science-based public health policies and clinical practices. Using the three decades of research reviewed and synthesized in the recent Surgeon General's Report entitled "Facing Addiction in the United States," this presentation argues that a similar science-based strategy would be possible, practical and cost effective to implement, with potential public benefits comparable those seen with cigarettes.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain two major brain circuits/systems disrupted in the course of addiction; 2) cite one example from each of the three components of effective addiction treatment: Medications, Behavioral Therapies, and Recovery Support Services; and 3) list two reasons to integrate treatment of substance use disorders and general healthcare.

PLEASE REFER TO THIS GUIDE WHEN MAKING YOUR SESSION SELECTIONS

Each session is identified by a five- or six-digit session number.

EXAMPLE
Session **72105** is a:
A. Short Course
B. On Monday
C. In the Morning

SESSION TYPE
A. FIRST DIGIT
1 =Plenary Sessions
3 =Symposia
4 =AM Brown Bag Sessions
5 =PM Brown Bag Sessions
6 =Meet the Expert Session
7 =Short Courses
19 = Sunday AACC University Sessions

SESSION DAY
B. SECOND DIGIT
1 = Sunday
2 = Monday
3 = Tuesday
4 = Wednesday
5 = Thursday

SESSION TIME
C. THIRD DIGIT
1 = am
2 = pm
4 = Mid-day

The last two digits are AACC internal numbers.

MEET THE EXPERT 10:30AM - 11:30AM

Modern, Effective Care for Substance Use Disorders: Findings from the 2016 Surgeon General's Facing Addiction Report

65101
San Diego Convention Center - 29D

Level: Basic
CE Credit: 1

MODERATOR
#Ann Gronowski, PhD, DABCC, FACB
Washington University School of Medicine, St. Louis, MO

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, toxicologists, laboratory technologists, and IVD industry scientists.

SESSION OVERVIEW: This session provides an excellent opportunity for a limited number of attendees to meet with Dr. A. Thomas McLellan, Retired Deputy Director of Office of National Drug Control Policy and Founder & Chairman Treatment Research Institute. Dr. McLellan was the principal developer of the Addiction Severity Index (ASI) and the Treatment Services Review (TSR), widely used substance abuse instruments. Dr. McLellan will discuss the 2016 Surgeon General's Report entitled "Facing Addiction in the United States," and strategies to combat the addiction epidemic.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain two major brain circuits/systems disrupted in the course of addiction; 2) cite one example from each of the three components of effective addiction treatment: Medications, Behavioral Therapies, and Recovery Support Services; and 3) list two reasons to integrate treatment of substance use disorders and general healthcare.

SPEAKER
Modern, Effective Care for Substance Use Disorders: Findings from the 2016 Surgeon General's Facing Addiction Report
*A. Thomas McLellan, PhD
Treatment Research Institute, Philadelphia, PA

SYMPOSIA 10:30AM - NOON

The Burden of Proof for Point-of-Care Glucose Monitoring in Critically Ill Patients

35103
San Diego Convention Center - 32AB

Level: Intermediate
CE Credit: 1.5*

MODERATOR
#Steven Cotten, PhD, DABCC
The Ohio State University Wexner Medical Center, Columbus, OH

** Credits for this session are pending. Attendees should check the mobile app or www.aacc.org/2017AM for updates.*

INTENDED AUDIENCE: POC coordinators, pathologists, laboratory directors, clinical chemists, technologists, and IVD industry scientists.

SESSION OVERVIEW: This session will explore the use of point-of-care (POC) glucose measurements in populations that may contain critically ill patients. The audience will be asked to decide who has the "burden of proof" for defining critically ill populations: regulatory agencies, device manufacturers, or healthcare institutions. Speakers will cover the current clinical indications and regulatory issues from the laboratory and IVD manufacturer perspective. Following the lectures, audience members will divide into groups based on who should assume the burden of proof and justify their choice to session participants.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) identify the clinical utility and analytical challenges of point of care glucose testing in hospitalized adult and pediatric patients; 2) define current regulatory requirements related to point of care glucose in the hospital setting; 3) describe the challenges for IVD companies in meeting both clinical and regulatory requirements for POC glucose testing platforms; and 4) discuss different strategies for implementing a POC glucose testing program in critically ill patients.

SPEAKERS
Clinical Indications and Analytical Challenges of Point-of-Care Glucose Testing in Hospitalized Patients
*Alison Woodworth, PhD, DABCC
University of Kentucky, Lexington, KY

Regulatory Updates, Intended Use and Approval for POC Glucose Devices
*James Nichols, PhD, DABCC, FACB
Vanderbilt University Medical Center, Nashville, TN

Intended Use Statements and Clinical Trial Study Design: An IVD Manufacturer Perspective
*Corinne Fantz, PhD, DABCC
Roche Diagnostic Corp, Indianapolis, IN

Are you B.R.A.V.E.? Critically Ill Exclusion Criteria for POC Glucose at an Academic Medical Center
#Steven Cotten, PhD, DABCC
Ohio State University Wexner Medical Center, Columbus, OH

SYMPOSIA 10:30AM - NOON

Global Issues Regarding High Sensitivity Cardiac Troponin Assays: Shifting Strategies to Early Rule Out of Myocardial Injury and Defining Appropriate Cutoffs for Outcomes Assessment

35104
San Diego Convention Center - 30ABC

Level: Advanced
CE Credit: 1.5

MODERATOR
***Fred Apple, PhD, DABCC**
Hennepin County Medical Center, Minneapolis, MN

Developed in cooperation with American College of Cardiology, Society of Academic Emergency Medicine, Clinical Collaborations Society Committee

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, technologists, IVD industry scientists, and regulatory experts.

SESSION OVERVIEW: This session will address high-sensitivity cardiac troponin assays (hs-cTnI, hs-cTnT) for a) the early rule out of myocardial injury and b) defining appropriate population cutoffs for outcome risk assessment of adverse events. Evidence-based strategies and test utilization will be emphasized.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain how clinical cutoffs for cTn are defined and recognize the need for sex-defined 99th percentile values with hs-cTn assay implementation; 2) understand that cTn is a biomarker used to detect myocardial injury; 3) apply clinical and laboratory strategies using hs-cTn assays that will improve the ability for an early rule out of myocardial injury and discharge; and 4) define a framework for establishing hs-cTn assays into laboratories for clinical use through clinical partnership and appropriate test utilization, with the goal of improving patient outcomes.

SPEAKERS

Clinical Chemist: Analytical Issues and Guidelines for Cardiac Biomarkers
*Fred Apple, PhD, DABCC
Hennepin County Medical Center, Minneapolis, MN

Emergency Medicine: Clinical Use of Cardiac Biomarkers in Emergency Department
*Judd Hollander, MD
Thomas Jefferson University, Philadelphia, PA

Cardiology: Clinical Use of Cardiac Biomarkers for In-Patient and Out-Patient Management
*Allan Jaffe, MD
Mayo Clinic, Rochester, MN

FOLLOW AACC @_AACC AND USE THE HASHTAG #2017AACC TO JOIN THE CONVERSATION.

SYMPOSIA 10:30AM - NOON

At the Juncture of Pain Management and Addiction

35106
San Diego Convention Center - 30DE

Level: Basic
CE Credit: 1.5

MODERATOR
#Bridgit Crews, PhD, DABCC
University of California, Irvine, Orange, CA

INTENDED AUDIENCE: Laboratory scientists, managers, directors, administration, and clinicians.

SESSION OVERVIEW: Alleviation of pain with opioids presents risks for addiction. Urine drug testing may be used to assess and monitor patients, but interpretation of results is not always straightforward. Most patients are managed by primary care physicians; however, those that are at high risk require management by specialists in pain management and addiction. This session will focus on the physician perspective regarding clinical decision making with opioids and the laboratorian's role as clinical consultant. The session will be case-based and involve audience participation through cellular devices.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) list the benefits and risks for patients treated with opioids; 2) describe the clinical decisions that are made when patients are treated with opioids; 3) describe methods used for urine drug testing; and 4) describe examples of urine drug testing results that may be misinterpreted.

SPEAKERS

Clinical Decision Making with Chronic Opioid Therapy
#Gregory Polston, MD
University of California San Diego, La Jolla, CA

Laboratorian's Role in Pain Medication Monitoring
#Bridgit Crews, PhD, DABCC
University of California, Irvine, Orange, CA

SHORT COURSE 10:30AM - NOON

Introduction to Translational and Clinical Metabolomics for Personalized Medicine

75102
San Diego Convention Center - 33AB

Level: Basic
CE Credit: 1.5

MODERATOR
#Timothy Garrett, PhD
University of Florida, Gainesville, FL

INTENDED AUDIENCE: Pathologists, laboratory directors, clinical chemists, clinical toxicologists, analytical chemists, clinical laboratory scientists, technologists, and IVD industry scientists.

SESSION OVERVIEW: The metabolome is a sum of all primary and secondary metabolites in a biological sample, which change as a function of health, time, and disease. They include endogenous and exogenous metabolites as a result of exposure to drugs, plants, and environment. Metabolomics is the analytical measurement of these metabolites. These measurements reflect the status of health, nutrition, infection and diseases. A key aspect of metabolomics is the utilization of state-of-the-art mass spectrometric approaches to detect and identify metabolites in biological fluids and tissues. While these technologies are extremely powerful to translational and clinical investigations, they also have a steep learning curve. This session will help define what is needed to overcome this barrier.

EXPECTED OUTCOMES: After this session, participants will be able to: 1) explain the application of high resolution mass spectrometry approaches to metabolomics; 2) recognize the current state of clinical metabolomics; and 3) utilize bioinformatics tools for interpreting data from metabolomic studies.

SPEAKERS

Advancing Informatics to Make Metabolomics Easier
#Gary Patti, PhD
Washington University in St. Louis, St. Louis, MO

Overview of Metabolomics in Translational and Clinical Studies
#Timothy Garrett, PhD
University of Florida, Gainesville, FL

SPEAKER DISCLOSURE (*) (+) (#)

* Speakers whose names are preceded by an asterisk (*) have disclosed, in accordance with ACCME Standards and the policy of the AACC, that they have a relationship that, in the context of their presentation, could be perceived by some people as a real or potential conflict of interest (e.g., ownership of stock, research grants, or consulting fees). The speakers do not consider their presentations to be influenced by these relationships.

Speakers who disclose that they have no relationships that could be perceived as a conflict of interest are noted with a (#). Disclosure forms are on file in the AACC office.

+ Speakers who had not returned a disclosure form by the time of printing are noted with a (+).

All speakers will have completed forms prior to the start of the Annual Scientific Meeting. A detailed handout on speaker disclosure will be distributed at the Annual Scientific Meeting.

AACC BOOTH, MEMBER LOUNGE & STORE

AACC BOOTH

Stop by and visit booth #3539 to learn how AACC is at the forefront of new approaches in laboratory medicine and how AACC is addressing the complexity of an evolving healthcare landscape and promoting new thinking and new skills.

NEW! AACC MEMBER LOUNGE

AACC members are welcome to stop by the Member Lounge located at the AACC booth #3539 on the Expo show floor. This member only benefit provides a place to recharge between sessions, mingle with colleagues, and participate in fun daily activities.

AACC Booth/Member Lounge Hours

Tuesday, Wednesday	9:30am - 5:00pm
Thursday	9:30am - 1:00pm

AACC STORE

Plan to visit the AACC store to examine some of AACC's new titles that have been released since last year's meeting and all the other bestsellers. AACC merchandise is available for purchase including t-shirts, AACC wearables, and gifts.

AACC Store Hours

Monday - Wednesday	9:00am - 5:00pm
Thursday	9:00am - 1:00pm

STOP BY AND VISIT THE AACC BOOTH #3539

AACC access PROGRAM

HELP THE NEXT GENERATION OF LABORATORY MEDICINE SCIENTISTS

AACC's **access** Program is a way for you to give back to the clinical chemistry profession. Through programs such as the International Travel Grant and SYCL Travel Grant, emerging laboratory scientists are supported and encouraged to contribute to excellence in the profession. These grants bring laboratorians from all over the world to the AACC Annual Scientific Meeting, allowing them to network with colleagues, attend cutting-edge scientific sessions and tour the AACC Clinical Lab Expo.

As one past international travel grantee describes her experience:

"It was a great challenge for my future development as a laboratory specialist to visit this meeting. I acquired new ideas for diagnostics, learned new basic guidelines for quality assurance in the laboratory and created friendships with many colleagues."

– Dr. Rozaliya Todorova

DONATE TODAY. HERE'S HOW:

- Go to www.aacc.org/about-aacc/access/contribute
- Call Stefanie Kleinman at +1 800.892.1400, ext. 1712, or at +1 202.835.8712
- Email Stefanie Kleinman at skleinman@aacc.org

Thank you to all our donors who made these grants possible this year. A list of recent donors is found at www.aacc.org/about-aacc/access/donors.

SPEAKER INDEX



Last Name	Speaker Session
Lewis, Michael	44128/54228
Li, Kai	32105
Little, Randie	43132/53232
Lo, Stanley	32416
Lo, Vanessa	42110/52210
Lockwood, Christina	62101
Logan, Barry	33215
Longhurst, Christopher	34219
Lu, Pang	32222
Luthra, Rajyalakshmi	72217
Lyon, Martha	34107
Mann, Peggy	192007
Mansukhani, Mahesh	34216
Masciotra, Silvina	33106
Masliah, Eliezer	32226
Master, Stephen	32227, 63102, 34106, 34220
Mathias, Patrick	192010, 34220
Mays, James	42118/52218
McCudden, Chris	33217, 34220
McGill, Mitchell	44118/54218
McLellan, A. Thomas	15001, 65101
Meeusen, Jeff	33214
Mejia, David, Esq.	32220
Meng, Qing	72103, 72217, 43112/53212
Merrill, Anna	72411, 43118/53218
Miller, Greg	34106
Miller, Danelle	33107
Mitsios, John	34105
Mohapatra, Seema	34207
Morrow, David	32109, 33220
Nagrath, Sunitha	33219
Nah, Eunhee	33104
Nayak, Samiksha	33219
Nerenz, Rob	72414, 33105, 44121/54221
Nichols, James	35103
Ning, Hsiao-Chen	34218
Nooney, Christiane	42120/52220
Nyholt-Bailey, Dana	34107
Ochs, Luann	192008
Okorodudu, Anthony	43114/53214, 44124/54224
Oliveira, Jennifer	192009
Oste, Christian	34218
Ou, Qishui	34218
Pang, Lu	32222
Papassotiriou, Ioannis	32108, 34218
Paquette, Erin	33107
Park, Jason	32106, 73210
Passiment, Elissa	34214
Patel, Khushbu	43122/53222, 74211
Patel, Nirali	32416

Last Name	Speaker Session
Patti, Gary	75102
Peng, Chung-Kang	32227, 63102
Perrotta, Peter	74210
Pesce, Amadeo	43126/53226
Peters, Philip	33106
Petersen, Cherie	191005, 42124/52224
Pillay, Tahir	191004
Polston, Gregory	35106
Poynter, Krista	43113/53213
Ptolemy, Adam	34218
Punyadeera, Chamindie	72218
Rackley, Craig	191001
Rai, Alex	34216
Rajasekhar, Anita	34105
Ramanathan, Lakshmi	72218
Randell, Edward	32108
Ricchiuti, Vincent	42102/52202
Rice, Todd	74211
Rifai, Nader	32109
Rinaldo, Piero	34215
Rissman, Robert	32226
Root, Charles	34214
Roper, Stephen	42114/52214
Rowden, Annette	33103
Sacks, David	32104, 33221
Sandhu, Paramjit	34121
Saunders, Carol	32106
Schifman, Ron	32219, 43101/53201
Schmidt, Robert	32219
Schneider, Randal	44126/54226
Schroeder, Lee	32107, 73211
Scott, Mitchell	33221
Scungio, Dan	44127/54227
Seccombe, David	192011
Sepiashvili, Lusia	32222
Shahangian, Shahram	43123/53223
Shaw, Leslie	32226
Shelton, Robert	32220
Shendure, Jay	13001, 63101
Shi, Run Zhang	42116/52216
Shirts, Brian	73211
Silbiger, Vivian	33104
Simmons, Rebecca	32128
Simons, Janet	42111/52211, 43111/53211
Sireci, Anthony	34104
Skala, Kimberly	192007
Smith, Breland	44106/54206
Snyder, Melissa	33213, 74102
Snyder, James	191006
Sobel, Mark	33107
Sobolesky, Philip	42117/52217
Sofronescu, Alina	42123/52223

Last Name	Speaker Session
Sohn, Augustine	34219
Song, Lu	42106/52206, 43104/53204
Sonntag, Oswald	43103/53203, 44104/54204
Spencer, Carole	32104
Stewart, Garrick	33220
Stine, Vince	34214
Strano, Michael	33219
Strickland, Sydney	42115/52215
Sugahara, Otoe	44111/54211
Suh-Lailam, Brenda	42101/52201, 33105
Swortwood, Madeleine	33215
Tacker, Danyel	44105/54205
Tesic, Vera	44103/54203
Than, Martin	34213
Thomas, Monica	192007
Thornalley, Paul	33221
Toffaletti, John	191001
Tolan, Nicole	33105, 34219
Travison, Thomas	33123
Truong, Dorothy	33104, 43120/53220, 44112/54212
Tsongalis, Gregory	34104
Tsui, Albert KY	34107
Tsui, Dana	72217
Twomey, Patrick	191004
Van, Bonny	191006
Van der Gugten, Grace	192012
Van Uum, Stan	32104
Vesper, Hubert	33123, 34106
Wang, Joseph	33219
Wang, Shu-Hua	32221
Wesolowski, Laura	33106
Westgard, Sten	191002
White-Al Habeeb, Nicole	43109/53209, 44122/54222
Whitley, Ronald	34215
Whitman, Jeffrey	32222
Wiencek, Joesph	44102/54202
Willrich, Maria Alice	72412, 74102
Wong, Steven	43131/53231
Woodruff, Teresa	12001, 62102
Woodworth, Alison	74211, 35103
Wu, Alan	72103, 34121
Wu, Gary	32128
Wu, Fang	44108/54208
Wyer, Lou Ann	192007
Xu, Weizhuo	34107
Yang, Yifei	42112/52212
Yarbrough, Melanie	33218, 34103, 34212
Yu, Hoi-Ying (Elsie)	44120/54220
Zhu, Yusheng	43102/53202, 33212

CONTINUING EDUCATION CREDIT

ACCREDITATION

The American Association for Clinical Chemistry, Inc. (AACC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AACC designates the following sessions for AMA PRA Category 1 Credit™ (refer to individual session descriptions to see number of designated credits):

- Plenary Sessions
- Short Courses
- Symposia
- Brown Bag Sessions
- Meet the Experts

AACC also designates the sessions listed for ACCENT® credit. AACC is an approved provider of continuing education (CE) for clinical laboratory scientists licensed in states that require documentation of CE, including California, Florida, Louisiana, Montana, Nevada, North Dakota, Rhode Island, Tennessee, and West Virginia. ACCENT® credit is also recognized by several organizations: AAB, ABCC, ACS, AMT, ASCLS, ASCP, ASM, CAP, IFCC, and NRCC.

Important Note: Please read session descriptions to check if both type of credit ACCENT® and AMA PRA Category 1 Credit™ are available (indicated as "CE Credit" in this guide), or if only ACCENT® credit is available.

Attendees should only claim credit commensurate with the extent of their participation in activities.

CE/CME CREDIT AND CERTIFICATE OF ATTENDANCE INFORMATION

1. Locate the CONTINUING EDUCATION SESSION RECORDING FORM in the back of this Program Guide.
2. As you attend sessions, write the session information on the form on page 99. *(Note: You will no longer be required to record a Continuing Education Code or "CE" Code to claim credit.)*
3. When you are ready to claim your credits, use the mobile app or go to **www.aacc.org/AMcredits17.** Log in using your badge number and last name. You will be instructed to evaluate each session attended; then print (or save) your Verification of Participation (credit) certificate.

   You can claim your credits at the end of each day, or after the meeting ends.

You may claim your credits on your own computer, laptop, tablet, or other electronic device, or you may use the computer located at the ACCENT/CME booth (Lobby F).

Credits for the 2017 AACC Annual Scientific Meeting must be claimed by June 1, 2018—with the exception of credits claimed by Florida-licensed laboratory professionals (see information below).

Special Notice for Florida Laboratory Professionals Receiving ACCENT® Credit

If you would like AACC to report your credits to CE BROKER, you must claim your credits within 30 days of the AACC Annual Scientific Meeting and provide your Florida license number when you go on-line to claim your ACCENT® credits.

Special Notice for California Clinical Laboratory Scientists Receiving ACCENT® Credit

When submitting your ACCENT® Verification of Participation certificate(s) to the California state licensing agency, be sure to add your signature in the designated space.

Credit amounts are subject to change.
For the most up-to-date information on credits available by session, check the mobile app or visit www.aacc.org/2017AM and select "Conference Program".

Eligibility to Earn Continuing Education Credit

You must be registered for the Annual Scientific Meeting to be eligible to earn continuing education credit (ACCENT® or *AMA PRA Category 1 Credit™*) for the following scientific sessions of the AACC Annual Scientific Meeting: Plenary, Symposia, Short Courses, Brown Bag Sessions, Meet the Experts, and the Poster Sessions. **Individuals registered as Guest/Spouse or Expo Only are not eligible to earn credit for these sessions.**

Certificate of Attendance

To obtain a certificate of attendance for the 69th AACC Annual Scientific Meeting, go to **www.aacc.org/AMcredits17** and follow the instructions to obtain your Certificate of Attendance. You will need your badge number located on your badge.

FREQUENTLY ASKED QUESTIONS

How do I get credit for the scientific sessions (Plenary, Symposia, Short Courses, Meet the Experts, Brown Bag, and Poster Sessions)?	When you are ready to claim your credits, use the mobile app or go to: **www.aacc.org/AMcredits17** and follow the instructions to evaluate each session you attended and then print (or save) your Verification of Participation (credit) certificate.
Will I need to record the CE code at the end of each session?	No, continuing education (CE) codes are no longer being used for continuing education credit.
What is the deadline for claiming credits or getting a Certificate of Attendance for the 69th AACC Annual Scientific Meeting?	The deadline for claiming credits and getting your Certificate of Attendance for this year's meeting is June 1, 2018, with the exception of Florida laboratory professionals (see further information below).
Do I need to take any additional steps for my ACCENT® credit if I am a clinical laboratory scientist in Florida?	Yes, if you would like AACC to report your credits to CE BROKER, enter your Florida Department of Health license number when you go online to obtain your ACCENT® credits. You must obtain your credits within 30 days of the AACC Annual Scientific Meeting.
Do I need to take any additional steps for my ACCENT® credit if I am a clinical laboratory scientist in California?	Yes, you must sign your ACCENT® Verification of Participation certificate(s) before submitting to the California state licensing agency.
How do I get ACCENT® credit for Poster Sessions?	To obtain ACCENT® credit for Poster Sessions, use the mobile app or go to **www.aacc.org/AMcredits17** and follow the same steps as you would for claiming credits for other scientific sessions.
What's the difference between ACCENT® credit and AMA PRA Category 1 Credit™?	ACCENT® credit is for clinical laboratory professionals, and *AMA PRA Category 1 Credit™* is for physicians only.
Can I obtain my continuing education credits or Certificate of Attendance on-site at the Annual Scientific Meeting?	Yes, there will be a computer at the ACCENT/CME booth (Lobby F). You may use your own computer, laptop, tablet, smart phone, or other electronic device.
How do I get my Certificate of Attendance for the 69th AACC Annual Scientific Meeting?	Check the mobile app or go to **www.aacc.org/AMcredits17** and follow the instructions to obtain your Certificate of Attendance. You will need your badge number located on your badge.
Who can answer additional questions about continuing education credit?	The AACC staff at the ACCENT/CME booth (Lobby F) will be glad to answer your questions, or you may send an email to education@aacc.org.

MORE QUESTIONS? Contact AACC Education at education@aacc.org.

AACC Learning Lab for Laboratory Medicine on NEJM Knowledge+

Increase proficiency, expand knowledge, and enhance your career.
SUBSCRIBE TODAY.

AACC® Learning Lab
technology by Area9 Learning

NEJM Knowledge+ | AACC Learning Lab

CONTINUING EDUCATION SESSION RECORDING FORM

BADGE NUMBER _____

OBTAINING YOUR CONTINUING EDUCATION CREDITS FOR THE SCIENTIFIC SESSIONS OF THE 69TH AACC ANNUAL SCIENTIFIC MEETING - JULY 30 THROUGH AUGUST 3, 2017

This form is for recording the scientific sessions you attended, i.e., Plenary Sessions, Symposia, Short Courses, Meet the Experts, Brown Bag, and Poster Sessions. All sessions, with the exception of the Poster Sessions, qualify for ACCENT® Credit and *AMA PRA Category 1 Credit*™, unless otherwise noted in the Program Guide. The Poster Sessions qualify for ACCENT® Credit only.

- As you attend sessions, write down the session information on this form (Note: You are no longer required to record a Continuing Education Code or "CE" Code).
- When you are ready, use the mobile app or go to **www.aacc.org/AMcredits17** and follow the instructions to evaluate each session you attended and then to print (or save) your Verification of Participation (credit) certificate.
- You may claim your credits on your own computer, laptop, tablet, smart phone or other electronic device, or you may use the computer on-site at the ACCENT/CME Booth.
- You may claim your credits at the end of each day or after the meeting ends.
- Continuing education credits must be obtained by June 1, 2018 (with the exception of Florida licensed laboratory professionals—see important note below).

Questions? Visit the ACCENT/CME booth (Lobby F), or contact the AACC Professional Education department at education@aacc.org.

IMPORTANT NOTE to Florida clinical laboratory scientists: If you have a Florida license and would like AACC to report your ACCENT® credits to CE BROKER, you must go online and obtain your credits within 30 days of the AACC Annual Scientific Meeting. Credits claimed after 30 days will have to be self-reported to CE Broker.

Session Date	Session Type (Plenary, Symposia, Short Courses, Meet the Experts, Brown Bag, and Poster Sessions only).	Session Number (Note: Poster Sessions do not have session numbers.)	Session Title	Credit Amount

(Additional spaces for recording sessions are provided on other side.)

BADGE NUMBER _____

Session Date	Session Type (Plenary, Symposia, Short Courses, Meet the Experts, Brown Bag, and Poster Sessions only).	Session Number (Note: Poster Sessions do not have session numbers.)	Session Title	Credit Amount

ELEVATE

THIS IS WHAT PARTNERS DO.

To support 2,000 physicians across 26 medical centers, Henry Ford Health System believes it takes more than technology to deliver world-class care.

That's why they've partnered with Beckman Coulter to integrate state-of-the-art instrumentation into their laboratory and optimize performance using Performance Partnership based on the Danaher Business System. It's this commitment to immediacy and perfection, through the collaboration of people and technology, that has enabled Henry Ford Health System to rapidly and accurately deliver 30 million test results from 12 million laboratory samples — and improve the care of 4.3 million patients.

Discover the difference at booth #3117 and find out more about Henry Ford Health System's unique story at **www.beckmancoulter.com/partners**

BECKMAN COULTER

Move healthcare forward.

DANAHER BUSINESS SYSTEM
CLINICAL INFORMATION MANAGEMENT TOOLS

COMPREHENSIVE, HIGH-QUALITY CLINICAL DIAGNOSTIC SOLUTIONS
TOP-TIER SERVICE AND UPTIME

For Beckman Coulter's worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact


BECKMAN COULTER
Move healthcare forward.
ENGAGE
THIS IS WHAT PARTNERS DO.
At Beckman Coulter, we believe in providing you with continuous learning for continuous growth.
At AACC, we're offering multiple education sessions on establishing best practices to improve patient care. Our industry experts will present:
› New products and technologies
› Helpful insights on creating a more efficient, cost-controlled laboratory
› Efficient testing guidelines and new system implementations to optimize your performance
At Beckman Coulter, helping our partners achieve their goals is what we do.
Get engaged. Visit beckmancoulter.com/aacc for session topics and schedule or JOIN US IN BOOTH #3117
DANAHER BUSINESS SYSTEM
CLINICAL INFORMATION MANAGEMENT TOOLS
COMPREHENSIVE, HIGH-QUALITY CLINICAL DIAGNOSTIC SOLUTIONS
TOP-TIER SERVICE AND UPTIME
© 2017 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. AD-52541
For Beckman Coulter's worldwide office locations and phone numbers, please visit www.beckmancoulter.com/contact